Endocrinology and Metabolism

Original Article

TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor: Hongxiang Huang, Jinhong Chen, Xingyu Tao, Peiyuan Zhong, Yanqiu Meng, Sujuan Peng, Wanying Luo, Zhiyong He, Shuai Luo, Xie Zhu, Zhihui Lu, Li Chen, Yangyang Liu; Received May 22, 2025 Accepted September 30, 2025 Published online February 10, 2026; DOI: https://doi.org/10.3803/EnM.2025.2471 [Epub ahead of print]

108 View
8 Download

Abstract PDF: Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, characterized by poor prognosis due to its high proliferative and invasive potential. Tumor metabolic reprogramming, particularly involving glucose metabolism, is essential for tumor survival. This study investigates the role of the Hippo pathway effector transcriptional co-activator with PDZ-binding motif (TAZ) in regulating gluconeogenesis and promoting tumorigenesis in HCC.
Methods
TAZ expression in HCC was analyzed using The Cancer Genome Atlas data and validated in clinical samples and cell lines. TAZ was overexpressed or silenced in HCC cell lines to evaluate its effects on cell proliferation, apoptosis, migration, and invasion. The expression and prognostic relevance of the gluconeogenesis-related genes phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) were examined, along with their correlation with TAZ expression. Tumor growth was assessed in nude mice. Interactions between TAZ and the glucocorticoid receptor (GR) were investigated using co-immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation assays.
Results
TAZ was significantly upregulated in HCC tissues and cell lines. TAZ overexpression enhanced proliferation, reduced apoptosis, and promoted migration and invasion. In contrast, PCK1 and G6PC were downregulated in HCC and showed a negative correlation with TAZ expression.
Conclusion
TAZ modulates gluconeogenesis and accelerates tumor growth, whereas its knockdown attenuates tumor progression. TAZ interacts with GR, suppressing its transcriptional activity on gluconeogenic gene promoters.

Songwon Lecture 2025

Postpartum Glucose Intolerance in Women with a History of Gestational Diabetes Mellitus: An In-Depth Review: Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho; Received December 15, 2025 Accepted December 23, 2025 Published online February 3, 2026; DOI: https://doi.org/10.3803/EnM.2025.2852 [Epub ahead of print]

182 View
18 Download

Abstract PDF: Gestational diabetes mellitus (GDM) is increasing in prevalence worldwide, and postpartum glucose intolerance represents one of the major complications after delivery in women with GDM. A wide range of risk factors for postpartum glucose intolerance have been identified, including ethnicity, genetic predisposition, age, obesity, pre-pregnancy body mass index, gestational weight gain, history of GDM, family history of diabetes, degree of hyperglycemia, insulin treatment, lipid profiles, and other metabolic factors. Lifestyle interventions, including weight loss, are thought to reduce the risk of postpartum glucose intolerance. Careful attention should be paid to the screening of postpartum glucose intolerance in women with GDM, and concerted efforts should be made to prevent or delay the development of diabetes and other metabolic disorders.

Review Article

Growth Hormone, Not Simply Just a Hormone for Growth: Kevin C. J. Yuen, Jaime Guevara-Aguirre, John J. Kopchick; Received November 21, 2025 Accepted December 18, 2025 Published online February 3, 2026; DOI: https://doi.org/10.3803/EnM.2025.2806 [Epub ahead of print]

289 View
51 Download

Abstract PDF: Since its discovery almost 100 years ago, growth hormone (GH) has been extensively studied to elucidate its structural characteristics, receptor interactions and its physiologic and non-physiologic effects. These actions include but are not limited to its effects on somatic growth, substrate metabolism, body composition, bone mineral density, cardiovascular system, and cognitive function. Contextually, recombinant human GH was approved for growth promotion in children and to enhance metabolic health in adult patients with GH deficiency (GHD), along with other clinical indications. Studies involving individuals and animal models exhibiting dysregulated GH levels, ranging from complete or partial GHD to GH excess, have unveiled a spectrum of several less evident GH actions. In this review, we exclude discussing the classic GH therapeutic applications but instead focus on the interplay between GH and glucose metabolism, fibrosis, and carcinogenesis that is observed with varying GH levels and action. We also discuss clinical data derived from studies in acromegaly and GHD patients (including individuals with congenital GH and insulin-like growth factor I [IGF-I] deficiencies), and attempt to integrate findings from cellular, animal and human studies with the aim of highlighting novel characteristics and underlying molecular pathways through which both GH and IGF-I exert their more subtle actions.

Original Article

Global Burden of Early-Onset Cancers Attributable to Metabolic Risk Factors from 1990 to 2021 and Projections to 2040: Wenmei Qiao, Kaijian Zhou, Liang He, Jiahui Guo, Qiqiang Guo, Jing Zhang, Yongze Li; Received July 24, 2025 Accepted October 21, 2025 Published online January 5, 2026; DOI: https://doi.org/10.3803/EnM.2025.2577 [Epub ahead of print]

435 View
19 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Early-onset cancers (diagnosed in individuals under 50 years of age) are increasingly contributing to the global cancer burden. Among the known contributors, specific metabolic risk factors—namely high body mass index (BMI) and high fasting plasma glucose (FPG)—have emerged as significant determinants. This study assessed the global burden of early-onset cancers attributable to these two metabolic risk factors and projected their trends through 2040.
Methods
Using data from the Global Burden of Disease 2021 study, we analyzed mortality, disability-adjusted life years (DALYs), and estimated annual percentage changes for early-onset cancers linked to metabolic risk factors, stratified by age, sex, and sociodemographic index (SDI). Future trends were projected based on these data.
Results
In 2021, the two metabolic risk factors (high FPG and high BMI) together accounted for 34,112 (95% uncertainty interval [UI], 15,037 to 54,888) deaths and 1,691,418 (95% UI, 762,923 to 2,698,657) DALYs from early-onset cancers, corresponding to mortality and DALY rates of 0.9 (95% UI, 0.4 to 1.4) and 42.8 (95% UI, 19.3 to 68.3) per 100,000 population, respectively. Between 1990 and 2021, both mortality and DALY rates rose significantly, with the greatest increases observed in individuals aged 30–34 years and in low-middle SDI regions. High FPG and high BMI were the leading contributors, with colorectal cancer showing the highest burden and liver cancer the most rapid growth. While high BMI predominated in most SDI regions, high FPG was more prominent in low-SDI countries, particularly among females. Projections indicate a continued rise in mortality and DALY rates through 2040.
Conclusion
High BMI and high FPG are major contributors to the global burden of early-onset cancers, with marked sex and socioeconomic disparities necessitating targeted interventions. Urgent strategies are required to mitigate metabolic risks and enhance early cancer detection, especially among vulnerable populations.

Review Article

Diabetes, obesity and metabolism
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration: Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh; Endocrinol Metab. 2025;40(6):851-865. Published online December 24, 2025; DOI: https://doi.org/10.3803/EnM.2025.2786

1,365 View
61 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as paradigm-shifting therapeutics that extend beyond glycemic regulation, to conferring profound hepatometabolic benefits. This review delineates the multifaceted mechanisms underlying metabolic dysfunction-associated steatotic liver disease (MASLD), with an emphasis on systemic metabolic remodeling, mitochondrial protection, and intracellular calcium restoration. By promoting glucosuria-induced energy depletion, SGLT2 inhibition alleviates insulin resistance, suppresses hepatic lipogenesis, and activates adenosine monophosphate-activated protein kinase (AMPK)–sirtuin 1 (SIRT1)–peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α pathways that reprogram hepatocellular metabolism toward achieving lipid oxidation and autophagy. Mechanistically, SGLT2 inhibitors restore intracellular Ca²⁺ homeostasis via sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) activation, mitigating endoplasmic reticulum (ER) stress and normalizing Ca²⁺–phosphoinositide (PIP)–protein kinase B (AKT) signaling, collectively reinforcing insulin responsiveness and ER-mitochondrial crosstalk. Clinically, these effects translate into consistently reducing hepatic fat, aminotransferases, and fibrosis markers in both diabetic and nondiabetic patients with MASLD. Furthermore, SGLT2 inhibitors uniquely integrate renal energy regulation with hepatic resilience through the Ca²⁺–PIP–SERCA axis, positioning them as prototype systemic modulators of metabolic homeostasis. Future translational efforts should refine patient stratification using metabolomic and Ca²⁺-imaging biomarkers to delineate therapeutic responders and advance next-generation SGLT2 analogs targeting Ca²⁺-dependent metabolic signaling. Collectively, SGLT2 inhibitors represent a new metabolic therapeutic class that unify glucose, lipid, and Ca²⁺ regulation to restore hepatocellular functions in metabolic liver diseases.

Citations

Citations to this article as recorded by

Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation
Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo
Biology.2026; 15(2): 148. CrossRef

Original Articles

Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol: Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin; Received July 26, 2025 Accepted October 13, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2579 [Epub ahead of print]

1,010 View
42 Download

Abstract PDF PubReader ePub: Background
Stage 2 or 3 connected insulin pens (CIPs) refer to tracking insulin pens that are capable of transmitting insulin dose data via cloud connectivity. Stage 4 CIPs feature a bolus calculator that determines appropriate insulin doses based on real-time continuous glucose monitoring (CGM) data, carbohydrate intake, previous dosing history, and preset parameters. Stage 5 CIPs additionally offer advanced decision-support features, such as education modules and coaching. However, the efficacy and safety of Stage 5 CIPs have not yet been established.
Methods
In this prospective, open-label, parallel-group, multicenter, randomized controlled trial, we will include adults aged ≥19 and <75 years with type 1 or type 2 diabetes receiving multiple daily insulin injections (MDI) and having glycosylated hemoglobin (HbA1c) levels of 7.5% to 12.0%. In total, 152 participants will be randomized in a 1:1 ratio to receive either Stage 5 CIPs with CGM or tracking insulin pens with CGM. Stage 5 CIPs include a Setup Wizard that recommends individualized initial settings and an algorithm that provides advanced insulin dosing guidance based on analyses of each participant’s CGM and insulin injection data. The primary outcome will be the change in HbA1c levels from baseline to week 12 (ClinicalTrials.gov, NCT07004153).
Conclusion
This trial will determine whether Stage 5 CIPs are superior to tracking insulin pens in improving glycemic control among adults with type 1 or type 2 diabetes treated with MDI. Overall, this study may offer a promising strategy for enhancing the management and outcomes of patients with diabetes.

Impact of Carbohydrate Intake Fluctuations on Glucose Profiles: Insights from Continuous Glucose Monitoring-Based Patient Clustering: Hyun Ah Kim, Kyung Hee Kim, Young Lee, Yoon-Ju Song, Joon Ho Moon, Sung Hee Choi, Tae Jung Oh; Received June 4, 2025 Accepted September 15, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2486 [Epub ahead of print]

495 View
34 Download

Abstract PDF PubReader ePub: Background
Continuous glucose monitoring (CGM) is widely applied in daily glucose management. However, its potential to categorize individuals based on glucose profiles is not fully established. This study employed CGM-based patient clustering and examined nutritional factors influencing glucose patterns.
Methods
This prospective observational study enrolled 34 individuals with diabetes. Retrospective professional CGM was conducted over 7 days, during which food intake was recorded. K-means clustering was performed using CGM-derived coefficient of variation (CV) and time in range. Macronutrient intake and its fluctuations were compared across clusters.
Results
Participants were grouped into cluster 1 (well-controlled), cluster 2 (highest CV), and cluster 3 (highest mean glucose). Baseline clinical characteristics, daily energy intake (kcal), and macronutrient intake did not differ significantly among clusters. However, carbohydrate intake fluctuations were greater in cluster 3 (CV 41.0%±32.1%, standard deviation [SD] 502.1±363.4 kcal) than in cluster 1 (CV 21.9%±9.0%, SD 260.2±94.1 kcal) and cluster 2 (CV 19.2%±9.1%, SD 250.2±126.1 kcal) (P=0.123 for CV; P=0.024 for SD). The SD (kcal) of carbohydrate intake was positively correlated with mean glucose levels (rho=0.88, P=0.023).
Conclusion
CGM enables categorization of individuals based on glucose profiles, and higher carbohydrate intake fluctuations are associated with poorer glycemic control. Personalized dietary strategies, particularly stabilizing carbohydrate intake, may support better glucose management in individuals with high mean glucose and low CV.

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Impact of Glucose Metabolism Status on the Association between Apolipoprotein A-I and Ischemic Risk in Patients with Coronary Artery Disease: A Large-Sample Cohort Study: Kailun Yan, Jiawen Li, Kexin Zhang, Menglu Liu, Pei Zhu, Xiaofang Tang, Deshan Yuan, Yuejin Yang, Runlin Gao, Jinqing Yuan, Xueyan Zhao; Endocrinol Metab. 2025;40(6):904-915. Published online November 7, 2025; DOI: https://doi.org/10.3803/EnM.2025.2407

776 View
28 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Apolipoprotein A-I (ApoA-I) is a key cardioprotective lipoprotein. Nevertheless, it remains unclear how ApoA-I relates to ischemic risk across glucose metabolism statuses in patients with coronary artery disease (CAD). This study investigated whether glucose metabolism status influences the association between ApoA-I and ischemic risk in CAD patients.
Methods
This cohort study included 10,724 consecutive CAD patients undergoing percutaneous coronary intervention, who were classified into diabetes mellitus (DM), pre-DM, and normal glucose regulation (NGR) groups. The primary clinical endpoint was major adverse cardiac and cerebrovascular event (MACCE), defined as a composite of all-cause death, myocardial infarction, revascularization, and stroke.
Results
Of the 10,232 patients ultimately included, 2,139 (20.9%) experienced MACCE over 5 years. A significant interaction was observed between ApoA-I levels and glucose metabolism status (P for interaction=0.041). In the DM group, an L-shaped association between ApoA-I and MACCE was found, with lower ApoA-I levels linked to a higher risk of MACCE (P for non-linearity= 0.044). Multivariate Cox regression analysis showed that patients in the lowest quintile of ApoA-I had a 1.327-fold increased risk of MACCE compared to those at the lowest risk (hazard ratio, 1.327; 95% confidence interval, 1.097 to 1.604). However, no significant association was observed in the pre-DM or NGR groups (both P>0.05).
Conclusion
This large-scale, 5-year follow-up study is the first to demonstrate that lower ApoA-I levels are associated with increased MACCE risk in CAD patients with DM, highlighting the potential value of ApoA-I in risk stratification and as a therapeutic target.

Effects of Progranulin Deficiency on Inflammation and Fibrosis in the Kidneys and Liver of Diabetic Mice Fed a High-Fat Diet: Hiroko Sakuma, Maki Murakoshi, Shinji Hagiwara, Terumi Shibata, Yusuke Suzuki, Tomohito Gohda; Received February 6, 2025 Accepted July 23, 2025 Published online September 30, 2025; DOI: https://doi.org/10.3803/EnM.2025.2339 [Epub ahead of print]

1,137 View
56 Download
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Progranulin (PGRN) is an important regulator of inflammation, insulin resistance, and autophagy. However, the effects of PGRN deficiency on these processes in the kidneys and liver in diabetes remain unclear. In addition, the differential effects of PGRN deficiency and sodium-glucose co-transporter-2 (SGLT2) inhibitors on these organs are unknown.
Methods
Three diabetic mouse models were used: high-fat diet and nicotinamide/streptozotocin-induced diabetic wild-type (WT) and PGRN-knockout (KO) mice (WT-diabetes mellitus [DM] and KO-DM, respectively) and WT-DM mice treated with an SGLT2 inhibitor (tofogliflozin; WT-DM/Tofo).
Results
Despite similar glycemic control in WT-DM/Tofo and KO-DM mice, expression of inflammation- and fibrosis-related genes in the kidneys was highest in WT-DM mice, lower in KO-DM mice, and lowest in WT-DM/Tofo mice. WT-DM/Tofo mice also showed increased anti-microtubule-associated protein 1A/1B-light chain 3B and decreased p62 protein levels compared with KO-DM mice. In contrast, hepatic mRNA levels related to inflammation and fibrosis were improved in both WT-DM/Tofo and KO-DM mice. Moreover, hepatic protein levels of peroxisome proliferator-activated receptor γ (PPARγ) were elevated in both groups compared with WT-DM mice, while those of PPARα were increased in WT-DM/Tofo mice compared with both WT-DM and KO-DM mice.
Conclusion
Kidney inflammation and fibrosis were ameliorated in WT-DM/Tofo mice, but these improvements were limited by autophagy insufficiency in KO-DM mice. Additionally, both WT-DM/Tofo and KO-DM mice demonstrated improved liver inflammation and fibrosis; in the former, this was associated with enhanced fatty acid oxidation via PPARα activation, while in the latter, it appeared to result from improved insulin sensitivity and anti-inflammatory effects through PPARγ activation.

Citations

Citations to this article as recorded by

Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy
Chiaki Kishida, Maki Murakoshi, Hiroko Sakuma, Terumi Shibata, Yusuke Suzuki, Tomohito Gohda
Journal of the Endocrine Society.2026;[Epub] CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
Endocrinology and Metabolism.2025; 40(6): 851. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study: Mi-sook Kim, Kyu-Na Lee, Jeongmin Lee, Jeongeun Kwak, Seung-Hwan Lee, Hyuk-Sang Kwon, Jing Hughes, Kyung-Do Han, Eun Young Lee; Endocrinol Metab. 2025;40(5):718-726. Published online May 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2271

3,727 View
92 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the association between the triglyceride-glucose (TyG) index, a marker of insulin resistance, and the risk of end-stage renal disease (ESRD) in individuals with type 2 diabetes mellitus (T2DM), focusing on variations by diabetes duration.
Methods
We analyzed 1,219,148 Korean adults with T2DM from National Health Insurance Service data who underwent biennial health evaluations (2015 to 2016). ESRD was defined using specific procedural codes (V codes), and Cox proportional hazard models were employed to estimate hazard ratios (HRs) for ESRD across TyG index quartiles and diabetes duration categories, adjusting for various confounders.
Results
Over 6,967,381 person-years of follow-up, 7,548 participants developed ESRD. Higher TyG index quartiles were independently associated with increased risk of ESRD, which was more pronounced with longer diabetes duration. The adjusted HR for ESRD in the highest TyG quartile (Q4) compared to the lowest quartile (Q1) was 1.235 (95% confidence interval [CI], 0.995 to 1.533) in new-onset diabetes, and 1.592 (95% CI, 1.465 to 1.730) in those with diabetes for ≥10 years. Compared to the lowest TyG quartile in new-onset diabetes, the adjusted HR for ESRD in the highest quartile with diabetes duration ≥10 years increased to 10.239 (95% CI, 8.440 to 12.422). Subgroup analysis revealed that a higher TyG index consistently increased the risk of ESRD, with stronger associations observed in younger individuals and those without comorbidities.
Conclusion
The TyG index is a significant predictor of ESRD in T2DM, particularly in those with prolonged diabetes duration. Targeting insulin resistance early may mitigate the risk of ESRD in this population.

Citations

Citations to this article as recorded by

Association between TYG-BMI index and asthma in adults over 45 years of age: analysis of Global Burden of Disease 2021, China Health and Retirement Longitudinal Study, and National Health and Nutrition Examination Survey data
Zhuolin Qin, Longqian Li, Cheng Wang
Journal of Asthma.2026; 63(2): 214. CrossRef

Review Article

Diabetes, obesity and metabolism
Advances in Continuous Glucose Monitoring: Clinical Applications: So Yoon Kwon, Jun Sung Moon; Endocrinol Metab. 2025;40(2):161-173. Published online April 8, 2025; DOI: https://doi.org/10.3803/EnM.2025.2370

20,382 View
618 Download
10 Web of Science
15 Crossref

Abstract PDF PubReader ePub

Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management, with benefits extending beyond traditional glucose monitoring approaches. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. While skin-related complications remain a concern, technological advancements have addressed many initial concerns. High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures. With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care.

Citations

Citations to this article as recorded by

Advancements in glucose biosensors: Innovations for wearable and real-time monitoring
Reetu Singh, Priyanshu Nema, Arpana Purohit, Satyamshyam Vishwakarma, Shyamji Tantuway, Pradhumn Namdeo, Ajay Kumar, Vandana Soni, Sushil Kumar Kashaw
Talanta.2026; 299: 129045. CrossRef
Continuous glucose monitoring in high-risk individuals
Zhiyue Chen, Yinbei Zhang, Lin Sun, Weiying Guo
Clinica Chimica Acta.2026; 580: 120733. CrossRef
Scoping review of subcutaneous glucose monitoring techniques
Eva Hrubá, Jan Kubíček, Martin Augustynek
Measurement.2026; 261: 119940. CrossRef
Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus
Mohammed Almehthel, Abdulghani Al-Saeed, Fahad Al-Sabaan, Faisal Al-Malky, Hawazen Zarif, Lamya Al-Zubaidi, Mohammed E. Al-Sofiani, Omar Abdulaal, Reem Al Argan, Saud Al Sifri, Turki Al-Harbi, Raed Aldahash
Frontiers in Endocrinology.2026;[Epub] CrossRef
Wearable microneedle sensors for continuous interstitial fluid monitoring
Junghyun Cho, Heeju Son, Jayoung Kim, Hyun Seok Song, Wonryung Lee
Biosensors and Bioelectronics.2026; 297: 118385. CrossRef
Efficacy of an AI-Enabled Low Glucose Prediction: A Pooled Performance Analysis With Capillary Blood Glucose as Ground Truth
Timor Glatzer, Ajandek Peak, Eemeli Leppäaho, Patrick Lustenberger, Pau Herrero, Magí Andorrà, Ellen van Maren
Journal of Diabetes Science and Technology.2026;[Epub] CrossRef
Respiratory Signal Processing and Analysis Using Flexible Capacitive Sensor Data
Bernardo A. Vicente, Raquel Sebastião, Alda Marques, Vitor Sencadas
Advanced Materials Technologies.2026;[Epub] CrossRef
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: A cross-sectional study
Ji Yoon Kim, Seohyun Kim, Sang Ho Park, Jin A Lee, So Hyun Cho, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin
Diabetes Research and Clinical Practice.2025; 226: 112325. CrossRef
Advancements in Continuous Glucose Monitoring: a Revolution in Diabetes Management
Kondreddy Vinod Kumar, Kamal Raj Yerraguntla, Maruthi Prasad Jenne, Abhilash Gadi, Akhila Sepoori, Anusha Gunda, Madhu Sri Gudivada
Biomedical Materials & Devices.2025;[Epub] CrossRef
SMART CARE FOR DIABETES: INTEGRATING TECHNOLOGY AND LIFESTYLE FOR BETTER OUTCOMES
Aleksandra Maciejczyk, Katarzyna Krupa, Weronika Głowacz, Janusz Świeczkowski-Feiz
International Journal of Innovative Technologies in Social Science.2025;[Epub] CrossRef
Identification of clinically meaningful automatically detected postprandial glucose excursions in individuals with type 1 diabetes using personal continuous glucose monitoring
Sang Ho Park, Rosa Oh, Seohyun Kim, Seung Hee Yang, Hanna Lee, Ji Yoon Kim, So Hyun Cho, Soojin Park, Gyuri Kim, Jae Hyeon Kim, Sang–Man Jin
Diabetes Research and Clinical Practice.2025; 229: 112951. CrossRef
Bridging the digital divide: student-led literacy initiatives in diabetes management
Pedro Almeida Moyano, Mohammed Raddaoui, Andrea de Barros Coscelli Ferraz, Gustavo José Martiniano Porfírio, Luciana Aparecida Campos, Ovidiu Constantin Baltatu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Continuous Glucose Monitoring for Pancreatogenic Diabetes After Total Pancreatectomy
Young Jae Cho, Inhyuck Lee, Yoon Soo Chae, Go‐Won Choi, Younsoo Seo, Youngmin Han, Hye‐sol Jung, Wooil Kwon, Joon Seong Park, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2025;[Epub] CrossRef
Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol
Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin
Endocrinology and Metabolism.2025;[Epub] CrossRef
Evolution and Future of Glucose Monitoring: From Blood Glucose Meters to Continuous Systems and Their Projected Impact in the Middle East and North Africa (MENA) Region
Omar Darkhabani, Abdalla Ahmed
Cureus.2025;[Epub] CrossRef

Original Articles

Diabetes, obesity and metabolism
Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction: Ji Eun Jun, Kyoung-Ah Kim, Nan-Hee Kim, Kwan-Woo Lee, In-Kyung Jeong, on Behalf of the BEYOND Investigators; Endocrinol Metab. 2025;40(2):278-288. Published online March 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2142

4,399 View
143 Download
2 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces hyperglycemia and obesity by inhibiting renal glucose reabsorption. This post hoc study evaluated clinical factors influencing patient response to dapagliflozin.
Methods
The analysis focused on patients treated with dapagliflozin (10 mg/day for 52 weeks) within the randomized, double-blind, parallel-group BEYOND trial. Adequate glycemic control (GC) was defined as a reduction in glycated hemoglobin (HbA1c) of ≥ 1.0% or the achievement of an HbA1c level <7.0% at week 52. Significant weight loss (WL) referred to a reduction in body weight of ≥3.0% at week 52. Participants were classified into four groups based on their GC and WL responses: GC+/WL+, GC+/WL−, GC−/WL+, and GC−/WL−.
Results
Among dapagliflozin recipients (n=56), at 52 weeks, HbA1c had decreased by 1.0%±0.8% from baseline, while body weight had declined by 2.4±3.1 kg. Overall, 69.6% of participants achieved GC+, and 57.1% achieved WL+. Male sex and shorter diabetes duration were significantly associated with achieving GC+. Conversely, higher estimated glomerular filtration rate was significantly linked to WL+. The only factor significantly associated with both GC+ and WL+ was shorter diabetes duration (odds ratio, 0.81; 95% confidence interval, 0.68 to 0.97; P=0.023). The GC+ and WL+ groups exhibited favorable responses beginning soon after dapagliflozin therapy was initiated. Furthermore, HbA1c decline was more strongly associated with reduction in visceral fat than with WL.
Conclusion
A short duration of diabetes and early response to treatment appear to represent key factors in maximizing the benefits of dapagliflozin for blood glucose and weight management.

Citations

Citations to this article as recorded by

A Pre‐Post Assessment of Blood Glucose Control Following Pharmacist‐Led Professional Continuous Glucose Monitoring in Rhode Island Primary Care Practices
Kelley Doherty Sanzen, Natalya S. Salganik, Susanne M. Campbell, Carolyn A. Karner, Pano M. Yeracaris, Stephen J. Kogut
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2026;[Epub] CrossRef
Identification of IL18/IL18R1 signaling as a predictive biomarker of SGLT2 inhibitor efficacy in type 2 diabetes
I-Jou Teng, Chien-Hsing Lee, Ying-Chen Chen, Sheng-Chiang Su, Chieh-Hua Lu, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Ming-Hsun Lin, Hsin-Ya Liu, Feng-Chih Kuo
iScience.2025; 28(10): 113594. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2025;[Epub] CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Association between the Triglyceride-Glucose Index and Cardiovascular Risk and Mortality across Different Diabetes Durations: A Nationwide Cohort Study: Jeongeun Kwak, Kyung-Do Han, Eun Young Lee, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Jeongmin Lee; Endocrinol Metab. 2025;40(4):548-560. Published online March 5, 2025; DOI: https://doi.org/10.3803/EnM.2024.2205

4,210 View
237 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to assess the association between triglyceride-glucose (TyG) index and cardiovascular disease (CVD) risk and mortality in a large cohort of diabetes patients.
Methods
A retrospective cohort study of 1,090,485 participants from the Korean National Health Insurance Service database was conducted. Participants were stratified into TyG quartiles.
Results
Higher TyG index quartiles were significantly associated with an increased CVD risk and mortality risk. In fully adjusted models, participants in the highest TyG quartile (Q4) had an 18% higher risk of CVD (hazard ratio [HR], 1.18; 95% confidence interval [CI], 1.13 to 1.23) and a 16% higher risk of mortality (HR, 1.16; 95% CI, 1.11 to 1.23) compared to those in the lowest quartile (Q1). The association was particularly pronounced in patients with fasting glucose ≥126 mg/dL (CVD [HR, 1.33; 95% CI, 1.29 to 1.37], mortality [HR, 1.23; 95% CI, 1.20 to 1.26]; P for interaction <0.001). Patients with a diabetes duration of ≥10 years showed the strongest association between the TyG index and CVD risk (HR, 1.44; 95% CI, 1.38 to 1.50), while the mortality risk was particularly elevated in those with a diabetes duration of less than 5 years (HR, 1.23; 95% CI, 1.18 to 1.30). Subgroup analyses revealed stronger associations between TyG index and CVD risk in younger participants, non-obese individuals, and non-smokers.
Conclusion
The TyG index is a significant predictor of CVD and mortality in diabetic patients, particularly in those with poor glycemic control or longer disease duration.

Citations

Citations to this article as recorded by

Preoperative triglyceride–glucose index as a metabolic predictor of surgical site infection after posterior lumbar fusion
Yu Hua, Shaoxing Li, Yuan Jiang, Jinwang Liu
Journal of Orthopaedic Surgery.2026;[Epub] CrossRef
Combined effect of triglyceride-glucose index and glucose disposal rate on cardio-cerebrovascular disease
Hongfei Yang, Chao Sun, Ya Li, You Zhou, Rui Wang, Yingxue Li, Marwan Salih Al-Nimer
PLOS One.2026; 21(2): e0342154. CrossRef
The Triglyceride-Glucose Index: A Practical Tool for Enhanced Cardiovascular Risk Stratification in Type 2 Diabetes
Jang Won Son
Endocrinology and Metabolism.2025; 40(4): 545. CrossRef
The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses
Jiajun Liu, Jinhua Kang, Pengpeng Liang, Zhangxiao Song, Guiyun Li, Xueshan Jin, Hongyan Wu
Cardiovascular Diabetology.2025;[Epub] CrossRef
Standardized Triglyceride-Glucose and Plasma Atherogenic Indices as Predictors of Diabetic Nephropathy and Coronary Artery Disease in Patients with Type 1 Diabetes Mellitus
Nazif Yalçın, Nizameddin Koca
European Journal of Therapeutics.2025;[Epub] CrossRef

Diabetes, obesity and metabolism
Plasma C-Peptide Levels and the Continuous Glucose Monitoring-Defined Coefficient of Variation in Risk Prediction for Hypoglycemia in Korean People with Diabetes Having Normal and Impaired Kidney Function: So Yoon Kwon, Jiyun Park, So Hee Park, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin; Endocrinol Metab. 2025;40(2):268-277. Published online February 27, 2025; DOI: https://doi.org/10.3803/EnM.2024.2083

3,912 View
88 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to investigate the predictive values of plasma C-peptide levels and the continuous glucose monitoring (CGM)-defined coefficient of variation (CV) in risk prediction for hypoglycemia in Korean people with diabetes with normal and impaired kidney function.
Methods
We analyzed data from 1,185 participants diagnosed with type 1 and type 2 diabetes who underwent blinded professional CGM between January 2009 and May 2021 at outpatient clinics. We explored correlations among CGM-defined CV, plasma C-peptide levels, and time below range at <70 and 54 mg/dL across different kidney function categories.
Results
In patients with chronic kidney disease (CKD) stages 1–2 (n=934), 89.3% who had a random plasma C-peptide level higher than 600 pmol/L exhibited a CV of ≤36%. Among those in CKD stage 3 (n=161) with a random plasma C-peptide level exceeding 600 pmol/L, 66.7% showed a CV of ≤36%. In stages 4–5 of CKD (n=90), the correlation between random C-peptide levels and CV was not significant (r=–0.05, P=0.640), including cases with a CV greater than 36% despite very high random plasma C-peptide levels. Random plasma C-peptide levels and CGM-assessed CV significantly predicted hypoglycemia in CKD stages 1–2 and 1–5, respectively.
Conclusion
The established C-peptide criteria in Western populations are applicable to Korean people with diabetes for hypoglycemic risk prediction, unless kidney function is impaired equivalent to CKD stage 3–5. The CGM-defined CV is informative for hypoglycemic risk prediction regardless of kidney function.

Citations

Citations to this article as recorded by

Continuous glucose monitoring in high-risk individuals
Zhiyue Chen, Yinbei Zhang, Lin Sun, Weiying Guo
Clinica Chimica Acta.2026; 580: 120733. CrossRef
The evolution of C-peptide's role in diabetes care
Laura Briggs, Alexander Read, Sarah Darch, Emma L. Williams, Wann Jia Loh, Julia S. Kenkre
Current Opinion in Endocrinology, Diabetes & Obesity.2026; 33(1): 16. CrossRef
Plasma C-Peptide Level and Continuous Glucose Monitoring-Derived Coefficient of Variation as a Predictable Risk Factor for Hypoglycemia in Koreans with Diabetes
Seung-Hyun Ko
Endocrinology and Metabolism.2025; 40(2): 198. CrossRef
Beneficial Role of Increased Glucose Infusion in Decompensated Type 2 Diabetes Patient
Marie Ticha, Ondrej Sobotka, Pavel Skorepa, Lubos Sobotka
Diabetology.2025; 6(6): 47. CrossRef

Review Articles

Diabetes, obesity and metabolism
Brown Fat and Metabolic Health: The Diverse Functions of Dietary Components: Zachary Brown, Takeshi Yoneshiro; Endocrinol Metab. 2024;39(6):839-846. Published online November 20, 2024; DOI: https://doi.org/10.3803/EnM.2024.2121

24,305 View
149 Download
2 Web of Science
2 Crossref

Abstract PDF PubReader ePub

Brown and beige adipocytes utilize a variety of substrates for cold-induced thermogenesis, contributing to the clearance of metabolites in circulation and, consequently, metabolic health. Food-derived compounds that exhibit agonistic activity at temperature-sensitive transient receptor potential channels may serve as cold mimics to elicit thermogenesis and substrate utilization in brown adipose tissue (BAT). In addition to fatty acids and glucose, branched-chain amino acids (BCAAs), which are essential amino acids obtained from foods, are actively catabolized in BAT through mitochondrial BCAA carrier (MBC). The relative contribution of BCAAs to fueling the tricarboxylic acid cycle as a substrate (i.e., anaplerosis) is estimated to be relatively small, yet BCAA catabolism in BAT exerts a critical role in systemic insulin sensitivity. The nature of this apparent tension remained unclear until the recent discovery that active BCAA catabolism in BAT through MBC is critical for the synthesis of metabolites such as glutathione, which is delivered to the liver to improve hepatic insulin sensitivity through redox homeostasis. Novel mechanistic insights into the control of BAT function and systemic metabolism reveal the therapeutic potential of food-derived compounds for improving metabolic flexibility and insulin sensitivity.

Citations

Citations to this article as recorded by

Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review
Gayatri Thapa, Pervej Alom Barbhuiya, Manash Pratim Pathak
Current Nutrition Reports.2026;[Epub] CrossRef
Beyond Calories: Redox Interactions in Adipose Tissue That Lead to Metabolic Pathologies
Alfredo Miranda-Martínez, Erika Rodríguez-Martínez, Pamela Barragán-Reséndiz, Selva Rivas-Arancibia
Physiologia.2025; 5(4): 50. CrossRef

Diabetes, obesity and metabolism
Regulation of Energy and Glucose Homeostasis by the Nucleus of the Solitary Tract and the Area Postrema: Kyla Bruce, Ameth N. Garrido, Song-Yang Zhang, Tony K.T. Lam; Endocrinol Metab. 2024;39(4):559-568. Published online August 1, 2024; DOI: https://doi.org/10.3803/EnM.2024.2025

6,995 View
248 Download
7 Web of Science
8 Crossref

Abstract PDF PubReader ePub

The central nervous system regulates feeding, weight and glucose homeostasis in rodents and humans, but the site-specific mechanisms remain unclear. The dorsal vagal complex in the brainstem that contains the nucleus of the solitary tract (NTS) and area postrema (AP) emerges as a regulatory center that impacts energy and glucose balance by monitoring hormonal and nutrient changes. However, the specific mechanistic metabolic roles of the NTS and AP remain elusive. This mini-review highlights methods to study their distinct roles and recent findings on their metabolic differences and similarities of growth differentiation factor 15 (GDF15) action and glucose sensing in the NTS and AP. In summary, future research aims to characterize hormonal and glucose sensing mechanisms in the AP and/or NTS carries potential to unveil novel targets that lower weight and glucose levels in obesity and diabetes.

Citations

Citations to this article as recorded by

Region-Specific Adult Neural Stem Cell Niches of the Mediobasal Hypothalamus and Medulla Oblongata
Eriko Furube, Rena Fujii, Yuri Nambu, Daishi Hiratsuka, Ryoichi Yoshimura, Seiji Miyata
Stem Cell Reviews and Reports.2026; 22(1): 222. CrossRef
Adipocyte-derived extracellular vesicles are key regulators of central leptin sensitivity and energy homeostasis
Jin Wang, Xuhong Zhang, Ye Zhu, Haixiang Sun, Xuetao Chen, Zhicong Zhao, Nina Zhang, Chenyu Zhang, Liang Li, Yan Bi
Cell Metabolism.2026; 38(1): 82. CrossRef
Brain circadian clocks timing the 24h rhythms of behavior
Jorge Mendoza
npj Biological Timing and Sleep.2025;[Epub] CrossRef
Hypothalamus and brainstem circuits in the regulation of glucose homeostasis
Zitian Lin, Yunxin Xuan, Yingshi Zhang, Qirui Zhou, Weiwei Qiu
American Journal of Physiology-Endocrinology and Metabolism.2025; 328(4): E588. CrossRef
Global Clock Coordination by the Brain Clock in the Suprachiasmatic Nucleus Through Relay and Amplification of Diffusible and Neural Signaling
Rae Silver, Yifan Yao, Jihwan Myung
European Journal of Neuroscience.2025;[Epub] CrossRef
The brainstem BBSome regulates glucose homeostasis and lean mass in a state-dependent manner
Connor Laule, Deng-Fu Guo, Yuying Zhao, Paul A. Williams, Donald A. Morgan, Younes Rouabhi, Miriam McDonough, Trevor Butler, Jon Resch, Kamal Rahmouni
Molecular Metabolism.2025; 100: 102222. CrossRef
Regional adiposity shapes brain and cognition in adults
Die Zhang, Yingji Fu, Chenye Shen, Chaoqiang Liu, Nanguang Chen, Hua Cao, Kui Kai Lau, Anqi Qiu
Nature Mental Health.2025; 3(10): 1168. CrossRef
Central and peripheral neural circuits regulating glucose homeostasis
Diego Espinoza, Finn Seibold, Sarah Stanley
npj Biomedical Innovations.2025;[Epub] CrossRef

Brief Report

Diabetes, obesity and metabolism
Ketonuria as an Indicator of Improvement of Renal Function in Patients with Type 2 Diabetes Receiving SGLT2 Inhibitor Treatment: Hyun Ah Kim, Han Na Jang, Sung Hye Kong, Young Lee, Sung Hee Choi, Young Min Cho, Hak Chul Jang, Tae Jung Oh; Endocrinol Metab. 2024;39(4):653-658. Published online May 16, 2024; DOI: https://doi.org/10.3803/EnM.2024.1919

5,574 View
156 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

We investigated the potential association between ketonuria during treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors and its renoprotective effect in patients with type 2 diabetes. We included 192 patients who had received SGLT2 inhibitors for more than 6 months. After propensity score matching, 52 patients each were allocated into groups with or without ketonuria, respectively. The estimated glomerular filtration rate exhibited a significant improvement only in subjects with ketonuria (without ketonuria: mean difference, –0.02 mL/min/1.73 m² [95% confidence interval (CI), –3.87 to 3.83 mL/min/1.73 m²] vs. with ketonuria: mean difference, 6.81 mL/min/1.73 m² [95% CI, 3.16 to 10.46 mL/min/1.73 m²]; P<0.001). Improvement in estimated glomerular filtration rate at 6 months was associated with female sex and lower baseline body weight, blood pressure, and triglyceride levels in patients with ketonuria. In conclusion, the presence of ketonuria was associated with the renoprotective effect of SGLT2 inhibitors, and female sex and the absence of metabolic syndrome components may serve as additional indicators of these medications’ substantial renoprotective effects in individuals with ketonuria.

Citations

Citations to this article as recorded by

Effects of a continuous remote care intervention including nutritional ketosis on kidney function and inflammation in adults with type 2 diabetes: a post-hoc latent class trajectory analysis
Shaminie J. Athinarayanan, Caroline G. P. Roberts, Stephen D. Phinney, Thomas Weimbs, Allon N. Friedman, Jeff S. Volek
Frontiers in Nutrition.2025;[Epub] CrossRef
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
Endocrinology and Metabolism.2025; 40(6): 851. CrossRef
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression
Melina Messing, Jacob A. Torres, Nickolas Holznecht, Thomas Weimbs
Nutrients.2024; 16(19): 3281. CrossRef

Original Article

Diabetes, obesity and metabolism
Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study: Jooyoung Cho, Ho-Chan Cho, Ohk-Hyun Ryu, Hyo-Jeong Kim, Chang Geun Kim, Young Ran Yun, Choon Hee Chung, on Behalf of the Task Force Team for Korean Hormone Reference Standards; Endocrinol Metab. 2024;39(3):489-499. Published online May 9, 2024; DOI: https://doi.org/10.3803/EnM.2023.1888

6,622 View
138 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The Korean Endocrine Hormone Reference Standard Data Center (KEHRS DC) has created reference standards (RSs) for endocrine hormones since 2020. This study is the first of its kind, wherein the KEHRS DC established RSs for serum Cpeptide levels in a healthy Korean population.
Methods
Healthy Korean adults were recruited from May 2021 to September 2023. After excluding participants according to our criteria, serum samples were collected; each participant could then choose between fasting glucose only or fasting glucose plus an oral glucose tolerance test (OGTT). If their sample showed high glucose (≥100 mg/dL) or hemoglobin A1c (HbA1c) (≥5.70%), their C-peptide levels were excluded from analyzing the RSs.
Results
A total of 1,532 participants were recruited; however, only the data of 1,050 participants were analyzed after excluding those whose samples showed hyperglycemia or high HbA1c. Post-30-minute OGTT data from 342 subjects and post-120-minute OGTT data from 351 subjects were used. The means±2 standard deviations and expanded uncertainties of fasting, post-30-minute and 120-minute OGTT C-peptide levels were 1.26±0.82 and 0.34–3.18, 4.74±3.57 and 1.14–8.33, and 4.85±3.58 and 1.25–8.34 ng/mL, respectively. Serum C-peptide levels correlated with obesity, serum glucose levels, and HbA1c levels.
Conclusion
The RSs for serum C-peptide levels established in this study are expected to be useful in both clinical and related fields.

Citations

Citations to this article as recorded by

Call for Standardization of C-Peptide Measurement
Erwin Schleicher, Kuanysh Kabytaev, Matthias Nauck, Dirk Müller-Wieland, Andreas Peter, Randie R. Little, Lutz Heinemann
Journal of Diabetes Science and Technology.2025;[Epub] CrossRef

Review Article

Diabetes, obesity and metabolism
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management: Jang Won Son, Soo Lim; Endocrinol Metab. 2024;39(2):206-221. Published online April 16, 2024; DOI: https://doi.org/10.3803/EnM.2024.1940

30,802 View
1,182 Download
14 Web of Science
16 Crossref

Abstract PDF PubReader ePub

Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein–coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1–glucagon and GIP–GLP-1–glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.

Citations

Citations to this article as recorded by

GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
André J. Scheen
Diabetes & Metabolism.2026; 52(1): 101708. CrossRef
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Mokhtar Rejili, Md Sadique Hussain, Yumna Khan, Faouzi Haouala, Subbulakshmi Ganesan, Samir Sahoo, Amrita Pal, Vimal Arora
Vascular Pharmacology.2026; 162: 107563. CrossRef
BIOTECHNOLOGY AND BIOENGINEERING INNOVATIONS IN PRECISION OBESITY MANAGEMENT: MECHANISTIC INSIGHTS, EMERGING PLATFORMS, AND TRANSLATIONAL PATHWAYS
MIN HO HAN, YOUN SEON HWANG, DO HYEON JIN, JIN WOO KIM
Journal of Mechanics in Medicine and Biology.2026;[Epub] CrossRef
The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan
Jonathan P. Bennett, Soo Lim
Journal of Obesity & Metabolic Syndrome.2025; 34(2): 120. CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual
Current Obesity Reports.2025;[Epub] CrossRef
Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
Kai Liu, Shu Liu, Dong Wang, Hong Qiao
Diabetes & Metabolism.2025; 51(6): 101696. CrossRef
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Mesk Alkhatib, Noor Almasri, Sakhr Alshwayyat, Hebah Almahariq, Bara M. Hammadeh, Zaid Taimeh, Lean Alkhatib, Anas Alshwayat, Nesreen A Saadeh, Mohammed Al-mahdi Al-kurdi
Future Science OA.2025;[Epub] CrossRef
Two decades of diabetes prevention: Sustained benefits, heterogeneous effects, and implications for precision prevention
Seung‐Hwan Lee
Journal of Diabetes Investigation.2025; 16(10): 1779. CrossRef
Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
Ting Jin, Yange Meng, Luping Ren, Yue Wang
Journal of Clinical Question.2025; 2(5): e90. CrossRef
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(6): 1287. CrossRef
Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation
Joyce Argaistieng, Bavani Visha Doraisamy, Hasseri Halim, Sharifah Sakinah Syed Alwi, Aida Azlina Ali, Sandra Maniam
International Journal of Obesity.2025;[Epub] CrossRef
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi
Biomedicines.2024; 12(8): 1630. CrossRef
Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
Katharina Gross, Christian Brinkmann
Frontiers in Endocrinology.2024;[Epub] CrossRef
Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients
Bandar T. Alenezi, Nadra Elfezzani, Rukhsana Uddin, Hinali Patel, Sydney Chester, Ahmed Abdelmaksoud, Mohammad H. Hussein, Sawsan A. Zaitone, Manal S. Fawzy, Hani Aiash, Eman A. Toraih
Journal of Clinical Medicine.2024; 13(16): 4896. CrossRef
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
T. I. Romantsova
Obesity and metabolism.2024; 21(4): 389. CrossRef
Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review
Anna Klasa, Aleksandra Ewa Sobaś, Kamil Biedka, Oliwia Ziobro, Katarzyna Błaszczyk, Jakub Maciej Bulski, Filip Maj, Karol Sornat, Barbara Pokora, Agata Estreicher
Medical Science Pulse.2024;[Epub] CrossRef

Original Article

Diabetes, obesity and metabolism
Effects of an Electronic Medical Records-Linked Diabetes Self-Management System on Treatment Targets in Real Clinical Practice: Retrospective, Observational Cohort Study: So Jung Yang, Sun-Young Lim, Yoon Hee Choi, Jin Hee Lee, Kun-Ho Yoon; Endocrinol Metab. 2024;39(2):364-374. Published online March 21, 2024; DOI: https://doi.org/10.3803/EnM.2023.1878; Correction in: Endocrinol Metab 2024;39(3):537

6,317 View
109 Download
2 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study evaluated the effects of a mobile diabetes management program called “iCareD” (College of Medicine, The Catholic University of Korea) which was integrated into the hospital’s electronic medical records system to minimize the workload of the healthcare team in the real clinical practice setting.
Methods
In this retrospective observational study, we recruited 308 patients. We categorized these patients based on their compliance regarding their use of the iCareD program at home; compliance was determined through self-monitored blood glucose inputs and message subscription rates. We analyzed changes in the ABC (hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol) levels from the baseline to 12 months thereafter, based on the patients’ iCareD usage patterns.
Results
The patients comprised 92 (30%) non-users, 170 (55%) poor-compliance users, and 46 (15%) good-compliance users; the ABC target achievement rate showed prominent changes in good-compliance groups from baseline to 12 months (10.9% vs. 23.9%, P<0.05), whereas no significant changes were observed for poor-compliance users and non-users (13.5% vs. 18.8%, P=0.106; 20.7% vs. 14.1%, P=0.201; respectively).
Conclusion
Implementing the iCareD can improve the ABC levels of patients with diabetes with minimal efforts of the healthcare team in real clinical settings. However, the improvement of patients’ compliance concerning the use of the system without the vigorous intervention of the healthcare team needs to be solved in the future.

Citations

Citations to this article as recorded by

Stakeholder Perspectives on Implementing DiabeText: Exploring Barriers and Facilitators for a Personalized Diabetes Self-Management SMS Intervention in Spain
Elena Gervilla-García, Patricia García-Pazo, Mireia Guillén-Solà, Federico Leguizamo, Ignacio Ricci-Cabello, María Jesús Serrano-Ripoll, Miquel Bennasar-Veny, Maria Antònia Fiol-deRoque, Escarlata Angullo-Martínez, Rocío Zamanillo-Campos
Diabetology.2026; 7(1): 17. CrossRef

Namgok Lecture 2023

Diabetes, obesity and metabolism
Hypothalamic AMP-Activated Protein Kinase as a Whole-Body Energy Sensor and Regulator: Se Hee Min, Do Kyeong Song, Chan Hee Lee, Eun Roh, Min-Seon Kim; Endocrinol Metab. 2024;39(1):1-11. Published online February 14, 2024; DOI: https://doi.org/10.3803/EnM.2024.1922

12,162 View
230 Download
8 Web of Science
8 Crossref

Abstract PDF PubReader ePub

5´-Adenosine monophosphate (AMP)-activated protein kinase (AMPK), a cellular energy sensor, is an essential enzyme that helps cells maintain stable energy levels during metabolic stress. The hypothalamus is pivotal in regulating energy balance within the body. Certain neurons in the hypothalamus are sensitive to fluctuations in food availability and energy stores, triggering adaptive responses to preserve systemic energy equilibrium. AMPK, expressed in these hypothalamic neurons, is instrumental in these regulatory processes. Hypothalamic AMPK activity is modulated by key metabolic hormones. Anorexigenic hormones, including leptin, insulin, and glucagon-like peptide 1, suppress hypothalamic AMPK activity, whereas the hunger hormone ghrelin activates it. These hormonal influences on hypothalamic AMPK activity are central to their roles in controlling food consumption and energy expenditure. Additionally, hypothalamic AMPK activity responds to variations in glucose concentrations. It becomes active during hypoglycemia but is deactivated when glucose is introduced directly into the hypothalamus. These shifts in AMPK activity within hypothalamic neurons are critical for maintaining glucose balance. Considering the vital function of hypothalamic AMPK in the regulation of overall energy and glucose balance, developing chemical agents that target the hypothalamus to modulate AMPK activity presents a promising therapeutic approach for metabolic conditions such as obesity and type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Cross-Talk Between Signaling and Transcriptional Networks Regulating Thermogenesis—Insights into Canonical and Non-Canonical Regulatory Pathways
Klaudia Simka-Lampa
International Journal of Molecular Sciences.2026; 27(2): 754. CrossRef
Neurobiological mechanisms of nicotine's effects on feeding and body weight
Ying Li, Jian Mao, Guobi Chai, Ruimao Zheng, Xingyu Liu, Jianping Xie
Neuroscience & Biobehavioral Reviews.2025; 169: 106021. CrossRef
Thermogenesis and Energy Metabolism in Brown Adipose Tissue in Animals Experiencing Cold Stress
Xuekai Zhang, Jin Xiao, Min Jiang, Clive J. C. Phillips, Binlin Shi
International Journal of Molecular Sciences.2025; 26(7): 3233. CrossRef
Gestational saccharin consumption disrupts gut-brain axis glucose homeostasis control in adolescent offspring rats in a sex-dependent manner
Beatriz Pacheco-Sánchez, Sonia Melgar-Locatelli, Raquel López-Merchán, María José Benítez-Marín, Marta Blasco-Alonso, Ernesto González-Mesa, Rubén Tovar, Pablo Rubio, Juan Suárez, Carlos Sanjuan, Fernando Rodríguez de Fonseca, Francisco Alén, Marialuisa d
Biology of Sex Differences.2025;[Epub] CrossRef
Molecular aspects of metformin’s anti-aging properties for muscle function and longevity in Drosophila melanogaster
Milind Umekar, Mohammad Qutub, Tanvi Premchandani, Amol Tatode, Jayshree Taksansde, Priyanka Singanwad, Mayur Kale, Mithun Maniyar, Ujban Md Hussain
Precision Medication.2025; 2(4): 100051. CrossRef
Paraventricular nucleus–locus coeruleus VGlut2 neural circuit regulates energy metabolism in mice
Haodong Liu, Penghui Li, Mingyang Yu, Xin Zhang, Hefeng Zhu, Yang He, Zelin Zhang, Xiaolong Li, Bingkun Teng, Jiaxin Fan, Wenchao Yang, Junzhe Yin, Qinqin Hao, Guifang Cao, Haijun Li, Shuying Liu, Yongqiang Li, Junguang Ren, Yujie Chen, Chenguang Du
Cell Death & Disease.2025;[Epub] CrossRef
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Federico Losada-Díaz, Santiago Lizarazo-Bocanegra, Juan J. Perdomo-Lugo, Sebastián A. Gutiérrez-Romero, Isabella Correa-Osio, Carlos O. Mendivil
Diabetes Therapy.2024; 15(11): 2279. CrossRef
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef

Original Article

Diabetes, obesity and metabolism
Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway: Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee; Endocrinol Metab. 2024;39(1):98-108. Published online January 3, 2024; DOI: https://doi.org/10.3803/EnM.2023.1786

6,281 View
201 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Sodium-dependent glucose cotransporter 2 (SGLT2) mediates glucose reabsorption in the renal proximal tubules, and SGLT2 inhibitors are used as therapeutic agents for treating type 2 diabetes mellitus. This study aimed to elucidate the effects and mechanisms of SGLT2 inhibition on hepatic glucose metabolism in both serum deprivation and serum supplementation states.
Methods
Huh7 cells were treated with the SGLT2 inhibitors empagliflozin and dapagliflozin to examine the effect of SGLT2 on hepatic glucose uptake. To examine the modulation of glucose metabolism by SGLT2 inhibition under serum deprivation and serum supplementation conditions, HepG2 cells were transfected with SGLT2 small interfering RNA (siRNA), cultured in serum-free Dulbecco’s modified Eagle’s medium for 16 hours, and then cultured in media supplemented with or without 10% fetal bovine serum for 8 hours.
Results
SGLT2 inhibitors dose-dependently decreased hepatic glucose uptake. Serum deprivation increased the expression levels of the gluconeogenesis genes peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), glucose 6-phosphatase (G6pase), and phosphoenolpyruvate carboxykinase (PEPCK), and their expression levels during serum deprivation were further increased in cells transfected with SGLT2 siRNA. SGLT2 inhibition by siRNA during serum deprivation induces nuclear localization of the transcription factor forkhead box class O 1 (FOXO1), decreases nuclear phosphorylated-AKT (p-AKT), and p-FOXO1 protein expression, and increases phosphorylated-adenosine monophosphate-activated protein kinase (p-AMPK) protein expression. However, treatment with the AMPK inhibitor, compound C, reversed the reduction in the protein expression levels of nuclear p- AKT and p-FOXO1 and decreased the protein expression levels of p-AMPK and PEPCK in cells transfected with SGLT2 siRNA during serum deprivation.
Conclusion
These data show that SGLT2 mediates glucose uptake in hepatocytes and that SGLT2 inhibition during serum deprivation increases gluconeogenesis via the AMPK/AKT/FOXO1 signaling pathway.

Citations

Citations to this article as recorded by

Development of Cellular Energy Metabolism During Differentiation of Human iPSCs into Cortical Neurons
Šárka Danačíková, Petr Pecina, Alena Pecinová, Jan Svoboda, David Vondrášek, Davide Alessandro Basello, Tomáš Čajka, Daniel Hadraba, Tomáš Mráček, Vladimír Kořínek, Jakub Otáhal
Molecular Neurobiology.2026;[Epub] CrossRef
Differential expression and correlation analysis of whole transcriptome for type 2 diabetes mellitus
Fang Liu, Aihong Peng, Xiaoli Zhu, Guangming Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Transcription Regulation of AgRP and POMC Genes
Dong Hee Kim, Min Jin Lee, Dasol Kang, Ah Reum Khang, Ji Hyun Bae, Joo Yeon Kim, Su Hyun Kim, Yang Ho Kang, Dongwon Yi
Current Issues in Molecular Biology.2024; 46(7): 7505. CrossRef
Sodium-glucose cotransporter 2 inhibitors ameliorate ER stress-induced pro-inflammatory cytokine expression by inhibiting CD36 in NAFLD progression in vitro
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Biochemical and Biophysical Research Communications.2024; 735: 150620. CrossRef

Brief Report

Diabetes, obesity and metabolism
Partial Deletion of Perk Improved High-Fat Diet-Induced Glucose Intolerance in Mice: Jooyeop Lee, Min Joo Kim, Seoil Moon, Ji Yoon Lim, Kyong Soo Park, Hye Seung Jung; Endocrinol Metab. 2023;38(6):782-787. Published online November 13, 2023; DOI: https://doi.org/10.3803/EnM.2023.1738

3,924 View
78 Download
1 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Although pancreatic endoplasmic reticulum kinase (PERK) is indispensable to beta cells, low-dose PERK inhibitor improved glucose- stimulated insulin secretion (GSIS) and hyperglycemia in diabetic mice. Current study examined if partial deletion of Perk (Perk^+/-) recapitulated the effects of PERK inhibitor, on the contrary to the complete deletion. Perk^+/- mice and wild-type controls were fed with a high-fat diet (HFD) for 23 weeks. Glucose tolerance was evaluated along with serum insulin levels and islet morphology. Perk^+/- mice on normal chow were comparable to wild-type mice in various metabolic features. HFD-induced obesity was not influenced by Perk reduction; however, HFD-induced glucose intolerance was significantly improved since 15-week HFD. HFD-induced compromises in GSIS were relieved by Perk reduction, accompanied by reductions in phosphorylated PERK and activating transcription factor 4 (ATF4) in the islets. Meanwhile, HFD-induced islet expansion was not significantly affected. In summary, partial deletion of Perk improved glucose tolerance and GSIS impaired by diet-induced obesity, without changes in body weights or islet mass.

Citations

Citations to this article as recorded by

The UPR-oxidative stress nexus in diabetes and obesity: Exploring innovative therapeutic approaches for metabolic control
Clinton Ayodeji Akanbi, Oluwafemi Adeleke Ojo
Obesity Medicine.2025; 57: 100634. CrossRef
Oral Indole-3-acetate Supplementation Increases the Abundance of Bifidobacterium pseudolongum and Akkermansia muciniphila in the Intestine of Mice on a High-Fat Diet
O. P. Shatova, A. A. Zabolotneva, S. A. Rumyantsev, A. V. Shestopalov
Russian Journal of Bioorganic Chemistry.2025; 51(5): 2041. CrossRef

Review Article

Diabetes, obesity and metabolism
The Benefits Of Continuous Glucose Monitoring In Pregnancy: Jee Hee Yoo, Jae Hyeon Kim; Endocrinol Metab. 2023;38(5):472-481. Published online October 11, 2023; DOI: https://doi.org/10.3803/EnM.2023.1805

17,915 View
566 Download
12 Web of Science
13 Crossref

Abstract PDF PubReader ePub

Previous studies have consistently demonstrated the positive effects of continuous glucose monitoring (CGM) on glycemic outcomes and complications of diabetes in people with type 1 diabetes. Guidelines now consider CGM to be an essential and cost-effective device for managing type 1 diabetes. As a result, insurance coverage for it is available. Evidence supporting CGM continues to grow and expand to broader populations, such as pregnant people with type 1 diabetes, people with type 2 diabetes treated only with basal insulin therapy, and even type 2 diabetes that does not require insulin treatment. However, despite the significant risk of hyperglycemia in pregnancy, which leads to complications in more than half of affected newborns, CGM indications and insurance coverage for those patients are unresolved. In this review article, we discuss the latest evidence for using CGM to offer glycemic control and reduce perinatal complications, along with its cost-effectiveness in pregestational type 1 and type 2 diabetes and gestational diabetes mellitus. In addition, we discuss future prospects for CGM coverage and indications based on this evidence.

Citations

Citations to this article as recorded by

The Use of Continuous Glucose Monitoring in Comparison to Self-Monitoring of Blood Glucose in Gestational Diabetes: A Systematic Review
Bhavadharini Balaji, Wesley Hannah, Polina V. Popova, Uma Ram, Mohan Deepa, Janeline Lunghar, Kumaran Uthra, Haritha Sagili, Sadishkumar Kamalanathan, Ranjit Mohan Anjana, Viswanathan Mohan
Journal of Diabetes Science and Technology.2026; 20(1): 173. CrossRef
Glucose circadian rhythm assessment in pregnant women for gestational diabetes screening
Rafael Bravo, Kyung Hyun Lee, Sarah A. Nazeer, Jocelyn A. Cornthwaite, Michal Fishel Bartal, Claudia Pedroza
International Journal of Obesity.2025; 49(1): 118. CrossRef
Quality of Life in Women With Gestational Diabetes Mellitus and Treatment Satisfaction Upon Intermittently Scanned Continuous Glucose Monitoring
Sookyung Won, Hyeon Ji Kim, Jee Yoon Park, Kyung Joon Oh, Sung Hee Choi, Hak Chul Jang, Joon Ho Moon
Journal of Korean Medical Science.2025;[Epub] CrossRef
Glucose time in range trajectories during pregnancy and association with adverse perinatal outcomes: a joint latent-class trajectory modeling approach
Sara M. Sauer, Isabel Fulcher, Ayodeji Sanusi, Ashley N. Battarbee
American Journal of Obstetrics & Gynecology MFM.2025; 7(6): 101669. CrossRef
Addressing the Diabetes Tsunami Requires Expanded Access to Diabetes Technologies
Davida F. Kruger, Christopher G. Parkin, Irl B. Hirsch, Grazia Aleppo, Janet B. McGill, Rodolfo J. Galindo, Carol J. Levy, Guillermo E. Umpierrez, George Grunberger, Richard M. Bergenstal
Journal of Diabetes Science and Technology.2025;[Epub] CrossRef
Prise de position d’un groupe d’experts – utilisation de la mesure en continu du glucose chez les patients vivant avec un diabète de type 2 en France
Michael Joubert, Benjamin Bouillet, Gaëtan Prevost, Bruno Vermesse, Helen Mosnier-Pudar, Jean-François Thébaut, Jean-Pierre Riveline, Noëlle Davoust, Bruno Guerci, Laurent Meyer
Médecine des Maladies Métaboliques.2025; 19(4): 331. CrossRef
Continuous glucose monitoring system in diabetes in pregnancy: a narrative review
Melanie Rodacki, Marcio Krakauer, Denise Reis Franco, Patricia Medici Dualib, Mauro Sancovski, Lenita Zajdenverg
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Case Studies From India: Management of Diabetes Using Continuous Glucose Monitoring
Ajay Kumar Gupta, Ajay Krishnan, Manu Kataria, Nishesh Jain
Cureus.2025;[Epub] CrossRef
Experiences of Women With Diabetes Using Wearable Continuous Glucose Monitors During Pregnancy: A Qualitative Descriptive Study
Hee Sun Kang, Hyang Rang Park, Jangmi Kang, Chun-Ja Kim
The Science of Diabetes Self-Management and Care.2025; 51(6): 559. CrossRef
Neonatal Outcomes and A1C Improved With Real-Time Continuous Glucose Monitoring in Pregnancy With Preexisting Type 2 Diabetes
Gail L. Nunlee-Bland, Rochanda Mitchell, Inez V. Reeves, Michal A. Young
Diabetes Spectrum.2025; 38(4): 461. CrossRef
Dispositivi indossabili per la gestione del diabete
Filippo CARLUCCI, Antonella TABUCCHI, Marcello FIORINI, Lucrezia GALASSO, Alessandro TERRENI
Biochimica Clinica.2025;[Epub] CrossRef
Wearable devices for glucose monitoring: A review of state-of-the-art technologies and emerging trends
Mohammad Mansour, M. Saeed Darweesh, Ahmed Soltan
Alexandria Engineering Journal.2024; 89: 224. CrossRef
Diagnosis and Treatment of Hyperglycemia in Pregnancy
Sneha Mohan, Aoife M. Egan
Endocrinology and Metabolism Clinics of North America.2024; 53(3): 335. CrossRef

Original Articles

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study: Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee, Committee of Big Data, Korean Endocrine Society; Endocrinol Metab. 2023;38(5):525-537. Published online September 7, 2023; DOI: https://doi.org/10.3803/EnM.2023.1765

6,679 View
151 Download
11 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the risk of cause-specific mortality according to glucose tolerance status in elderly South Koreans.
Methods
A total of 1,292,264 individuals aged ≥65 years who received health examinations in 2009 were identified from the National Health Information Database. Participants were classified as normal glucose tolerance, impaired fasting glucose, newly-diagnosed diabetes, early diabetes (oral hypoglycemic agents ≤2), or advanced diabetes (oral hypoglycemic agents ≥3 or insulin). The risk of system-specific and disease-specific deaths was estimated using multivariate Cox proportional hazards analysis.
Results
During a median follow-up of 8.41 years, 257,356 deaths were recorded. Diabetes was associated with significantly higher risk of all-cause mortality (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.57 to 1.60); death due to circulatory (HR, 1.49; 95% CI, 1.46 to 1.52), respiratory (HR, 1.51; 95% CI, 1.47 to 1.55), and genitourinary systems (HR, 2.22; 95% CI, 2.10 to 2.35); and neoplasms (HR, 1.30; 95% CI, 1.28 to 1.32). Diabetes was also associated with a significantly higher risk of death due to ischemic heart disease (HR, 1.70; 95% CI, 1.63 to 1.76), cerebrovascular disease (HR, 1.46; 95% CI, 1.41 to 1.50), pneumonia (HR, 1.69; 95% CI, 1.63 to 1.76), and acute or chronic kidney disease (HR, 2.23; 95% CI, 2.09 to 2.38). There was a stepwise increase in the risk of death across the glucose spectrum (P for trend <0.0001). Stroke, heart failure, or chronic kidney disease increased the risk of all-cause mortality at every stage of glucose intolerance.
Conclusion
A dose-dependent association between the risk of mortality from various causes and severity of glucose tolerance was noted in the elderly population.

Citations

Citations to this article as recorded by

Inverse association between obesity and suicidal death risk
Joonyub Lee, Seung-Hwan Lee, Mee-Kyoung Kim, Hyuk-Sang Kwon, Jae-Seung Yun, Yeoree Yang, Kun-Ho Yoon, Jae-Hyoung Cho, Chi-Un Pae, Kyungdo Han, Jang Won Son
BMC Psychiatry.2025;[Epub] CrossRef
The growing range of complications of diabetes mellitus
Peter S. Hamblin, Anthony W. Russell, Stella Talic, Sophia Zoungas
Trends in Endocrinology & Metabolism.2025; 36(10): 943. CrossRef
The association between new insulin resistance indices and all-cause mortality in elderly patients with diabetes: a prospective cohort study
Yanling Yang, Zhigu Liu, Beisi Lin, Yintong Huang, Hongrong Deng, Xubin Yang, Longyi Zeng, Jinhua Yan, Wen Xu
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality
Juan Reyes-Barrera, Rosalinda Posadas-Sánchez, Gilberto Vargas-Alarcón, Guillermo C. Cardoso-Saldaña, Paloma Almeda-Valdes, Omar Yaxmehen Bello Chavolla, Luis Ortiz-Hernandez, Neftali Eduardo Antonio-Villa
Scientific Reports.2025;[Epub] CrossRef
Glucose tolerance and mortality across 24 cancer types and stages: A K‐CURE Nationwide registry study
Kyung‐Hun Sung, Jin Yu, Seyoon Kim, Mee Kyoung Kim, Yong‐Moon Mark Park, Kyungdo Han, Seung‐Hwan Lee
Diabetes, Obesity and Metabolism.2025;[Epub] CrossRef
Effect of glucose variability on the mortality of adults aged 75 years and over during the first year of the COVID-19 pandemic
Miguel A. Salinero-Fort, F. Javier San Andrés-Rebollo, Juan Cárdenas-Valladolid, José Mostaza, Carlos Lahoz, Fernando Rodriguez-Artalejo, Paloma Gómez-Campelo, Pilar Vich-Pérez, Rodrigo Jiménez-García, José M. de-Miguel-Yanes, Javier Maroto-Rodriguez, Bel
BMC Geriatrics.2024;[Epub] CrossRef
Islet transplantation in Korea
Joonyub Lee, Kun‐Ho Yoon
Journal of Diabetes Investigation.2024; 15(9): 1165. CrossRef
All-cause and cause-specific mortality risks in individuals with diabetes living alone: A large-scale population-based cohort study
Jae-Seung Yun, Kyungdo Han, Bongseong Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Yu-Bae Ahn, Yong-Moon Mark Park, Seung-Hwan Lee
Diabetes Research and Clinical Practice.2024; 217: 111876. CrossRef
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures
Kyoung Hwa Ha, Dae Jung Kim
Endocrinology and Metabolism.2024; 39(5): 669. CrossRef
Osteoporosis incidence and its associated factors in the older Korean population: findings from a population-based cohort study
Tanmoy Das, Md Abdullah Al Jubayer Biswas, Prosanta Mondal, Sabuj Sarker, Hyun J.“June” Lim
Archives of Osteoporosis.2024;[Epub] CrossRef
Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
JAMA Network Open.2024; 7(11): e2443918. CrossRef
The Characteristics and Risk of Mortality in the Elderly Korean Population
Sunghwan Suh
Endocrinology and Metabolism.2023; 38(5): 522. CrossRef

Diabetes, obesity and metabolism
Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study: Joon Ho Moon, Yongkang Kim, Tae Jung Oh, Jae Hoon Moon, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi, Nam H. Cho; Endocrinol Metab. 2023;38(4):406-417. Published online August 3, 2023; DOI: https://doi.org/10.3803/EnM.2023.1703

18,326 View
346 Download
32 Web of Science
29 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
While the triglyceride-glucose (TyG) index is a measure of insulin resistance, its association with cardiovascular disease (CVD) has not been well elucidated. We evaluated the TyG index for prediction of CVDs in a prospective large communitybased cohort.
Methods
Individuals 40 to 70 years old were prospectively followed for a median 15.6 years. The TyG index was calculated as the Ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2]. CVDs included any acute myocardial infarction, coronary artery disease or cerebrovascular disease. We used a Cox proportional hazards model to estimate CVD risks according to quartiles of the TyG index and plotted the receiver operating characteristics curve for the incident CVD.
Results
Among 8,511 subjects (age 51.9±8.8 years; 47.5% males), 931 (10.9%) had incident CVDs during the follow-up. After adjustment for age, sex, body mass index, diabetes mellitus, hypertension, total cholesterol, smoking, alcohol, exercise, and C-reactive protein, subjects in the highest TyG quartile had 36% increased risk of incident CVD compared with the lowest TyG quartile (hazard ratio, 1.36; 95% confidence interval, 1.10 to 1.68). Carotid plaque, assessed by ultrasonography was more frequent in subjects in the higher quartile of TyG index (P for trend=0.049 in men and P for trend <0.001 in women). The TyG index had a higher predictive power for CVDs than the homeostasis model assessment of insulin resistance (HOMA-IR) (area under the curve, 0.578 for TyG and 0.543 for HOMA-IR). Adding TyG index on diabetes or hypertension alone gave sounder predictability for CVDs.
Conclusion
The TyG index is independently associated with future CVDs in 16 years of follow-up in large, prospective Korean cohort.

Citations

Citations to this article as recorded by

Elevated triglyceride-glucose index as a predictor of carotid plaque incidence: Insights from a comprehensive meta-analysis
Arankesh Mahadevan, Bhavin A. Patel, Sashwath Srikanth, Raja Godasi, Rupak Desai
The American Journal of the Medical Sciences.2025; 369(2): 197. CrossRef
Analysis of the correlation between the serum triglyceride glucose index and the risk of death in patients on maintenance hemodialysis: a retrospective cohort study
Xiaokeng Chi, Shuxin Chen, Zhe Huang, Rong Zhou, Zhicheng Su, Qiujun Mai, Yilin Xu, Jianxin Wan
PeerJ.2025; 13: e18781. CrossRef
Assessing the predictive value of elevated triglycerides, triglyceride-glucose index (TyG), and TG/HDL ratios for cardiovascular disease and mortality during 20 years of follow-up: Tehran lipid and glucose study
Shayesteh Khalili, Atieh Amouzegar, Seyed Sattar Dorost, Fereidoun Azizi, Aryan Salahi-Niri
Clinical Biochemistry.2025; 136: 110891. CrossRef
Association between triglyceride-glucose index and carotid atherosclerosis in Chinese steelworkers: a cross-sectional study
Haoyue Cao, Qinglin Li, Juxiang Yuan
Scientific Reports.2025;[Epub] CrossRef
Association between the triglyceride-glucose index and silent myocardial infarction in the general population
Min Dai, Dongze Li, Jing Yu, Yi Liu, Qin Zhang, Wei Zhang, Yan Zhong, Zhi Wan, Menglin Tang, Yongli Gao, Li Rao
Scientific Reports.2025;[Epub] CrossRef
Integrative Multi‐Omics and Routine Blood Analysis Using Deep Learning: Cost‐Effective Early Prediction of Chronic Disease Risks
Zhibin Dong, Pei Li, Yi Jiang, Zhihan Wang, Shihui Fu, Hebin Che, Meng Liu, Xiaojing Zhao, Chunlei Liu, Chenghui Zhao, Qin Zhong, Chongyou Rao, Siwei Wang, Suyuan Liu, Dayu Hu, Dongjin Wang, Juntao Gao, Kai Guo, Xinwang Liu, En Zhu, Kunlun He
Advanced Science.2025;[Epub] CrossRef
Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study
So Hyun Cho, Gyuri Kim, Kyu-na Lee, Rosa Oh, Ji Yoon Kim, Myunghwa Jang, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim
Scientific Reports.2025;[Epub] CrossRef
The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study
Mi-sook Kim, Kyu-Na Lee, Jeongmin Lee, Jeongeun Kwak, Seung-Hwan Lee, Hyuk-Sang Kwon, Jing Hughes, Kyung-Do Han, Eun Young Lee
Endocrinology and Metabolism.2025; 40(5): 718. CrossRef
Associations Between Novel Lipid Indicators and the Risk of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Yazhi Wang, Mingkang Zhang, Peng Wang
Lipids.2025; 60(6): 407. CrossRef
The triglyceride-glucose index, a marker of insulin resistance, as a predictor of thrombotic risk in atrial fibrillation
José Miguel Rivera-Caravaca, Eva Soler-Espejo, María Pilar Ramos-Bratos, Raquel López-Gálvez, Eduardo González-Lozano, Gregory Y. H. Lip, Francisco Marín, Vanessa Roldán
Cardiovascular Diabetology.2025;[Epub] CrossRef
The Impact of Triglyceride-Glucose Index Trajectories on Incidence and Recurrent Cardiovascular Events: Evidence from a Retrospective Cohort Study
Yuan Xu, Gonglong Wu, Long Jiang, Xinlei Yang, Chengjin Wen, Yulan Yang, Hui Hu
Vascular Health and Risk Management.2025; Volume 21: 557. CrossRef
Association between the Triglyceride-Glucose Index and Cardiovascular Risk and Mortality across Different Diabetes Durations: A Nationwide Cohort Study
Jeongeun Kwak, Kyung-Do Han, Eun Young Lee, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Jeongmin Lee
Endocrinology and Metabolism.2025; 40(4): 548. CrossRef
Does diabetes status modify the association between the triglyceride-glucose index and major adverse cardiovascular events in patients with coronary heart disease? A systematic review and meta-analysis of longitudinal cohort studies
Shicong Xu, Zhihui Zhang, Jing Li, Yiyan Ding, Yuanguo Chen, Yunxia Zhou, Shenglin Hu
Cardiovascular Diabetology.2025;[Epub] CrossRef
Predictive performance of traditional and novel anthropometric indices for diabetes and hypertension
Mozhgan Pezeshki, Shirin Esmaeili, Armita Mahdavi‐Gorabi, Tahereh Sadegi, Zahra Farhad Kiaee, Omid Assar, Kiavash Semnani, Mostafa Qorbani
Journal of Diabetes Investigation.2025; 16(12): 2213. CrossRef
Asociación del Índice de triglicéridos-glucosa (Índice TyG) y el riesgo cardiovascular en docentes de educación superior.
Luiggi Oscar Solano-Maza, Jhon Bryan Mina-Ortiz, Anita María Murillo-Zavala, Karina Maricela Merchán-Villafuerte
Innova Science Journal.2025; 3(4): 397. CrossRef
Association of the triglyceride-glucose index with cardiovascular outcomes across cardiovascular-kidney-metabolic syndrome stages
Byung Sik Kim, Hyun-Jin Kim, Shinje Moon, Hasung Kim, Jungkuk Lee, Jeong-Hun Shin
The Korean Journal of Internal Medicine.2025; 40(6): 961. CrossRef
Association between the triglyceride-glucose index and carotid plaque progression in patients with type 2 diabetes mellitus: a retrospective cohort study
Zhangxiang Zhu, Xuan Xu, Guojuan Wang, Qianqian Zhang, Ying Li, Jun Zhu, Li Chen, Qibao Ye, Mingwei Chen
Frontiers in Endocrinology.2025;[Epub] CrossRef
Associations Between Serum Selenium, Zinc, and Copper Levels and Cognitive Function in the Elderly
Piangporn Charernwat, Sirintorn Chansirikarnjana, Pachara Panpunuan, Piyamitr Sritara, Jintana Sirivarasai
Nutrients.2025; 17(24): 3872. CrossRef
Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus
Kaisheng Yuan, Bing Wu, Ruiqi Zeng, Fuqing Zhou, Ruixiang Hu, Cunchuan Wang
Diabetes, Obesity and Metabolism.2024; 26(1): 169. CrossRef
Association between the triglyceride glucose index and chronic total coronary occlusion: A cross-sectional study from southwest China
Kaiyong Xiao, Huili Cao, Bin Yang, Zhe Xv, Lian Xiao, Jianping Wang, Shuiqing Ni, Hui Feng, Zhongwei He, Lei Xv, Juan Li, Dongmei Xv
Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(4): 850. CrossRef
The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
Younan Yao, Bo Wang, Tian Geng, Jiyan Chen, Wan Chen, Liwen Li
Cardiovascular Diabetology.2024;[Epub] CrossRef
Comparison of triglyceride glucose index and modified triglyceride glucose indices in prediction of cardiovascular diseases in middle aged and older Chinese adults
Cancan Cui, Yitian Qi, Jiayin Song, Xinyun Shang, Tianjiao Han, Ning Han, Siqi Yue, Yining Zha, Zhonghang Xu, Jiannan Li, Lin Liu
Cardiovascular Diabetology.2024;[Epub] CrossRef
Triglyceride-glucose index predicts type 2 diabetes mellitus more effectively than oral glucose tolerance test-derived insulin sensitivity and secretion markers
Min Jin Lee, Ji Hyun Bae, Ah Reum Khang, Dongwon Yi, Mi Sook Yun, Yang Ho Kang
Diabetes Research and Clinical Practice.2024; 210: 111640. CrossRef
Prognostic value of triglyceride-glucose index for left ventricular remodeling in nondiabetic ST-elevation myocardial infarction patients
Tolga Han Efe, Engin Algül
Biomarkers in Medicine.2024; 18(6): 243. CrossRef
Triglyceride-Glucose Index as Predictor for Hypertension, CHD and STROKE Risk among Non-Diabetic Patients: A NHANES Cross-Sectional Study 2001–2020
Bisher Sawaf, Sarya Swed, Hidar Alibrahim, Haidara Bohsas, Tirth Dave, Mohamad Nour Nasif, Wael Hafez, Fatema Ali Asgar Tashrifwala, Yazan Khair Eldien Jabban, Safwan Al-Rassas, Heba haj Saleh, Abdul Rehman Zia Zaidi, Baraa Alghalyini, Shaymaa Abdelmaboud
Journal of Epidemiology and Global Health.2024; 14(3): 1152. CrossRef
An Increasing Triglyceride–Glucose Index Is Associated with a Pro-Inflammatory and Pro-Oxidant Phenotype
Beverley Adams-Huet, Ishwarlal Jialal
Journal of Clinical Medicine.2024; 13(13): 3941. CrossRef
Inflammatory and Metabolic Predictors of Mortality in Pulmonary Thromboembolism: A Focus on the Triglyceride–Glucose Index and Pan-Immune Inflammation Value
Murat Bilgin, Emre Akkaya, Recep Dokuyucu
Journal of Clinical Medicine.2024; 13(19): 6008. CrossRef
The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes
Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal
Lipids in Health and Disease.2024;[Epub] CrossRef
Evaluation of the novel three lipid indices for predicting five- and ten-year incidence of cardiovascular disease: findings from Kerman coronary artery disease risk factors study (KERCADRS)
Alireza Jafari, Hamid Najafipour, Mitra Shadkam, Sina Aminizadeh
Lipids in Health and Disease.2023;[Epub] CrossRef

Diabetes, obesity and metabolism
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION): Byung Wan Lee, KyungWan Min, Eun-Gyoung Hong, Bon Jeong Ku, Jun Goo Kang, Suk Chon, Won-Young Lee, Mi Kyoung Park, Jae Hyeon Kim, Sang Yong Kim, Keeho Song, Soon Jib Yoo; Endocrinol Metab. 2023;38(3):328-337. Published online June 28, 2023; DOI: https://doi.org/10.3803/EnM.2023.1688

8,113 View
437 Download
4 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study evaluated the efficacy and safety of add-on gemigliptin in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with metformin and dapagliflozin.
Methods
In this randomized, placebo-controlled, parallel-group, double-blind, phase III study, 315 patients were randomized to receive either gemigliptin 50 mg (n=159) or placebo (n=156) with metformin and dapagliflozin for 24 weeks. After the 24-week treatment, patients who received the placebo were switched to gemigliptin, and all patients were treated with gemigliptin for an additional 28 weeks.
Results
The baseline characteristics were similar between the two groups, except for body mass index. At week 24, the least squares mean difference (standard error) in hemoglobin A1c (HbA1c) changes was –0.66% (0.07) with a 95% confidence interval of –0.80% to –0.52%, demonstrating superior HbA1c reduction in the gemigliptin group. After week 24, the HbA1c level significantly decreased in the placebo group as gemigliptin was administered, whereas the efficacy of HbA1c reduction was maintained up to week 52 in the gemigliptin group. The safety profiles were similar: the incidence rates of treatment-emergent adverse events up to week 24 were 27.67% and 29.22% in the gemigliptin and placebo groups, respectively. The safety profiles after week 24 were similar to those up to week 24 in both groups, and no new safety findings, including hypoglycemia, were noted.
Conclusion
Add-on gemigliptin was well tolerated, providing comparable safety profiles and superior efficacy in glycemic control over placebo for long-term use in patients with T2DM who had poor glycemic control with metformin and dapagliflozin.

Citations

Citations to this article as recorded by

Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
Myung Jin Kim, Yun Kyung Cho, Sehee Kim, Jung Yoon Moon, Chang Hee Jung, Woo Je Lee
Diabetes, Obesity and Metabolism.2025; 27(9): 5019. CrossRef
Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
Miao Yu, Tong Wang, Chun Xu, Yan Bi, Ling Gao, Guang Wang, Guangda Xiang, Yaoming Xue, Tao Yang, Deying Kang, Zhiguang Zhou, Lixin Guo, Xinhua Xiao
Diabetes, Obesity and Metabolism.2025; 27(S9): 3. CrossRef
Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef
Missing imputation under estimand framework using treatment policy strategy for intercurrent events
Jaehyuk Kim, Eunjung Song, Siyoen Kil
Communications for Statistical Applications and Methods.2025; 32(6): 783. CrossRef
Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
Kyung Ah Han, You‐Cheol Hwang, Shin Je Moon, Ho Chan Cho, Hye Jin Yoo, Sung Hee Choi, Suk Chon, Kyoung‐Ah Kim, Tae Nyun Kim, Jun Goo Kang, Cheol‐Young Park, Jong Chul Won, Eunjoo Cho, Jeongyun Kim, Kyong Soo Park
Diabetes, Obesity and Metabolism.2024; 26(9): 3743. CrossRef

Namgok Lecture 2022

Diabetes, Obesity and Metabolism
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes: Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho; Endocrinol Metab. 2023;38(1):1-9. Published online February 13, 2023; DOI: https://doi.org/10.3803/EnM.2023.103

8,740 View
494 Download
5 Web of Science
6 Crossref

Abstract PDF PubReader ePub

To maintain normal glucose homeostasis after a meal, it is essential to secrete an adequate amount of insulin from pancreatic β-cells. However, if pancreatic β-cells solely depended on the blood glucose level for insulin secretion, a surge in blood glucose levels would be inevitable after the ingestion of a large amount of carbohydrates. To avoid a deluge of glucose in the bloodstream after a large carbohydrate- rich meal, enteroendocrine cells detect the amount of nutrient absorption from the gut lumen and secrete incretin hormones at scale. Since insulin secretion in response to incretin hormones occurs only in a hyperglycemic milieu, pancreatic β-cells can secrete a “Goldilocks” amount of insulin (i.e., not too much and not too little) to keep the blood glucose level in the normal range. In this regard, pancreatic β-cell sensitivity to glucose and incretin hormones is crucial for maintaining normal glucose homeostasis. In this Namgok lecture 2022, we review the effects of current anti-diabetic medications on pancreatic β-cell sensitivity to glucose and incretin hormones.

Citations

Citations to this article as recorded by

GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2025; 26(3): 413. CrossRef
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(6): 1287. CrossRef
Initial Combination Therapy in Type 2 Diabetes
Ji Yoon Kim, Nam Hoon Kim
Endocrinology and Metabolism.2024; 39(1): 23. CrossRef
Impact of Some Natural and Artificial Sweeteners Consumption on Different Hormonal Levels and Inflammatory Cytokines in Male Rats: In Vivo and In Silico Studies
Dina Mostafa Mohammed, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, Abdulaziz Alhossan, Rasha Hamed Al-Serwi, Amr Farouk
ACS Omega.2024; 9(28): 30364. CrossRef
Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
Muthanna K. Zaki, Mohammed N. Abed, Fawaz A. Alassaf
Journal of Bone Metabolism.2024; 31(3): 169. CrossRef
Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2024; 48(6): 1135. CrossRef

Review Articles

Diabetes, Obesity and Metabolism
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus: Jin Yu, Seung-Hwan Lee, Mee Kyoung Kim; Endocrinol Metab. 2022;37(1):26-37. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2022.105

34,735 View
1,541 Download
46 Web of Science
46 Crossref

Abstract PDF PubReader ePub

Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.

Citations

Citations to this article as recorded by

Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction
Ghaith K. Mansour, Sarah B. Hammo, Muhammad Raihan Sajid
Frontiers in Medicine.2026;[Epub] CrossRef
Continuous glucose monitoring data for artificial intelligence-based predictive glycemic event: A potential aspect for diabetic care
Lim Pei Ying, Oh Xin Yin, Ong Wei Quan, Neha Jain, Jayashree Mayuren, Manisha Pandey, Bapi Gorain, Mayuren Candasamy
International Journal of Diabetes in Developing Countries.2025; 45(2): 272. CrossRef
Drug origami: A computation-guided approach for customizable drug release kinetics of oral formulations
Hao Huang, Haoyu Zhang, Ningjie Du, Yidan Lyu, Jiahang Xu, Haoran Fu, Yixin Guan, Kewang Nan
Matter.2025; 8(1): 101878. CrossRef
Long-term levels of bile acids, fibroblast growth factor-19, and glucagon-like peptide-1 after bariatric surgery
Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song
Asian Journal of Surgery.2025; 48(1): 356. CrossRef
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on in-hospital mortality following pneumonia without heart failure: A retrospective cohort study of older adults with diabetes
Hiroki Maki, Toshiaki Isogai, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
Respiratory Investigation.2025; 63(1): 88. CrossRef
Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
Ji Yoon Kim, Jee Hee Yoo, Nam Hoon Kim, Jae Hyeon Kim
Journal of Diabetes Science and Technology.2025;[Epub] CrossRef
Screening for Type 2 Diabetes Mellitus: A Systematic Review of Recent Economic Evaluations
Zixuan Jin, Joshua Rothwell, Ka Keat Lim
Value in Health.2025; 28(6): 959. CrossRef
Comparison of Real-Time and Intermittently-Scanned Continuous Glucose Monitoring for Glycemic Control in Type 1 Diabetes Mellitus: Nationwide Cohort Study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetes & Metabolism Journal.2025; 49(3): 436. CrossRef
Temporal Trends and Outcomes of Peripheral Artery Disease and Critical Limb Ischemia in the United States
Chayakrit Krittanawong, Kimberly Imoh, Song Peng Ang, Yusuf Kamran Qadeer, Hafeez Ul Hassan Virk, Mahboob Alam, Carl J Lavie, Raman Sharma
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine.2025; 24(2): e0377. CrossRef
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: A cross-sectional study
Ji Yoon Kim, Seohyun Kim, Sang Ho Park, Jin A Lee, So Hyun Cho, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin
Diabetes Research and Clinical Practice.2025; 226: 112325. CrossRef
Factors Influencing Primary Care Physicians’ Adjustment of Oral Anti-Diabetic Drugs in Patients with Type 2 Diabetes Mellitus: A Qualitative Research Study
Natasha Sheng Yeng Leng, Shera Chaterji, Aminath Shiwaza Moosa, Patricia Ching Yen Chia, Lay Geok Lian, ZhengHua Li, Natalie Ming Foong Hooi, Beth Shin Rei Lau, Ngiap Chuan Tan
Journal of Primary Care & Community Health.2025;[Epub] CrossRef
Pakistan’s first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies
Amna Saeed, Sundus Shukar, Najwa Ali Yasin, Caijun Yang, Minghuan Jiang, Muhammad Majid Aziz, Haris Zahoor, Muhammad Sunnan-Ud-Din, Yu Fang, Zaheer-Ud-Din Babar
Frontiers in Pharmacology.2025;[Epub] CrossRef
Cinnamaldehyde promotes diabetic wound healing via synergetic effects of AGE/RAGE-mediated macrophage polarization affecting fibroblast activation and angiogenesis, and Nrf2-dependent antioxidants
Wenhui Yu, Heng Xu, Xin Yuan, Wenyu Chen, Yimin Hao, Gang Zhao
Biochemical and Biophysical Research Communications.2025; 781: 152519. CrossRef
Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches
Benson M. Hamooya, Lukundo Siame, Lweendo Muchaili, Sepiso K. Masenga, Annet Kirabo
Frontiers in Nutrition.2025;[Epub] CrossRef
Current Status of Continuous Glucose Monitoring Use in South Korean Type 1 Diabetes Mellitus Population–Pronounced Age-Related Disparities: Nationwide Cohort Study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetes & Metabolism Journal.2025; 49(5): 1040. CrossRef
Huiyang Shengji Unguent Promotes Lymphangiogenesis and Wound Healing in Diabetic Chronic Wounds: Combined Insights from Proteomics and in vivo and in vitro Analyses
Fangning Yu, Li Lin, Xiao Tang, Xiujuan He, Xuying Xu
Journal of Inflammation Research.2025; Volume 18: 12883. CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
GV effects of diabetes mellitus on clinical outcomes of patients with acute heart failure: A systematic review and meta-analysis
Linna Zhao, Juanjuan Zhang, Weizhe Liu, Cheng Dai, Aiying Li, Oyelola A. Adegboye
PLOS One.2025; 20(12): e0338653. CrossRef
Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes
Subo Dey, Jasmine Garg, Andy Wang, Eva Holzner, William H. Frishman, Wilbert S. Aronow
Cardiology in Review.2024; 32(3): 285. CrossRef
Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents
Tingting Zhang, Andrew R. Zullo, Kaleen (Kaley) N. Hayes, Dae Hyun Kim, Yoojin Lee, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry
Journal of the American Medical Directors Association.2024; 25(3): 454. CrossRef
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
Diabetes Technology & Therapeutics.2024; 26(4): 222. CrossRef
Body composition and metabolic syndrome in patients with type 1 diabetes
Qiong Zeng, Xiao-Jing Chen, Yi-Ting He, Ze-Ming Ma, Yi-Xi Wu, Kun Lin
World Journal of Diabetes.2024; 15(1): 81. CrossRef
The best internal structure of the Diabetes Quality of Life Measure (DQOL) in Brazilian patients
Denilson Menezes Almeida, Aldair Darlan Santos-de-Araújo, José Mário Costa Brito Júnior, Marcela Cacere, André Pontes-Silva, Cyrene Piazera Costa, Maria Cláudia Gonçalves, José Márcio Soares Leite, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai
BMC Public Health.2024;[Epub] CrossRef
Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317. CrossRef
SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka
Prospects in Pharmaceutical Sciences.2024; 22(1): 16. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial
Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim
Diabetologia.2024; 67(7): 1235. CrossRef
Optimizing postprandial glucose prediction through integration of diet and exercise: Leveraging transfer learning with imbalanced patient data
Shinji Hotta, Mikko Kytö, Saila Koivusalo, Seppo Heinonen, Pekka Marttinen, Everson Nunes
PLOS ONE.2024; 19(8): e0298506. CrossRef
Diet and gut microbiome: Impact of each factor and mutual interactions on prevention and treatment of type 1, type 2, and gestational diabetes mellitus
Davide Menafra, Mattia Proganò, Nicola Tecce, Rosario Pivonello, Annamaria Colao
Human Nutrition & Metabolism.2024; 38: 200286. CrossRef
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin
Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F. Pollock, Waqas Ahmed, Gregory J. Norman, Sang-Man Jin, Jae Hyeon Kim
Journal of Medical Economics.2024; 27(1): 1245. CrossRef
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures
Kyoung Hwa Ha, Dae Jung Kim
Endocrinology and Metabolism.2024; 39(5): 669. CrossRef
Utilisation of blood glucose test strips in insulin-requiring people with diabetes mellitus using continuous glucose monitoring in Saxony-Anhalt – Analysis of health insurance data
Sara Lena Lückmann, Antonia Förster, Stephanie Heinrich, Christian Buhtz, Gabriele Meyer, Rafael Mikolajczyk, Steffen Fleischer
Diabetes Research and Clinical Practice.2024; 218: 111935. CrossRef
Clinical Profile, Comorbidities and Therapies in Type 2 Diabetes Patients on Sitagliptin-Based Therapy in Indian Outpatient Setting
Khurshid A Bhat, Kiran P Singh, Hanumantha Rao Maddukuri, S N Routray, Shreya Sharma, Surendra Kumar Sharma, Kamlesh Patel, Veena Kinare, Pradip Mate, R V Lokesh Kumar
Cureus.2024;[Epub] CrossRef
Glycemic control and associated factors in patients with type 2 diabetes in Southwest Ethiopia: a prospective observational study
Aster Wakjira Garedo, Gorfineh Teshome Tesfaye, Rahel Tamrat, Evelien Wynendaele
BMC Endocrine Disorders.2024;[Epub] CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease
Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim
npj Parkinson's Disease.2023;[Epub] CrossRef
Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
Ji Yoon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2023; 47(1): 42. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study
Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Cardiovascular Diabetology.2023;[Epub] CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
BMC Public Health.2023;[Epub] CrossRef
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo
International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef
Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study
You Lee Yang, Eun-Ok Im, Yunmi Kim
BMC Nursing.2023;[Epub] CrossRef
Access to novel anti-diabetic agents in resource limited settings: A brief commentary
Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang
World Journal of Diabetes.2023; 14(7): 939. CrossRef
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar
Annals of Medicine.2023;[Epub] CrossRef
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya
Expert Opinion on Pharmacotherapy.2023; 24(18): 2187. CrossRef
Analysis of the management and therapeutic performance of diabetes mellitus employing special target
Hong-Yan Sun, Xiao-Yan Lin
World Journal of Diabetes.2023; 14(12): 1721. CrossRef
Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats
Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Ana-Maria Pelin, Liliana Lacramioara Pavel, Ilie Cristian Drochioi, Gina Eosefina Botnariu
Medicina.2022; 58(11): 1620. CrossRef
The Effectiveness of Eye Movement Desensitization and Reprocessing Therapy on Death Anxiety and Perceived Stress in Patients with Type 2 Diabetes
Sh Valizadeh Shafagh, S Taklavi, R Kazemi
Journal of Health and Care.2022; 24(3): 245. CrossRef

Diabetes, Obesity and Metabolism
Homeostatic Regulation of Glucose Metabolism by the Central Nervous System: Jong Han Choi, Min-Seon Kim; Endocrinol Metab. 2022;37(1):9-25. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1364

19,991 View
659 Download
26 Web of Science
28 Crossref

Abstract PDF PubReader ePub

Evidence for involvement of the central nervous system (CNS) in the regulation of glucose metabolism dates back to the 19th century, although the majority of the research on glucose metabolism has focused on the peripheral metabolic organs. Due to recent advances in neuroscience, it has now become clear that the CNS is indeed vital for maintaining glucose homeostasis. To achieve normoglycemia, specific populations of neurons and glia in the hypothalamus sense changes in the blood concentrations of glucose and of glucoregulatory hormones such as insulin, leptin, glucagon-like peptide 1, and glucagon. This information is integrated and transmitted to other areas of the brain where it eventually modulates various processes in glucose metabolism (i.e., hepatic glucose production, glucose uptake in the brown adipose tissue and skeletal muscle, pancreatic insulin and glucagon secretion, renal glucose reabsorption, etc.). Errors in these processes lead to hyper- or hypoglycemia. We here review the current understanding of the brain regulation of glucose metabolism.

Citations

Citations to this article as recorded by

Expanding the understanding of insulin resistance in brain and periphery
Wenqiang Chen, Stephanie Kullmann, Elizabeth M. Rhea
Trends in Endocrinology & Metabolism.2026; 37(1): 17. CrossRef
Biological Indicators of Cardiovascular Health by Foster Care History in Adults
Darlynn M. Rojo-Wissar, Sean R. Womack, Tomas Baka, Adam P. Spira, Ryan D. Davidson, Eric S. Zhou, Candice A. Alfano, Chandra L. Jackson, Michael A. Grandner, Stephanie H. Parade
American Journal of Preventive Medicine.2026; 70(1): 108097. CrossRef
Dorzagliatin shows potential in preventing cognitive impairment in diabetes: evidence from Mendelian randomization analysis and animal study
Jiangxia Ni, Ke Wang, Lingge Feng, Chuyi Wang, Changhong Li, Yelin Chen, Li Chen
Frontiers in Endocrinology.2026;[Epub] CrossRef
Modulation of the association between blood glucose homeostasis and social hierarchy among co-housed mice by diet and amygdala activities
Rikako Ukichi, Yukari Takahashi, Momoyo Ibukuro, Yae K. Sugimura, Keiichiro Matoba, Rimei Nishimura, Fusao Kato
The Journal of Physiological Sciences.2026; 76(1): 100058. CrossRef
Antipsychotic-Induced Dysregulation of Glucose Metabolism Through the Central Nervous System: A Scoping Review of Animal Models
Emily Au, Kristoffer J. Panganiban, Sally Wu, Kira Sun, Bailey Humber, Gary Remington, Sri Mahavir Agarwal, Adria Giacca, Sandra Pereira, Margaret Hahn
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.2025; 10(3): 244. CrossRef
Neuronal Regulation of Feeding and Energy Metabolism: A Focus on the Hypothalamus and Brainstem
Jing Chen, Meiting Cai, Cheng Zhan
Neuroscience Bulletin.2025; 41(4): 665. CrossRef
Systemic Glucose Homeostasis Requires Pancreatic but Not Neuronal ATP-sensitive Potassium Channels
Athena H Li, Wen-Sheng Tsai, Wen-Hao Tsai, Shi-Bing Yang
Function.2025;[Epub] CrossRef
Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms
Omar Gammoh, Esam Qnais, Alaa A. A. Aljabali, Taher Hatahet, Abdelrahim Alqudah
Molecular Biology Reports.2025;[Epub] CrossRef
Effects of different feeding strategies on ion-transporting, energy metabolism and intestinal health of Nile tilapia (Oreochromis niloticus) under saline-alkaline stress
Jinquan Fan, Yuxi Yan, Yuxin Lin, Yuxing Huang, Erchao Li, Liqiao Chen, Xiaodan Wang
Aquaculture Reports.2025; 44: 103033. CrossRef
Glucose sensing and homeostasis by adipocyte GPCR
Nazmul Hasan, Kavaljit H. Chhabra
Frontiers in Endocrinology.2025;[Epub] CrossRef
Metaflammation’s Role in Systemic Dysfunction in Obesity: A Comprehensive Review
Ioana-Maria Crasan, Matei Tanase, Corina Elena Delia, Gratiela Gradisteanu-Pircalabioru, Anisoara Cimpean, Elena Ionica
International Journal of Molecular Sciences.2025; 26(21): 10445. CrossRef
Aging Effects on Metabolic Sensor and Glycogen Metabolism in Old Male vs. Female Rat Primary Hypothalamic Astrocyte Cultures
Rami Shrestha, Madhu Babu Pasula, Karen Patrice Briski
Neuroglia.2025; 6(4): 41. CrossRef
Orexinergic pathway as a potential therapeutic candidate for the modulation of glucose homeostasis
Jean Claude Hakizimana, Pelagie Izabayo, Zephyrin Izukwizabigenza, Abdullateef Isiaka Alagbonsi
Frontiers in Physiology.2025;[Epub] CrossRef
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function
Wenran Ren, Jianhui Chen, Wenjing Wang, Qingqing Li, Xia Yin, Guanglei Zhuang, Hong Zhou, Wenwen Zeng
Neuron.2024; 112(6): 972. CrossRef
Hypothalamic astrocyte NAD+ salvage pathway mediates the coupling of dietary fat overconsumption in a mouse model of obesity
Jae Woo Park, Se Eun Park, Wuhyun Koh, Won Hee Jang, Jong Han Choi, Eun Roh, Gil Myoung Kang, Seong Jun Kim, Hyo Sun Lim, Chae Beom Park, So Yeon Jeong, Sang Yun Moon, Chan Hee Lee, Sang Yeob Kim, Hyung Jin Choi, Se Hee Min, C. Justin Lee, Min-Seon Kim
Nature Communications.2024;[Epub] CrossRef
Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells
Praveen Sahu, Ignacio G. Camarillo, Raji Sundararajan
Exploration of Targeted Anti-tumor Therapy.2024; 5(1): 54. CrossRef
Redox imbalance and metabolic defects in the context of Alzheimer disease
Fabio Di Domenico, Chiara Lanzillotta, Marzia Perluigi
FEBS Letters.2024; 598(17): 2047. CrossRef
Acid sphingomyelinase inhibition induces cerebral angiogenesis post-ischemia/reperfusion in an oxidative stress-dependent way and promotes endothelial survival by regulating mitochondrial metabolism
Ayan Mohamud Yusuf, Mina Borbor, Tanja Hussner, Carolin Weghs, Britta Kaltwasser, Matthias Pillath-Eilers, Bernd Walkenfort, Richard Kolesnick, Erich Gulbins, Dirk M. Hermann, Ulf Brockmeier
Cell Death & Disease.2024;[Epub] CrossRef
Brown Fat and Metabolic Health: The Diverse Functions of Dietary Components
Zachary Brown, Takeshi Yoneshiro
Endocrinology and Metabolism.2024; 39(6): 839. CrossRef
Reduced Blood to Brain Glucose Transport as the Cause for Hyperglycemia: A Model That Resolves Multiple Anomalies in Type 2 Diabetes
Akanksha Ojha, Milind Watve
Qeios.2024;[Epub] CrossRef
Obesity-associated microglial inflammatory activation paradoxically improves glucose tolerance
John D. Douglass, Kelly M. Ness, Martin Valdearcos, Alice Wyse-Jackson, Mauricio D. Dorfman, Jeremy M. Frey, Rachael D. Fasnacht, Olivia D. Santiago, Anzela Niraula, Jineta Banerjee, Megan Robblee, Suneil K. Koliwad, Joshua P. Thaler
Cell Metabolism.2023; 35(9): 1613. CrossRef
Phenotypic screening using waveform analysis of synchronized calcium oscillations in primary cortical cultures
Richi Sakaguchi, Saki Nakamura, Hiroyuki Iha, Masaki Tanaka, Ming Tatt Lee
PLOS ONE.2023; 18(4): e0271782. CrossRef
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression
Se Jong Oh, Namhun Lee, Kyung Rok Nam, Kyung Jun Kang, Sang Jin Han, Jae Yong Choi
Molecular Imaging and Biology.2023; 25(4): 735. CrossRef
A Survey of Deep Learning for Alzheimer’s Disease
Qinghua Zhou, Jiaji Wang, Xiang Yu, Shuihua Wang, Yudong Zhang
Machine Learning and Knowledge Extraction.2023; 5(2): 611. CrossRef
Potassium channels in behavioral brain disorders. Molecular mechanisms and therapeutic potential: A narrative review
Kazi Asraful Alam, Pernille Svalastoga, Aurora Martinez, Jeffrey Colm Glennon, Jan Haavik
Neuroscience & Biobehavioral Reviews.2023; 152: 105301. CrossRef
Recent progress in microbial cell surface display systems and their application on biosensors
HAIYING CHEN, YUQING WU, BAOJIAN HUANG, LEI HAN
BIOCELL.2023; 47(6): 1213. CrossRef
Knockout of Nur77 Leads to Amino Acid, Lipid, and Glucose Metabolism Disorders in Zebrafish
Yang Xu, Juanjuan Tian, Qi Kang, Hang Yuan, Chengdong Liu, Zhehui Li, Jie Liu, Mingyu Li
Frontiers in Endocrinology.2022;[Epub] CrossRef
Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes
Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 2939. CrossRef

Original Articles

Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Frequency of Exposure to Impaired Fasting Glucose and Risk of Mortality and Cardiovascular Outcomes: Seung-Hwan Lee, Kyungdo Han, Hyuk-Sang Kwon, Mee Kyoung Kim; Endocrinol Metab. 2021;36(5):1007-1015. Published online October 21, 2021; DOI: https://doi.org/10.3803/EnM.2021.1218

8,045 View
153 Download
14 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Metabolic abnormalities, such as impaired fasting glucose (IFG), are dynamic phenomena; however, it is unclear whether the timing of IFG exposure and cumulative exposure to IFG are related to cardiovascular disease (CVD) and mortality risk.
Methods
Data were extracted from a nationwide population-based cohort in South Korea for adults (n=2,206,679) who were free of diabetes and had 4 years of consecutive health examination data. Fasting blood glucose levels of 100 to 125 mg/dL were defined as IFG, and the number of IFG diagnoses for each adult in the 4-year period was tabulated as the IFG exposure score (range, 0 to 4). Adults with persistent IFG for the 4-year period received a score of 4.
Results
The median follow-up was 8.2 years. There were 24,820 deaths, 13,502 cases of stroke, and 13,057 cases of myocardial infarction (MI). IFG exposure scores of 1, 2, 3, and 4 were associated with all-cause mortality (multivariable-adjusted hazard ratio [aHR], 1.11; 95% confidence interval [CI], 1.08 to 1.15; aHR, 1.16; 95% CI, 1.12 to 1.20; aHR, 1.20; 95% CI, 1.15 to 1.25; aHR, 1.18; 95% CI, 1.11 to 1.25, respectively) compared with an IFG exposure score of 0. Adjusting for hypertension and dyslipidemia attenuated the slightly increased risk of MI or stroke associated with high IFG exposure scores, but significant associations for allcause mortality remained.
Conclusion
The intensity of IFG exposure was associated with an elevated risk of all-cause mortality, independent of cardiovascular risk factors. The association between IFG exposure and CVD risk was largely mediated by the coexistence of dyslipidemia and hypertension.

Citations

Citations to this article as recorded by

Impact of cumulative exposure to a high TG to HDL-C ratio on type 2 diabetes risk in young adults
Jung Heo, Byungpyo Kim, Kyungdo Han, Jae-Hyuk Lee, Seo-Young Sohn, Jiyeon Ahn, Whi-An Kwon, Moon Jung Kim, Eun-Young Doo, Min-Kyung Lee
Journal of Clinical Lipidology.2025; 19(2): 267. CrossRef
Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis
Min Cheol Chang, Seung Min Chung, Sang Gyu Kwak
Reviews on Environmental Health.2024; 39(4): 791. CrossRef
Cumulative exposure to impaired fasting glucose and gastrointestinal cancer risk: A nationwide cohort study
Byeong Yun Ahn, Bokyung Kim, Sanghyun Park, Sang Gyun Kim, Kyungdo Han, Soo‐Jeong Cho
Cancer.2024; 130(10): 1807. CrossRef
Diabetes severity and the risk of depression: A nationwide population-based study
Yunjung Cho, Bongsung Kim, Hyuk-Sang Kwon, Kyungdo Han, Mee Kyoung Kim
Journal of Affective Disorders.2024; 351: 694. CrossRef
Triglyceride-glucose index is associated with the risk of impaired fasting glucose in Chinese elderly individuals
Jie Liu, Feng Yi, Kai Duan, Haibo Liu
Scientific Reports.2024;[Epub] CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease
Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim
npj Parkinson's Disease.2023;[Epub] CrossRef
Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up
Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim
Respiratory Research.2023;[Epub] CrossRef
Construction and Validation of a Model for Predicting Impaired Fasting Glucose Based on More Than 4000 General Population
Cuicui Wang, Xu Zhang, Chenwei Li, Na Li, Xueni Jia, Hui Zhao
International Journal of General Medicine.2023; Volume 16: 1415. CrossRef
Factors Affecting High Body Weight Variability
Kyungdo Han, Mee Kyoung Kim
Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163. CrossRef
Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study
Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee
Scientific Reports.2023;[Epub] CrossRef
A Longitudinal Retrospective Observational Study on Obesity Indicators and the Risk of Impaired Fasting Glucose in Pre- and Postmenopausal Women
Myung Ji Nam, Hyunjin Kim, Yeon Joo Choi, Kyung-Hwan Cho, Seon Mee Kim, Yong-Kyun Roh, Kyungdo Han, Jin-Hyung Jung, Yong-Gyu Park, Joo-Hyun Park, Do-Hoon Kim
Journal of Clinical Medicine.2022; 11(10): 2795. CrossRef
Current Trends of Big Data Research Using the Korean National Health Information Database
Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
Diabetes & Metabolism Journal.2022; 46(4): 552. CrossRef
Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people
Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Kun-Ho Yoon, Seung-Hwan Lee
European Journal of Preventive Cardiology.2022; 29(14): 1866. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
Scientific Reports.2022;[Epub] CrossRef

Diabetes, Obesity and Metabolism
How Can We Adopt the Glucose Tolerance Test to Facilitate Predicting Pregnancy Outcome in Gestational Diabetes Mellitus?: Kyeong Jin Kim, Nam Hoon Kim, Jimi Choi, Sin Gon Kim, Kyung Ju Lee; Endocrinol Metab. 2021;36(5):988-996. Published online October 15, 2021; DOI: https://doi.org/10.3803/EnM.2021.1107

7,499 View
130 Download
7 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated how 100-g oral glucose tolerance test (OGTT) results can be used to predict adverse pregnancy outcomes in gestational diabetes mellitus (GDM) patients.
Methods
We analyzed 1,059 pregnant women who completed the 100-g OGTT between 24 and 28 weeks of gestation. We compared the risk of adverse pregnancy outcomes according to OGTT patterns by latent profile analysis (LPA), numbers to meet the OGTT criteria, and area under the curve (AUC) of the OGTT graph. Adverse pregnancy outcomes were defined as a composite of preterm birth, macrosomia, large for gestational age, low APGAR score at 1 minute, and pregnancy-induced hypertension.
Results
Overall, 257 participants were diagnosed with GDM, with a median age of 34 years. An LPA led to three different clusters of OGTT patterns; however, there were no significant associations between the clusters and adverse pregnancy outcomes after adjusting for confounders. Notwithstanding, the risk of adverse pregnancy outcome increased with an increase in number to meet the OGTT criteria (P for trend=0.011); odds ratios in a full adjustment model were 1.27 (95% confidence interval [CI], 0.72 to 2.23), 2.16 (95% CI, 1.21 to 3.85), and 2.32 (95% CI, 0.66 to 8.15) in those meeting the 2, 3, and 4 criteria, respectively. The AUCs of the OGTT curves also distinguished the patients at risk of adverse pregnancy outcomes; the larger the AUC, the higher the risk (P for trend=0.007).
Conclusion
The total number of abnormal values and calculated AUCs for the 100-g OGTT may facilitate tailored management of patients with GDM by predicting adverse pregnancy outcomes.

Citations

Citations to this article as recorded by

Association of prenatal glycemic marker cumulative exposure with placental DNA methylation change
Tesfa D Habtewold, Richard J Biedrzycki, Prabhavi Wijesiriwardhana, Nigus G Asefa, Fasil Tekola-Ayele
The Journal of Clinical Endocrinology & Metabolism.2026;[Epub] CrossRef
Association between area under the curve of oral glucose tolerance test and the risk of preterm birth among women with gestational diabetes mellitus: a mediation effect of gestational weight gain
Jing Liu, Huibin Li, Xue Wang, Beibei Liu, Dan He, Gang Zhang, Yan Gao
BMC Pregnancy and Childbirth.2025;[Epub] CrossRef
Association between the glucose pattern in oral glucose tolerance test and adverse pregnancy outcomes among non-diabetic women
Fangping Zhou, Binbin Yin, Ya Xi, Jinghua Zhang, Yongying Bai
Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
Dynamic OGTT-derived C-peptide trajectories for metabolic heterogeneity and adverse pregnancy outcomes in gestational diabetes mellitus: a nested case‒control study
Xinyue Wang, Zhangya He, Jing Ji, Simin Zhang, Jinglin Li, Jiahui Zhang, Wenlu Yu, Hexiang Yang, Zhen Han, Yang Mi, Xiaoqin Luo
BMC Medicine.2025;[Epub] CrossRef
First Trimester Mean Glucose Level on Continuous Glucose Monitoring Is Associated with Infant Birth Weight
Phaik Ling Quah, Lay Kok Tan, Serene Pei Ting Thain, Ngee Lek, Shephali Tagore, Bernard Su Min Chern, Seng Bin Ang, Ann Wright, Michelle Jong, Kok Hian Tan
Diabetes & Metabolism Journal.2025; 49(6): 1262. CrossRef
Risk factors combine in a complex manner in assessment for macrosomia
Yi-Wen Wang, Yan Chen, Yong-Jun Zhang
BMC Public Health.2023;[Epub] CrossRef
Association of the Severity of Hypertensive Disorders in Pregnancy with Birthweight, Childhood Obesity, and Blood Pressure at Age 7
Yan Chen, Yiwen Wang, Yanjun Li, Guodong Ding, Yongjun Zhang
Nutrients.2023; 15(14): 3104. CrossRef

Diabetes, Obesity and Metabolism
Role of TRPV4 Channel in Human White Adipocytes Metabolic Activity: Julio C. Sánchez, Aníbal Valencia-Vásquez, Andrés M. García; Endocrinol Metab. 2021;36(5):997-1006. Published online October 14, 2021; DOI: https://doi.org/10.3803/EnM.2021.1167

7,334 View
147 Download
7 Web of Science
7 Crossref

Abstract PDF PubReader ePub

Background
Intracellular calcium (Ca²⁺) homeostasis plays an essential role in adipocyte metabolism and its alteration is associated with obesity and related disorders. Transient receptor potential vanilloid 4 (TRPV4) channels are an important Ca²⁺ pathway in adipocytes and their activity is regulated by metabolic mediators such as insulin. In this study, we evaluated the role of TRPV4 channels in metabolic activity and adipokine secretion in human white adipocytes.
Methods
Human white adipocytes were freshly cultured and the effects of the activation and inhibition of TRPV4 channels on lipolysis, glucose uptake, lactate production, and leptin and adiponectin secretion were evaluated.
Results
Under basal and isoproterenol-stimulated conditions, TRPV4 activation by GSK1016709A decreased lipolysis whereas HC067047, an antagonist, increased lipolysis. The activation of TRPV4 resulted in increased glucose uptake and lactate production under both basal conditions and insulin-stimulated conditions; in contrast HC067047 decreased both parameters. Leptin production was increased, and adiponectin production was diminished by TRPV4 activation and its inhibition had the opposite effect.
Conclusion
Our results suggested that TRPV4 channels are metabolic mediators involved in proadipogenic processes and glucose metabolism in adipocyte biology. TRPV4 channels could be a potential pharmacological target to treat metabolic disorders.

Citations

Citations to this article as recorded by

Comparative Hypothalamic Proteomic Analysis Between Diet-Induced Obesity and Diet-Resistant Rats
Pengjiao Xi, Shuhui Ma, Derun Tian, Yanna Shen
International Journal of Molecular Sciences.2025; 26(5): 2296. CrossRef
Obesity, bone marrow adiposity, and leukemia: Time to act
Vijay Kumar, John H. Stewart
Obesity Reviews.2024;[Epub] CrossRef
TRP channels associated with macrophages as targets for the treatment of obese asthma
Wenzhao Zhu, Dinxi Bai, Wenting Ji, Jing Gao
Lipids in Health and Disease.2024;[Epub] CrossRef
Multidisciplinary Advances Address the Challenges in Developing Drugs against Transient Receptor Potential Channels to Treat Metabolic Disorders
Yibing Wang
ChemMedChem.2023;[Epub] CrossRef
Ion channels regulate energy homeostasis and the progression of metabolic disorders: Novel mechanisms and pharmacology of their modulators
Wenyi Wu, Jianan Zheng, Ru Wang, Yibing Wang
Biochemical Pharmacology.2023; 218: 115863. CrossRef
Potential lipolytic regulators derived from natural products as effective approaches to treat obesity
Xi-Ding Yang, Xing-Cheng Ge, Si-Yi Jiang, Yong-Yu Yang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Adipokines: Deciphering the cardiovascular signature of adipose tissue
Joseph C. Galley, Shubhnita Singh, Wanessa M.C. Awata, Juliano V. Alves, Thiago Bruder-Nascimento
Biochemical Pharmacology.2022; 206: 115324. CrossRef

Mineral, Bone & Muscle
Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: Jeonghoon Ha, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Seung Hyun Ko, Moo Il Kang, Sung Dae Moon, Ki-Hyun Baek; Endocrinol Metab. 2021;36(4):895-903. Published online August 9, 2021; DOI: https://doi.org/10.3803/EnM.2021.1026

10,740 View
279 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

Background
Prospective comparative studies on the effects of various antidiabetic agents on bone metabolism are limited. This study aimed to assess changes in bone mass and biochemical bone markers in postmenopausal patients with type 2 diabetes mellitus (T2DM).
Methods
This prospective, multicenter, open-label, comparative trial included 264 patients with T2DM. Patients who had received a metformin, or sulfonylurea/metformin combination (Group 1); a thiazolidinedione combination (Group 2); a dipeptidyl peptidase-4 inhibitor (gemigliptin) combination (Group 3); or an sodium-glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4) were prospectively treated for 12 months; bone mineral density (BMD) and bone turnover marker (BTM) changes were evaluated.
Results
The femoral neck BMD percentage changes were −0.79%±2.86% (Group 1), −2.50%±3.08% (Group 2), −1.05%±2.74% (Group 3), and −1.24%±2.91% (Group 4) (P<0.05). The total hip BMD percentage changes were −0.57%±1.79% (Group 1), −1.74%±1.48% (Group 2), −0.75%±1.87% (Group 3), and −1.27%±1.72% (Group 4) (P<0.05). Mean serum BTM (C-terminal type 1 collagen telopeptide and procollagen type 1 amino-terminal propeptide) levels measured during the study period did not change over time or differ between groups.
Conclusion
Significant bone loss in the femoral neck and total hip was associated with thiazolidinedione combination regimens. However, bone loss was not significantly associated with combination regimens including gemigliptin or empagliflozin. Caution should be exercised during treatment with antidiabetic medications that adversely affect the bone in patients with diabetes at a high risk of bone loss.

Citations

Citations to this article as recorded by

Dapagliflozin Improves High‐Fat Diet‐Induced Cognitive Impairment in Female Mice
Xiaolin Chen, Mingxia Fan, Zhuoni Xiao, Xiaoxing Xiong
Brain and Behavior.2025;[Epub] CrossRef
Proteases and Osteoporosis: A Comprehensive Review of Their Role in Bone Health
Syed Sufian Ahmad, Faraha Ahmed, Sayeed Ahmad, Mohammad Ahmed Khan
Current Drug Targets.2025; 26(7): 489. CrossRef
Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis
Lili Huang, Wei Zhong, Xinghuan Liang, Huijuan Wang, Shi-en Fu, Zuojie Luo
Journal of Clinical Densitometry.2024; 27(1): 101455. CrossRef
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
Soo Lim, Seung‐Hwan Lee, Kyung‐Wan Min, Chang Beom Lee, Sang Yong Kim, Hye Jin Yoo, Nan Hee Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won, Hyuk Sang Kwon, Mi Kyung Kim, Jung Hwan Park, In‐Kyung Jeong, Sungrae Kim
Diabetes, Obesity and Metabolism.2024; 26(6): 2188. CrossRef
Bone Loss in Diabetes Mellitus: Diaporosis
Krisztina Kupai, Hsu Lin Kang, Anikó Pósa, Ákos Csonka, Tamás Várkonyi, Zsuzsanna Valkusz
International Journal of Molecular Sciences.2024; 25(13): 7269. CrossRef
The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef
The effect of antidiabetic drugs on bone metabolism: a concise review
Stavroula Psachna, Maria Eleni Chondrogianni, Konstantinos Stathopoulos, Antonis Polymeris, Antonios Chatzigeorgiou, Efstathios Chronopoulos, Symeon Tournis, Eva Kassi
Endocrine.2024; 87(3): 907. CrossRef
Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert Consensus
Banshi Saboo, Shashank Joshi, Amit Gupta, Anuj Maheshwari, Bharat Saboo, Brij Mohan Makkar, Ganapathi Bantwal, Jothydev Kesavadev, L Sreenivasamurthy, Mangesh Tiwaskar, Manoj Chawla, Minakshisundaram Shunmugavelu, Nagendra Kumar Singh, Pratap Jethwani, Sa
Journal of the Association of Physicians of India.2024; 72(7): 79. CrossRef
Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study
Yilin Hou, Xiaoyu Hou, Qian Nie, Qiuyang Xia, Rui Hu, Xiaoyue Yang, Guangyao Song, Luping Ren
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1177. CrossRef
Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
European Journal of Pharmacology.2023; 957: 175946. CrossRef

Review Article

Diabetes
Cardiorenal Protection in Diabetic Kidney Disease: Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney; Endocrinol Metab. 2021;36(2):256-269. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2021.987

10,729 View
334 Download
12 Web of Science
16 Crossref

Abstract PDF PubReader ePub

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Citations

Citations to this article as recorded by

Construction, evaluation, and applications of renal barrier-on-a-chip system
Tuya Naren, Weikang Lv, Abdellah Aazmi, Yujun Wang, Haoran Yu, Jie Ying Lee, Huixiang Yang, Mengfei Yu, Xiuxiu Jiang, Huayong Yang, Liang Ma
Bioactive Materials.2026; 59: 421. CrossRef
Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial
Ayodele Odutayo, Deepak L. Bhatt, Vikas S. Sridhar, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Renato D. Lopes, Benjamin M. Scirica, Kausik K. Ray, Michael J. Davies, Phillip Banks, Manon Girard, Subodh V
Circulation: Heart Failure.2026;[Epub] CrossRef
The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence
Jin Hwa Kim
The Journal of Korean Diabetes.2025; 26(1): 5. CrossRef
Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
Soumitra Ray, J Ezhilan, Rajiv Karnik, Ashish Prasad, Rajashree Dhar
Journal of Diabetology.2024; 15(2): 131. CrossRef
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
Mustafa Arici, Bulent Altun, Mustafa Araz, Aysegul Atmaca, Tevfik Demir, Tevfik Ecder, Galip Guz, Dilek Gogas Yavuz, Alaattin Yildiz, Temel Yilmaz
Frontiers in Medicine.2024;[Epub] CrossRef
Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
Ayodele Odutayo, Adeera Levin
Clinical Journal of the American Society of Nephrology.2023; 18(5): 557. CrossRef
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinology and Metabolism.2023; 38(1): 43. CrossRef
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
Endocrinology and Metabolism.2023; 38(4): 359. CrossRef
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
A Young Sim, Da Hyun Choi, Jong Youl Kim, Eun Ran Kim, A-ra Goh, Yong-ho Lee, Jong Eun Lee
Biomedicine & Pharmacotherapy.2023; 168: 115755. CrossRef
Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
Emma S. Speedtsberg, Martin Tepel
Frontiers in Endocrinology.2023;[Epub] CrossRef
Management of CKD
Nimrit Goraya, Jennifer D. Moran
Nephrology Self-Assessment Program.2022; 21(2): 146. CrossRef
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research.2021; 172: 105859. CrossRef
Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
Ayodele Odutayo, Bruno R. da Costa, Tiago V. Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A. Hincapié, Aquila Akingbade, Myanca Rodrigues, Arnav Agarwal, Bishoy Lawendy, Pakeezah Saadat, Jacob A. Udell, Francesco Cosentino, Peter
Journal of the American Heart Association.2021;[Epub] CrossRef
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez, José Luis Gorriz
touchREVIEWS in Endocrinology.2021; 17(2): 84. CrossRef
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca-Correa, Ricardo Correa-Rotter
Frontiers in Medicine.2021;[Epub] CrossRef

Original Article

Clinical Study
High Serum-Induced AhRL Is Associated with Prevalent Metabolic Syndrome and Future Impairment of Glucose Tolerance in the Elderly: Youngmi Kim Pak, Hoon Sung Choi, Wook Ha Park, Suyeol Im, P. Monica Lind, Lars Lind, Hong Kyu Lee; Endocrinol Metab. 2021;36(2):436-446. Published online April 19, 2021; DOI: https://doi.org/10.3803/EnM.2020.883

6,694 View
121 Download
6 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
High circulating levels of dioxins and dioxin-like chemicals, acting via the aryl hydrocarbon receptor (AhR), have previously been linked to diabetes. We now investigated whether the serum AhR ligands (AhRL) were higher in subjects with metabolic syndrome (MetS) and in subjects who had developed a worsened glucose tolerance over time.
Methods
Serum AhRL at baseline was measured by a cell-based AhRL activity assay in 70-year-old subjects (n=911) in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. The main outcome measures were prevalent MetS and worsening of glucose tolerance over 5 years of follow-up.
Results
AhRL was significantly elevated in subjects with prevalent MetS as compared to those without MetS, following adjustment for sex, smoking, exercise habits, alcohol intake and educational level (P=0.009). AhRL at baseline was higher in subjects who developed impaired fasting glucose or diabetes at age 75 years than in those who remained normoglycemic (P=0.0081). The odds ratio (OR) of AhRL for worsening glucose tolerance over 5 years was 1.43 (95% confidence interval [CI], 1.13 to 1.81; P=0.003, continuous variables) and 2.81 (95% CI, 1.31 to 6.02; P=0.008, in the highest quartile) adjusted for sex, life style factors, body mass index, and glucose.
Conclusion
These findings support a large body of epidemiologic evidence that exposure to AhR transactivating substances, such as dioxins and dioxin-like chemicals, might be involved in the pathogenesis of MetS and diabetes development. Measurement of serum AhRL in humans can be a useful tool in predicting the onset of metabolic disorders.

Citations

Citations to this article as recorded by

Correlation between environmental pollutant exposure and cardiopulmonary health by serum biomarker analysis in the Swedish elderly population
Youngmi Kim Pak, Suyeol Im, Hoon Sung Choi, Lars Lind, Monica Lind, Hong Kyu Lee
International Journal of Environmental Health Research.2025; 35(5): 1156. CrossRef
Hepatic AhR Activation by TCDD Induces Obesity and Steatosis via Hepatic Plasminogen Activator Inhibitor-1 (PAI-1)
Seung Jun Oh, Suyeol Im, Sora Kang, Aden Geonhee Lee, Byung Cheol Lee, Youngmi Kim Pak
International Journal of Molecular Sciences.2025; 26(17): 8452. CrossRef
Association between polychlorinated biphenyl (PCB) and dioxin with metabolic syndrome (METS): a systematic review and meta-analysis
Mohd Danial Mohd Efendy Goon, Sarah Zulkifli, Siti Suhana Abdullah Soheimi, Sharaniza Ab. Rahim, Normala Abd Latip, Norbaya Hashim, Nirmala Devi Kerisnan, Nasehir Khan E. M. Yahaya, Alias Mohamed, Siti Hamimah Sheikh Abdul Kadir
Scientific Reports.2024;[Epub] CrossRef
Relationships among Dioxin-like Mitochondria Inhibitor Substances (MIS)-Mediated Mitochondria Dysfunction, Obesity, and Lung Function in a Korean Cohort
Hoonsung Choi, Kyungho Ha, Jin Taek Kim, Min Kyong Moon, Hyojee Joung, Hong Kyu Lee, Youngmi Kim Pak
Toxics.2024; 12(10): 735. CrossRef
An Interactive Online App for Predicting Diabetes via Machine Learning from Environment-Polluting Chemical Exposure Data
Rosy Oh, Hong Kyu Lee, Youngmi Kim Pak, Man-Suk Oh
International Journal of Environmental Research and Public Health.2022; 19(10): 5800. CrossRef
A Novel Aryl Hydrocarbon Receptor Antagonist HBU651 Ameliorates Peripheral and Hypothalamic Inflammation in High-Fat Diet-Induced Obese Mice
Sora Kang, Aden Geonhee Lee, Suyeol Im, Seung Jun Oh, Hye Ji Yoon, Jeong Ho Park, Youngmi Kim Pak
International Journal of Molecular Sciences.2022; 23(23): 14871. CrossRef

Review Article

Diabetes
Continuous Glucose Monitoring in the Hospital: M. Citlalli Perez-Guzman, Trisha Shang, Jennifer Y. Zhang, Donna Jornsay, David C. Klonoff; Endocrinol Metab. 2021;36(2):240-255. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2021.201

29,979 View
830 Download
41 Web of Science
42 Crossref

Abstract PDF PubReader ePub

Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.

Citations

Citations to this article as recorded by

Scoping review of subcutaneous glucose monitoring techniques
Eva Hrubá, Jan Kubíček, Martin Augustynek
Measurement.2026; 261: 119940. CrossRef
Impact of real-time continuous glucose monitoring and personalized digital health coaching on glycemic control and lifestyle in patients with type 2 diabetes and prediabetes
Yujin Park, Hye Rin Choi, Ji-eun Lee, Boram Choi, Chang-bo Noh, Jae-Heon Kang, Ye Seul Bae
Primary Care Diabetes.2026; 20(1): 61. CrossRef
Using technology to support diabetes care in hospital: Guidelines from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) group and Diabetes Technology Network (DTN) UK
Parizad Avari, Pratik Choudhary, Alistair Lumb, Shivani Misra, Gerry Rayman, Daniel Flanagan, Ketan Dhatariya
Diabetic Medicine.2025;[Epub] CrossRef
Clinical trial protocol for continuous glucose monitoring in critical care at Hospital Clinic of Barcelona (CGM‐UCI23)
Marc Pañero‐Moreno, Eva Maria Guix‐Comellas, Alberto Villamor‐Ordozgoiti
Nursing in Critical Care.2025;[Epub] CrossRef
Using Diabetes Technology in Hospitalized Patients
Deborah L. McCrea
Critical Care Nursing Clinics of North America.2025; 37(1): 35. CrossRef
Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: A systematic review and meta-analysis of randomized controlled trials
Gabriel Cavalcante Lima Chagas, Larissa Teixeira, Mariana R.C. Clemente, Rafael Cavalcante Lima Chagas, Diego Vinicius Santinelli Pestana, Lorenna Rodrigues Silva Sombra, Bruno B. Lima, Rodolfo J. Galindo, Marconi Abreu
Diabetes Research and Clinical Practice.2025; 220: 111986. CrossRef
Continuous glucose monitoring in the ruling out recurrent insulinoma
M. Yu. Yukina, E. A. Troshina, N. F. Nuralieva, O. Yu. Rebrova, N. G. Mokrysheva
Endocrine Surgery.2025; 18(4): 25. CrossRef
In-Hospital Diabetes Management by a Diabetes Team and Insulin Titration Algorithms Based on Continuous Glucose Monitoring or Point-of-Care Glucose Testing in Patients With Type 2 Diabetes (DIATEC): A Randomized Controlled Trial
Mikkel T. Olsen, Carina K. Klarskov, Signe H. Jensen, Louise M. Rasmussen, Birgitte Lindegaard, Jonas A. Andersen, Hans Gottlieb, Suzanne Lunding, Ulrik Pedersen-Bjergaard, Katrine B. Hansen, Peter L. Kristensen
Diabetes Care.2025; 48(4): 569. CrossRef
Transformative Advances in Continuous Glucose Monitoring and the Impact of FDA Over‐the‐Counter Approval on Diabetes Care
Zain Afridi, Sameer Abdul Rauf, Syed Muhammad Nabil Ashraf, Md Ariful Haque
Health Science Reports.2025;[Epub] CrossRef
Prise de position d’un groupe d’experts – utilisation de la mesure en continu du glucose chez les patients vivant avec un diabète de type 2 en France
Michael Joubert, Benjamin Bouillet, Gaëtan Prevost, Bruno Vermesse, Helen Mosnier-Pudar, Jean-François Thébaut, Jean-Pierre Riveline, Noëlle Davoust, Bruno Guerci, Laurent Meyer
Médecine des Maladies Métaboliques.2025; 19(4): 331. CrossRef
Continuous Glucose Monitoring Systems in Diabetes Management: A Qualitative Analysis Based on User Experiences
Ayten Kaya
Medical Records.2025; 7(2): 491. CrossRef
Top Ten Tips Palliative Care Clinicians Should Know About Managing Diabetes at End-of-Life
Rebekka DePew, Tonya Hershman, Monica Giles, William E. Rosa, Kimberly Curseen
Journal of Palliative Medicine.2025;[Epub] CrossRef
Exploring Authentication Protocols for Secure and Efficient Internet of Medical Things Systems
Seungbin Lee, Kyeong A Kang, Soowang Lee, Jiyoon Kim
Electronics.2025; 14(21): 4164. CrossRef
Performance and clinical relevance of continuous glucose monitoring during early brain injury in subarachnoid hemorrhage
Daniel Santana, Alejandra Mosteiro, Leire Pedrosa, Gabriel Pujol-Fontrodona, Luigi Zattera, Mariano Werner, Emilio Ortega, Laura Llull, Ramón Torné, Sergio Amaro
Scientific Reports.2025;[Epub] CrossRef
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
Diabetes Technology & Therapeutics.2024; 26(4): 222. CrossRef
Glucose management in critically ill adults: A qualitative study from the experiences of health care providers
Miao Huang, Li Yang, Chuanlai Zhang, Xiuni Gan
Heliyon.2024; 10(3): e24545. CrossRef
Summary of clinical investigation plan for The DIATEC trial: in-hospital diabetes management by a diabetes team and continuous glucose monitoring or point of care glucose testing – a randomised controlled trial
Mikkel Thor Olsen, Carina Kirstine Klarskov, Ulrik Pedersen-Bjergaard, Katrine Bagge Hansen, Peter Lommer Kristensen
BMC Endocrine Disorders.2024;[Epub] CrossRef
Nurses’ practice of metabolic monitoring for patients on antipsychotics in Lesotho
Relebohile P. Matete, Libuseng M. Rathobei
South African Journal of Psychiatry.2024;[Epub] CrossRef
Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery
Tae Sang Yu, Soojeong Song, Junwoo Yea, Kyung‐In Jang
Advanced Sensor Research.2024;[Epub] CrossRef
Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation
Nicola Tecce, Davide Menafra, Mattia Proganò, Mario Felice Tecce, Rosario Pivonello, Annamaria Colao
Healthcare.2024; 12(18): 1823. CrossRef
Perioperative glucose monitoring with continuous glucose monitors identifies risk factors for post-transplant diabetes mellitus in kidney transplant recipients
Jiyoung Shin, Eun-Ah Jo, Hye Yong Woo, Ara Cho, Myeonghyeon Ko, Sangwan Kim, Ahram Han, Jongwon Ha, Sangil Min
Scientific Reports.2024;[Epub] CrossRef
High Frequency of Severe Hyperglycemia Observed During Intensive Hematologic Care: A Prospective Study Using Continuous Glucose Monitoring
Marieke Tienstra, Janneke W. de Boer, Jaap A. van Doesum, Kylie Keijzer, Linde M. Morsink, Carin L.E. Hazenberg, Emanuele Ammatuna, Gerwin A. Huls, Pratik Choudhary, Rijk O.B. Gans, Valerie R. Wiersma, Tom van Meerten, Peter R. van Dijk
Endocrine Practice.2024; 30(12): 1141. CrossRef
The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record
Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff
Journal of Diabetes Science and Technology.2023; 17(2): 495. CrossRef
Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey
Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan
Nursing in Critical Care.2023; 28(6): 931. CrossRef
Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center
Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris
Endocrine Practice.2023; 29(3): 155. CrossRef
Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations
Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo
Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263. CrossRef
Type 1 Diabetes Overview and Perioperative Management
Grace B. Nelson, Kathryn M. Sumpter
Orthopedic Clinics of North America.2023; 54(3): 287. CrossRef
Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas
Journal of Diabetes Science and Technology.2023; 17(3): 656. CrossRef
Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review
Eileen R. Faulds, Kathleen M. Dungan, Molly McNett
Current Diabetes Reports.2023; 23(6): 69. CrossRef
Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis
Esther Park, Minsun Kim
Diabetes Technology & Therapeutics.2023; 25(8): 529. CrossRef
Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality
Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2023; 25(12): 883. CrossRef
A randomized trial of continuous glucose monitoring to improve post‐transplant glycemic control
Nicholas Jandovitz, Sam J. George, Mersema Abate, Adam M. Kressel, Alexandra C. Bolognese, Lawrence Lau, Vinay Nair, Elliot Grodstein
Clinical Transplantation.2023;[Epub] CrossRef
More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data
Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann
Journal of Diabetes Science and Technology.2022; 16(1): 3. CrossRef
Continuous glucose monitoring in the hospital: an update in the era of COVID-19
Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis
Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1. CrossRef
Breakthrough technology for in-hospital glucose monitoring
David Kerr, David Klonoff
The Lancet Diabetes & Endocrinology.2022; 10(5): 304. CrossRef
The Role of the Diabetes Care and Education Specialist in the Hospital Setting

The Science of Diabetes Self-Management and Care.2022; 48(3): 184. CrossRef
Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives
Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth
Journal of Clinical Medicine.2022; 11(9): 2408. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Stress-Induced Hyperglycemia: Consequences and Management
Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne
Cureus.2022;[Epub] CrossRef
Hospital Diabetes Meeting 2022
Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math
Journal of Diabetes Science and Technology.2022; 16(5): 1309. CrossRef
Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study
Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho
Diabetes Care.2022; 45(10): 2224. CrossRef
The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting
Rebecca Rick Longo, Renu Joshi
Diabetes Spectrum.2022; 35(4): 405. CrossRef

Original Article

Clinical Study
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis: Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim; Endocrinol Metab. 2021;36(2):388-400. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.912

11,820 View
418 Download
17 Web of Science
21 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.
Methods
We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.
Results
Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.
Conclusion
SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Omarigliptin ameliorates cisplatin-induced renal damage: Cross-talk between glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and TXNIP/NLRP3 inflammasome/gasdermin D axis
Shuruq E. Alsufyani, Hany H. Arab, Azza A.K. El-Sheikh, El-Shaimaa A. Arafa, Ahmed Fouad Hussein Hashad, Reham M. Goda, Tamer M. Naguib, Maaly A. Abd Elmaaboud, Mennatallah A. Elkady, Ahmed M. Kabel
Life Sciences.2025; 376: 123758. CrossRef
Expert consensus on solutions to improve implementation of NICE type 2 diabetes guideline (NG28) by health systems in England: a Delphi panel by the INNOVATE-28 Working Group
Waqas Tahir, Hannah Beba, Gail Fortes-Mayer, Partha Kar, Nazish Khan, Nicola Milne, Jim Moore, Sharvanu Saha, Marc Atkin
BMJ Open.2025; 15(6): e093955. CrossRef
Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
Hsiao‐Wei Wang, Ming‐Hsien Tsai, Yu‐Wei Fang, Kuo‐Cheng Lu, Joshua Wang, Chien‐Lin Lu
Diabetes, Obesity and Metabolism.2025; 27(11): 6188. CrossRef
Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C Green, David J Tunnicliffe, Giovanni Pellegrino, Tadashi Toyama, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2024; 20(2): 212. CrossRef
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2024; 132(07): 340. CrossRef
Clinical Management of Type II DM in patients Showing Progressive Increase in the Creatinine Level – A Cross-sectional Study
Prabhudatta Mohapatra, Durga Madhab Kar, Karmajeet Rath, Abhisek Pal
Research Journal of Pharmacy and Technology.2024; : 2719. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2023; 19(5): 658. CrossRef
Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, Natnicha Poonchuay, Rizky Abdulah
Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1. CrossRef
Different nursing interventions on sleep quality among critically ill patients: A systematic review and network meta-analysis
Daijin Huang, Yumei Li, Jing Ye, Chang Liu, Dongyan Shen, Yunhui Lv
Medicine.2023; 102(52): e36298. CrossRef
New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist
Pavel Weber, Hana Meluzínová, Dana Weberová
Klinická farmakologie a farmacie.2022; 35(4): 118. CrossRef
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
Hongwei Cao, Tao Liu, Li Wang, Qiuhe Ji
Diabetes, Obesity and Metabolism.2022; 24(8): 1448. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2022; 18(5): 623. CrossRef
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on inte
Iskandar Idris, Ruiqi Zhang, Jil B. Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
Diabetes, Obesity and Metabolism.2022; 24(11): 2138. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2022; 130(S 01): S80. CrossRef
Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221. CrossRef
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
Rheumatology.2022;[Epub] CrossRef
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Chan-Hee Jung
Endocrinology and Metabolism.2021; 36(2): 339. CrossRef
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André J. Scheen
Diabetes & Metabolism.2021; 47(6): 101275. CrossRef

Review Article

Diabetes
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020: Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee; Endocrinol Metab. 2021;36(1):41-50. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2021.106

7,885 View
190 Download
3 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.

Citations

Citations to this article as recorded by

Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes
Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon
Scientific Reports.2022;[Epub] CrossRef
Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study
Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu
International Journal of Environmental Research and Public Health.2022; 19(13): 8036. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef

Original Articles

Clinical Study
Predictive Performance of Glycated Hemoglobin for Incident Diabetes Compared with Glucose Tolerance Test According to Central Obesity: Suji Yoo, Jaehoon Jung, Hosu Kim, Kyoung Young Kim, Soo Kyoung Kim, Jungwha Jung, Jong Ryeal Hahm, Jong Ha Baek; Endocrinol Metab. 2020;35(4):873-881. Published online December 23, 2020; DOI: https://doi.org/10.3803/EnM.2020.798

7,706 View
128 Download
2 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To examine whether glycated hemoglobin (HbA1c) test would be a suitable screening tool for detecting high-risk subjects for diabetes compared to oral glucose tolerance test (OGTT) according to accompanied central obesity.
Methods
In this prospective population-based cohort study, both OGTT and HbA1c tests were performed and continued every 2 years up to 12 years among individuals with non-diabetic state at baseline (aged 40 to 69 years, n=7,512). Incident diabetes was established by a doctor, HbA1c ≥6.5%, and/or fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-hour postprandial glucose (2hPG) level based on OGTT ≥200 mg/dL. Discriminative capacities of high HbA1c (≥5.7%) versus high 2hPG (≥140 mg/dL) for predicting incident diabetes were compared using Cox-proportional hazard regression and C-index.
Results
During the median 11.5 years of follow-up period, 1,341 (17.6%) developed diabetes corresponding to an incidence of 22.1 per 1,000 person-years. Isolated high 2hPG was associated with higher risk for incident diabetes (hazard ratio [HR], 4.29; 95% confidence interval [CI], 3.56 to 5.17) than isolated high HbA1c (HR, 2.79; 95% CI, 2.40 to 3.26; P<0.05). In addition, high 2hPG provided better discriminatory capacity than high HbA1c (C-index 0.79 vs. 0.75, P<0.05). Meanwhile, in subjects with central obesity, the HR (3.95 [95% CI, 3.01 to 5.18] vs. 2.82 [95% CI, 2.30 to 3.46]) and discriminatory capacity of incident diabetes (C-index 0.75 vs. 0.75) between two subgroups became comparable.
Conclusion
Even though the overall inferior predictive capacity of HbA1c test than OGTT, HbA1c test might plays a complementary role in identifying high risk for diabetes especially in subjects with central obesity with increased sensitivity.

Citations

Citations to this article as recorded by

Assessing blood sugar measures for predicting new-onset diabetes and cardiovascular disease in community-dwelling adults
Jung-Hwan Kim, Yaeji Lee, Chung-Mo Nam, Yu-Jin Kwon, Ji-Won Lee
Endocrine.2024; 86(2): 528. CrossRef

Clinical Study
Cross-Sectional and Longitudinal Examination of Insulin Sensitivity and Secretion across Puberty among Non-Hispanic Black and White Children: Shannon E. Marwitz, Megan V. Gaines, Sheila M. Brady, Sarah J. Mi, Miranda M. Broadney, Susan Z. Yanovski, Van S. Hubbard, Jack A. Yanovski; Endocrinol Metab. 2020;35(4):847-857. Published online November 18, 2020; DOI: https://doi.org/10.3803/EnM.2020.771

7,649 View
108 Download
10 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Few studies using criterion measures of insulin sensitivity (SI) and insulin secretory capacity (ISC) have been conducted across puberty to adulthood. We examined how SI and ISC change from pre-puberty through adulthood.
Methods
Hyperglycemic clamp studies were performed in a convenience sample of non-Hispanic Black (NHB) and White children evaluated at age 6 to 12 years and at approximately 5-year intervals into adulthood (maximum age 27 years). SI and ISC (first-phase and steady-state insulin secretion) were determined cross-sectionally in 133 unique participants across puberty and in adulthood. Additionally, longitudinal changes in SI and ISC were compared at two timepoints among three groups defined by changes in pubertal development: pre-pubertal at baseline and late-pubertal at follow-up (n=27), early-pubertal at baseline and late-pubertal at follow-up (n=27), and late-pubertal at baseline and adult at follow-up (n=24).
Results
Cross-sectionally, SI was highest in pre-puberty and early puberty and lowest in mid-puberty (analysis of covariance [ANCOVA] P=0.001). Longitudinally, SI decreased from pre-puberty to late puberty (P<0.001), then increased somewhat from late puberty to adulthood. Cross-sectionally, first-phase and steady-state ISC increased during puberty and decreased in adulthood (ANCOVA P<0.02). Longitudinally, steady-state and first-phase ISC increased from pre-puberty to late puberty (P<0.007), and steady-state ISC decreased from late puberty to adulthood. The NHB group had lower SI (P=0.003) and greater first-phase and steady-state ISC (P≤0.001), independent of pubertal development.
Conclusion
This study confirms that SI decreases and ISC increases transiently during puberty and shows that these changes largely resolve in adulthood.

Citations

Citations to this article as recorded by

The relationship of changes in insulin demand and insulin adequacy over the life course
Yingchai Zhang, Claudia H. T. Tam, Eric S. H. Lau, Noel Y. H. Ng, Aimin Yang, Baoqi Fan, Hongjiang Wu, Cadmon K. P. Lim, Elaine Y. K. Chow, Andrea O. Y. Luk, Alice P. S. Kong, Wing Hung Tam, Juliana C. N. Chan, Ronald C. W. Ma
Diabetologia.2025; 68(3): 526. CrossRef
Youth-Onset Type 2 Diabetes Before and After COVID-19 Pandemic-Related Public Health Restrictions: Trends in Incidence, Severity, and Remission
Jody Beth Grundman, Elizabeth Estrada, Rachel Longendyke, Stephanie T. Chung
Journal of Clinical Medicine.2025; 14(22): 7995. CrossRef
Exploratory Longitudinal Analysis of the Circulating CHIT1 Activity in Pediatric Patients with Obesity
Ioana Țaranu, Nicoleta Răcătăianu, Cristina Drugan, Cristina-Sorina Cătană, Andreea-Manuela Mirea, Diana Miclea, Sorana D. Bolboacă
Children.2023; 10(1): 124. CrossRef
Insulin Clearance in Health and Disease
Sonia M. Najjar, Sonia Caprio, Amalia Gastaldelli
Annual Review of Physiology.2023; 85(1): 363. CrossRef
Influence of puberty on relationships between body composition and blood pressure: a cross-sectional study
Esther A. Kwarteng, Lisa M. Shank, Loie M. Faulkner, Lucy K. Loch, Syeda Fatima, Suryaa Gupta, Hannah E. Haynes, Kaitlin L. Ballenger, Megan N. Parker, Sheila M. Brady, Anna Zenno, Marian Tanofsky-Kraff, Jack A. Yanovski
Pediatric Research.2023; 94(2): 781. CrossRef
Distribution of OGTT-Related Variables in Patients with Cystic Fibrosis from Puberty to Adulthood: An Italian Multicenter Study
Andrea Foppiani, Fabiana Ciciriello, Arianna Bisogno, Silvia Bricchi, Carla Colombo, Federico Alghisi, Vincenzina Lucidi, Maria Catena, Mariacristina Lucanto, Andrea Mari, Giorgio Bedogni, Alberto Battezzati
Journal of Personalized Medicine.2023; 13(3): 469. CrossRef
Fat-free/lean body mass in children with insulin resistance or metabolic syndrome: a systematic review and meta-analysis
Diana Paola Córdoba-Rodríguez, Iris Iglesia, Alejandro Gomez-Bruton, Gerardo Rodríguez, José Antonio Casajús, Hernan Morales-Devia, Luis A. Moreno
BMC Pediatrics.2022;[Epub] CrossRef
Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
Journal of General Internal Medicine.2022; 37(16): 4153. CrossRef
An update of the consensus statement on insulin resistance in children 2010
Veronica Maria Tagi, Sona Samvelyan, Francesco Chiarelli
Frontiers in Endocrinology.2022;[Epub] CrossRef
Dietary sugar restriction reduces hepatic de novo lipogenesis in boys with fatty liver disease
Stephanie T. Chung, Sheela N. Magge
Journal of Clinical Investigation.2021;[Epub] CrossRef

Clinical Study
Insulin Secretion and Insulin Resistance Trajectories over 1 Year after Kidney Transplantation: A Multicenter Prospective Cohort Study: Jun Bae Bang, Chang-Kwon Oh, Yu Seun Kim, Sung Hoon Kim, Hee Chul Yu, Chan-Duck Kim, Man Ki Ju, Byung Jun So, Sang Ho Lee, Sang Youb Han, Cheol Woong Jung, Joong Kyung Kim, Su Hyung Lee, Ja Young Jeon; Endocrinol Metab. 2020;35(4):820-829. Published online November 18, 2020; DOI: https://doi.org/10.3803/EnM.2020.743

8,261 View
139 Download
10 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated the changing patterns of insulin secretion and resistance and risk factors contributing to the development of post-transplant diabetes mellitus (PTDM) in kidney recipients under tacrolimus-based immunosuppression regimen during 1 year after transplantation.
Methods
This was a multicenter prospective cohort study. Of the 168 subjects enrolled in this study, we analyzed a total 87 kidney transplant recipients without diabetes which was assessed by oral glucose tolerance test before transplantation. We evaluated the incidence of PTDM and followed up the index of insulin secretion (insulinogenic index [IGI]) and resistance (homeostatic model assessment for insulin resistance [HOMA-IR]) at 3, 6, 9 months, and 1 year after transplantation by oral glucose tolerance test and diabetes treatment. We also assessed the risk factors for incident PTDM.
Results
PTDM developed in 23 of 87 subjects (26.4%) during 1 year after transplantation. More than half of total PTDM (56.5%) occurred in the first 3 months after transplantation. During 1 year after transplantation, insulin resistance (HOMA-IR) was increased in both PTDM and no PTDM group. In no PTDM group, the increase in insulin secretory function to overcome insulin resistance was also observed. However, PTDM group showed no increase in insulin secretion function (IGI). Old age, status of prediabetes and episode of acute rejection were significantly associated with the development of PTDM.
Conclusion
In tacrolimus-based immunosuppressive drugs regimen, impaired insulin secretory function for reduced insulin sensitivity contributed to the development of PTDM than insulin resistance during 1 year after transplantation.

Citations

Citations to this article as recorded by

Association of Myosteatosis and of Graft Loss after Kidney Transplantation
Marcel Zorgdrager, Yi Liu, Jingyao Hong, Nidhi Ghildayal, Tim D.A. Swaab, Stephan J.L. Bakker, Alain R. Viddeleer, Babak J. Orandi, Omid Shafaat, Clifford R. Weiss, Dorry Segev, Mara McAdams-DeMarco, Robert A. Pol
Clinical Journal of the American Society of Nephrology.2026; 21(1): 118. CrossRef
Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection
Zetong Tao, Zilong Luo, Zifeng Zou, Weicong Ye, Yanglin Hao, Xiaohan Li, Kexiao Zheng, Jie Wu, Jiahong Xia, Yang Zhao, Yongjun Wang, Xi Zhang
Frontiers in Immunology.2025;[Epub] CrossRef
Immunomodulation in post-transplant diabetes mellitus: Challenges and management
Hanan Maoz, Amir Elalouf
Transplant Immunology.2025; 93: 102304. CrossRef
Incidence and Risk Factors of Obesity and Overweight in Kidney Transplant Recipients and Their Effect on Graft Outcome
Muhammad Abdul Mabood Khalil, Nihal Mohammed Sadagah, Hinda Hassan Khideer Mahmood, Abdulrahman Ibn Almuataz Wasfi Ezzi, Sultan Abdullah M. Alghamdi, Faisal Saud H. Alsulami, Ahmed Abdelahad Basha, Mohamed Abdelmonem Said Ahmed, Islam Nabil Sharabas, Hith
Journal of Transplantation.2025;[Epub] CrossRef
Prevalence of new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis
Qiufeng Du, Tao Li, Xiaodong Yi, Shuang Song, Jing Kang, Yunlan Jiang
Acta Diabetologica.2024; 61(7): 809. CrossRef
Normalization of impaired glucose tolerance after kidney transplantation is associated with improved β-cell function
Maiko Miyamoto, Akinobu Nakamura, Aika Miya, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Naoya Iwahara, Kiyohiko Hotta, Nobuo Shinohara, Tatsuya Atsumi
American Journal of Physiology-Endocrinology and Metabolism.2024; 327(2): E194. CrossRef
Association between HOMA2 based beta-cell function or insulin resistance and long-term outcomes in kidney transplant recipients with type 2 diabetes
Mehdi Maanaoui, Florence Debillon, Rémi Lenain, Frédérique Defrance, Marie-Christine Vantyghem, Marine Van Triempont, François Provôt, Mikael Chetboun, Julie Kerr-Conte, Aghiles Hamroun, Marie Frimat, Violeta Raverdy, François Pattou, Marc Hazzan, Françoi
Scientific Reports.2024;[Epub] CrossRef
Distúrbio do eixo hipotálamo-hipófise-gonadal e sua associação com resistência à insulina em receptores de transplante renal
Lourdes Balcázar-Hernández, Victoria Mendoza-Zubieta, Baldomero González-Virla, Brenda González-García, Mariana Osorio-Olvera, Jesús Ubaldo Peñaloza-Juarez, Irene Irisson-Mora, Martha Cruz-López, Raúl Rodríguez-Gómez, Ramón Espinoza-Pérez, Guadalupe Varga
Brazilian Journal of Nephrology.2023; 45(1): 77. CrossRef
Hypothalamic-pituitary-gonadal axis disturbance and its association with insulin resistance in kidney transplant recipients
Lourdes Balcázar-Hernández, Victoria Mendoza-Zubieta, Baldomero González-Virla, Brenda González-García, Mariana Osorio-Olvera, Jesús Ubaldo Peñaloza-Juarez, Irene Irisson-Mora, Martha Cruz-López, Raúl Rodríguez-Gómez, Ramón Espinoza-Pérez, Guadalupe Varga
Brazilian Journal of Nephrology.2023; 45(1): 77. CrossRef
Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients
Le Wang, Jin Huang, Yajuan Li, Kewei Shi, Sai Gao, Wangcheng Zhao, Shanshan Zhang, Chenguang Ding, Wei Gao
Endocrine.2023; 81(1): 58. CrossRef
Changes in glucose metabolism among recipients with diabetes 1 year after kidney transplant: a multicenter 1-year prospective study
Jun Bae Bang, Chang-Kwon Oh, Yu Seun Kim, Sung Hoon Kim, Hee Chul Yu, Chan-Duck Kim, Man Ki Ju, Byung Jun So, Sang Ho Lee, Sang Youb Han, Cheol Woong Jung, Joong Kyung Kim, Hyung Joon Ahn, Su Hyung Lee, Ja Young Jeon
Frontiers in Endocrinology.2023;[Epub] CrossRef
Pretransplant evaluation and the risk of glucose metabolic alterations after renal transplantation: a prospective study
Arminda Fariña-Hernández, Domingo Marrero-Miranda, Estefania Perez-Carreño, Antonia De Vera-Gonzalez, Alejandra González, Cristian Acosta-Sorensen, Ana Elena Rodríguez-Rodríguez, Tatiana Collantes, Marta del Pino García, Ana Isabel Rodríguez-Muñoz, Carla
Nephrology Dialysis Transplantation.2022;[Epub] CrossRef

Review Article

Diabetes
Lessons from Use of Continuous Glucose Monitoring Systems in Digital Healthcare: Hun-Sung Kim, Kun-Ho Yoon; Endocrinol Metab. 2020;35(3):541-548. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.675

12,976 View
212 Download
15 Web of Science
18 Crossref

Abstract PDF PubReader ePub

We live in a digital world where a variety of wearable medical devices are available. These technologies enable us to measure our health in our daily lives. It is increasingly possible to manage our own health directly through data gathered from these wearable devices. Likewise, healthcare professionals have also been able to indirectly monitor patients’ health. Healthcare professionals have accepted that digital technologies will play an increasingly important role in healthcare. Wearable technologies allow better collection of personal medical data, which healthcare professionals can use to improve the quality of healthcare provided to the public. The use of continuous glucose monitoring systems (CGMS) is the most representative and desirable case in the adoption of digital technology in healthcare. Using the case of CGMS and examining its use from the perspective of healthcare professionals, this paper discusses the necessary adjustments required in clinical practices. There is a need for various stakeholders, such as medical staff, patients, industry partners, and policy-makers, to utilize and harness the potential of digital technology.

Citations

Citations to this article as recorded by

Analysis of experiences on telemedicine pilot projects from the perspectives of doctors, pharmacists, and patients
Yeryeon Jung, Hyunah Kim, Jeong-Yeon Kim, Seongwoo Seo, Youseok Kim, Min Jung Ko, Hun-Sung Kim
The Korean Journal of Internal Medicine.2026; 41(1): 131. CrossRef
A Pilot Study Examining If the Additional Use of a Continuous Glucose Monitoring Is Helpful for Glucose Control in Older Adults
Kwang Joon Kim, Yang Sun Park, Eunseo Sun, Euna Jo, Jiwon Shinn, Hyeon Woo Yim, Chang Oh Kim, Hun-Sung Kim
Yonsei Medical Journal.2025; 66(6): 346. CrossRef
Evolving Regulations in Telemedicine Pilot Project: Insights Into Law, Practice, and Patient Care through International Case Studies
Jiwon Shinn, Yeryeon Jung, Jeong-Yeon Kim, Seongwoo Seo, Eunseol Lee, Youseok Kim, Min Jung Ko, Hun-Sung Kim
Journal of Korean Medical Science.2025;[Epub] CrossRef
Using digital tools to improve diabetes care in India with continuous glucose monitoring
Jothydev Kesavadev, Banshi Saboo, Manoj S. Chawla, Ambika Gopalakrishnan Unnikrishnan, Timothy C. Dunn, Mangesh Harihar Tiwaskar
Therapeutic Advances in Endocrinology and Metabolism.2025;[Epub] CrossRef
Bridging the digital divide: student-led literacy initiatives in diabetes management
Pedro Almeida Moyano, Mohammed Raddaoui, Andrea de Barros Coscelli Ferraz, Gustavo José Martiniano Porfírio, Luciana Aparecida Campos, Ovidiu Constantin Baltatu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Managing Talent Among Healthcare Human Resource: Strategies for a New Normal
Divya Aggarwal, Vijit Chaturvedi, Anandhi Ramachandran, Taniya Singh
Journal of Health Management.2024; 26(2): 384. CrossRef
Current status of remote collaborative care for hypertension in medically underserved areas
Seo Yeon Baik, Kyoung Min Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 33. CrossRef
Using medical big data for clinical research and legal considerations for the protection of personal information: the double-edged sword
Raeun Kim, Jiwon Shinn, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 8. CrossRef
Diverse perspectives on remote collaborative care for chronic disease management
Seo Yeon Baik, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 26. CrossRef
Expectations and concerns regarding medical advertisements via large commercial medical platform advertising companies: a legal perspective
Raeun Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2024; 6(2): 48. CrossRef
Ortho-digital dynamics: Exploration of advancing digital health technologies in musculoskeletal disease management
Zulipikaer Maimaiti, Zhuo Li, Zhiyuan Li, Jun Fu, Chi Xu, Jiying Chen, Wei Chai, Liang Liu
DIGITAL HEALTH.2024;[Epub] CrossRef
Development of a T2D App for Elderly Users: Participatory Design Study via Heuristic Evaluation and Usability Testing
Zhengyang Liu, Xinran Yu
Electronics.2024; 13(19): 3862. CrossRef
Patent analysis of digital sensors for continuous glucose monitoring
Olena Litvinova, Magdalena Eitenberger, Aylin Bilir, Andy Wai Kan Yeung, Emil D. Parvanov, ArunSundar MohanaSundaram, Jarosław Olav Horbańczuk, Atanas G. Atanasov, Harald Willschke
Frontiers in Public Health.2023;[Epub] CrossRef
Personalized Nutrition 2020: Proceedings from the American Nutrition Association’s 61st Annual Summit
Victoria A. Y. Behm, Corinne L. Bush
Journal of the American College of Nutrition.2021; 40(4): 397. CrossRef
Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians
Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Perceptron: Basic Principles of Deep Neural Networks
Eung-Hee Kim, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 64. CrossRef
Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions
Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Digital health and diabetes: experience from India
Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan
Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub] CrossRef

Original Article

Clinical Study
Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study: Min Cheol Chang, Jong-Moon Hwang, Jae-Han Jeon, Sang Gyu Kwak, Donghwi Park, Jun Sung Moon; Endocrinol Metab. 2020;35(3):595-601. Published online August 26, 2020; DOI: https://doi.org/10.3803/EnM.2020.719

10,552 View
190 Download
21 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Coronavirus disease 2019 (COVID-19) has become a global pandemic, which prompts a consensus for the necessity to seek risk factors for this critical disease. Risk factors affecting mortality of the disease remain elusive. Diabetes and hyperglycemia are known to negatively affect a host’s antiviral immunity. We evaluated the relationship between a history of diabetes, fasting plasma glucose (FPG) levels and mortality among severely ill patients with COVID-19.
Methods
This was a retrospective cohort study that assessed 106 adult inpatients (aged ≥18 years) from two tertiary hospitals in Daegu, South Korea. The participants were transferred to tertiary hospitals because their medical condition required immediate intensive care. The demographic and laboratory data were compared between COVID-19 patients who survived and those who did not.
Results
Compared with the survivor group, age, and the proportions of diabetes, chronic lung disease and FPG were significantly higher in the deceased group. In the Cox proportional hazards regression model for survival analysis, FPG level and age were identified as significant predictors of mortality (P<0.05). The threshold values for predicting high mortality were age >68 years and FPG of 168 mg/dL, respectively. Among those without diabetes, high FPG remained a significant predictor of mortality (P<0.04).
Conclusion
High FPG levels significantly predicted mortality in COVID-19, regardless of a known history of diabetes. These results suggest intensive monitoring should be provided to COVID-19 patients who have a high FPG level.

Citations

Citations to this article as recorded by

Novel non-invasive glucose concentration sensor by phase shift of patch antenna
Shasha Yang, Shiwen Gao, Yi Zhuang, Lifeng Wang, Zhenxiang Yi, Lei Wang
Measurement.2026; 261: 119930. CrossRef
Assessment of serum biomarker changes following the COVID-19 pandemic and vaccination: a cohort study in Sylhet, Bangladesh
Shangida Akther, Fairoz Samiha, Sabrina Amita Sony, Mohammad Anamul Haque, Mohammad Abul Hasnat, S. M. Saiful Islam, Shamim Ahmed, Mohammad Abdullah-Al-Shoeb
Frontiers in Public Health.2025;[Epub] CrossRef
Hyperglycemia, diabetes, and de novo diabetes in patients hospitalized in intensive care units for COVID-19 in Colombia: Results from a longitudinal cohort study
John Jaime Sprockel, Ana Maria Perez, Maria Camila Chamorro, Jose Alejandro Vergel, Ximena Espinosa, Juan Carlos Vargas, Carlos Angarita, Jhon Edinson Parra
The Journal of Critical Care Medicine.2025; 11(3): 257. CrossRef
Construction of a Personalized Prediction Model for Diabetic Lung Infection Based on Machine Learning
Qian Shen
Clinical Endocrinology.2025; 103(6): 815. CrossRef
Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study
Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2024; 39(3): 479. CrossRef
Testing AI predictions that hyperglycemia-induced non-enzymatic glycation of immune system proteins impairs diabetic immunity
Thomas Turkette, Andrew Decker, Robert Root-Bernstein
Computational and Structural Biotechnology Reports.2024; 1: 100015. CrossRef
Fasting Plasma Glucose Levels at the Time of Admission Predict 90-Day Mortality in Patients with Viral Pneumonia. A Prospective Study
Jie Xu, Jianyu Zhao, Liyuan Wu, Xinxin Lu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(05): 290. CrossRef
Influence of Fasting Plasma Glucose Level on Admission of COVID-19 Patients: A Retrospective Study
Yingying Zhao, Huichun Xing, Yong Xu
Journal of Diabetes Research.2022; 2022: 1. CrossRef
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
Pathogens.2022; 11(5): 563. CrossRef
Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019
Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Jay S. Kaufman, Kristin Carson-Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Mohammad Reza Beyranvand, Mohammad Ali Mansournia, Amir Almasi-Hashiani, Gary S. Collins, Ali-Asghar Kolahi
Frontiers in Endocrinology.2022;[Epub] CrossRef
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, Giovenale Moirano, Franco Arturi
Frontiers in Endocrinology.2022;[Epub] CrossRef
SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose
Xiujun Zhang, Guocan Si, Huifen Lu, Wei Zhang, Shuqin Zheng, Zeyu Huang, Longgen Liu, Yuan Xue, Guojun Zheng
Virology Journal.2022;[Epub] CrossRef
Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19
Alon Y. Mazori, Ilana Ramer Bass, Lili Chan, Kusum S. Mathews, Deena R. Altman, Aparna Saha, Howard Soh, Huei Hsun Wen, Sonali Bose, Emily Leven, Jing Gennie Wang, Gohar Mosoyan, Pattharawin Pattharanitima, Giampaolo Greco, Emily J. Gallagher
Endocrine Practice.2021; 27(2): 95. CrossRef
The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis
Li Zhang, Jie Hou, Fu-Zhe Ma, Jia Li, Shuai Xue, Zhong-Gao Xu
Archives of Virology.2021; 166(8): 2071. CrossRef
Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis
M Zuin, G Rigatelli, C Bilato, C Cervellati, G Zuliani, L Roncon
QJM: An International Journal of Medicine.2021; 114(6): 390. CrossRef
National early warning score on admission as risk factor for invasive mechanical ventilation in COVID-19 patients
Min Cheol Chang, Tae Uk Kim, Donghwi Park
Medicine.2021; 100(19): e25917. CrossRef
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients
Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn
Endocrinology and Metabolism.2021; 36(4): 769. CrossRef
Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
BMJ Open.2021; 11(10): e052777. CrossRef
COVID-19 und Diabetes: Folgen der Pandemie
Baptist Gallwitz, Wolfgang Rathmann
Deutsches Ärzteblatt Online.2021;[Epub] CrossRef
Incidence of Post-Traumatic Stress Disorder after Coronavirus Disease
Min Cheol Chang, Donghwi Park
Healthcare.2020; 8(4): 373. CrossRef

Brief Report

Diabetes
Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance: Eugene Han, Nan Hee Cho, Seong-Su Moon, Hochan Cho; Endocrinol Metab. 2020;35(2):480-483. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.480

7,502 View
130 Download
7 Web of Science
6 Crossref

Abstract PDF PubReader ePub

We investigated proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations in individuals with normoglycemia, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT). This was a pilot, cross-sectional study including 92 individuals who had not been diagnosed with or treated for diabetes. We measured PCSK9 levels in three groups of subjects; namely, normoglycemia (n=57), IFG (n=21), and IGT (n=14). Individuals with IFG and IGT showed higher PCSK9 concentrations than those in the normoglycemic group, with the highest serum PCSK9 concentrations found in individuals with IGT (55.25±15.29 ng/mL for normoglycemia, 63.47±17.78 ng/mL for IFG, 72.22±15.46 ng/mL for IGT, analysis of variance P=0.001). There were no significant differences in high- or low-density lipoprotein cholesterol among groups. Serum PCSK9 levels are increased in patients with prediabetes compared to subjects with normoglycemia.

Citations

Citations to this article as recorded by

High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population
Kuan-Hung Yeh, Lung-An Hsu, Ngoc Yen Tran, Semon Wu, Yu-Lin Ko
Lipids in Health and Disease.2025;[Epub] CrossRef
Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels
Wen Guo, Qin Cui, Zhenzhen Fu, Qun Zhang, Jue Jia
Journal of Clinical Lipidology.2024; 18(6): e995. CrossRef
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang Yang, Yeying Wang, Yuwen Wang, Tingyu Ke, Ling Zhao
PeerJ.2024; 12: e17676. CrossRef
Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
Thomas Grewal, Christa Buechler
International Journal of Molecular Sciences.2022; 23(3): 1070. CrossRef
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień
Metabolites.2022; 12(3): 256. CrossRef
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Lipids in Health and Disease.2021;[Epub] CrossRef

Original Article

Clinical Study
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim; Endocrinol Metab. 2020;35(2):329-338. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.329

11,160 View
269 Download
16 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Methods
This was a 6-month retrospective case-control study in subjects with uncontrolled T2D (glycated hemoglobin [HbA1c] >7%) on conventional treatment. The study group started add-on therapy with empagliflozin (10 mg once a day) while the control group was up-titrated with existing medication, using either monotherapy or a combination of metformin, sulfonylurea, and a dipeptidyl peptidase-4 inhibitor. The primary endpoints included changes in HbA1c, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PP2) levels. Secondary outcomes included changes in body composition, body mass index (BMI), and serum ketone bodies, and urinary excretion of sodium, potassium, chlorine, calcium, phosphorus, and glucose.
Results
After treatment, the reduction in HbA1c was significantly greater in the empagliflozin group than in controls (from 8.6%±1.6% to 7.6%±1.5% vs. 8.5%±1.1% to 8.1%±1.1%; P<0.01). Similar patterns were found in FPG and PP2 levels. Empagliflozin decreased systolic and diastolic blood pressure, triglycerides, and alanine and aspartate aminotransferase levels. Body weight, BMI, waist circumference, fat mass, and abdominal visceral fat area decreased significantly while lean body mass was maintained. Total ketones, β-hydroxybutyrate, and acetoacetate levels increased significantly after empagliflozin.
Conclusion
In addition to glucose lowering, an empagliflozin add-on regimen decreased blood pressure and body fat, and improved metabolic profiles significantly. Empagliflozin add-on is superior to dose escalation in patients with T2D who have inadequate glycemic control on standard medications.

Citations

Citations to this article as recorded by

Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study
Soo Lim, Cheol Young Park, In Kyung Jeong, Ji Sung Yoon, Sang Yong Kim, Eun Seok Kang, Junghyun Noh, Kyu Yeon Hur, Sungrae Kim
Journal of Diabetes and its Complications.2026; 40(1): 109214. CrossRef
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Fatemeh Moosaie, Shiva Abedinzadeh, Soghra Rabizadeh, Kimia Daneshvar, Mohammadamin Noorafrooz, Fatemeh Alsadat Mojtahedi, Niloofar Deravi, Seyede Marzie Fatemi Abhari, Akam Ramezani, Alipasha Meysamie, Marzieh Hajibabaei, Sahar Karimpour Reyhan, Mahsa Ab
Scientific Reports.2025;[Epub] CrossRef
SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
Mihaela-Simona Popoviciu, Teodor Salmen, Delia Reurean-Pintilei, Vlad Voiculescu, Anca Pantea Stoian
Medicina.2025; 61(3): 548. CrossRef
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, E
The Journal of Clinical Pharmacology.2025; 65(11): 1460. CrossRef
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Yong-ho Lee, Soo Lim, Melanie J. Davies
Nature Reviews Endocrinology.2025; 21(12): 783. CrossRef
Literature Review on the Effects of Functional Food Ingredients for Blood Glucose and Body Fat Reduction on Glycemic Control in Insulin Resistance and Diabetes
Nohyeon Kim, Minhee Lee, Yoo Kyung Park, Jeongmin Lee
Journal of the Korean Society of Food Science and Nutrition.2025; 54(10): 805. CrossRef
Independent association of thigh muscle fat density with vascular events in Korean adults
Hun Jee Choe, Won Chang, Matthias Blüher, Steven B. Heymsfield, Soo Lim
Cardiovascular Diabetology.2024;[Epub] CrossRef
Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
Minji Sohn, Seoungyeon Nam, Michael A. Nauck, Soo Lim
BMC Medicine.2024;[Epub] CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2022; 191(4): 1647. CrossRef
A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat
Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy, Eunsook S. Jin
Metabolism Open.2022; 13: 100161. CrossRef
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects
Soo Lim, Minji Sohn, Yujin Shin, Ele Ferrannini
Diabetes, Obesity and Metabolism.2022; 24(4): 757. CrossRef
Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks
Minji Sohn, Ji Eun Lee, MinGeun Ahn, YongKeun Park, Soo Lim
Scientific Reports.2021;[Epub] CrossRef
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study
Yujin Shin, Haeri Choi, Soo Lim
Diabetes Research and Clinical Practice.2021; 175: 108843. CrossRef
Impact of COVID-19 and Associated Preventive Measures on Cardiometabolic Risk Factors in South Korea
Minji Sohn, Bo Kyung Koo, Ho Il Yoon, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Soo Lim
Journal of Obesity & Metabolic Syndrome.2021; 30(3): 248. CrossRef

Review Article

Obesity and Metabolism
Effects of Cardiovascular Risk Factor Variability on Health Outcomes: Seung-Hwan Lee, Mee Kyoung Kim, Eun-Jung Rhee; Endocrinol Metab. 2020;35(2):217-226. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.217

14,143 View
227 Download
33 Web of Science
37 Crossref

Abstract PDF PubReader ePub

Innumerable studies have suggested “the lower, the better” for cardiovascular risk factors, such as body weight, lipid profile, blood pressure, and blood glucose, in terms of health outcomes. However, excessively low levels of these parameters cause health problems, as seen in cachexia, hypoglycemia, and hypotension. Body weight fluctuation is related to mortality, diabetes, obesity, cardiovascular disease, and cancer, although contradictory findings have been reported. High lipid variability is associated with increased mortality and elevated risks of cardiovascular disease, diabetes, end-stage renal disease, and dementia. High blood pressure variability is associated with increased mortality, myocardial infarction, hospitalization, and dementia, which may be caused by hypotension. Furthermore, high glucose variability, which can be measured by continuous glucose monitoring systems or self-monitoring of blood glucose levels, is associated with increased mortality, microvascular and macrovascular complications of diabetes, and hypoglycemic events, leading to hospitalization. Variability in metabolic parameters could be affected by medications, such as statins, antihypertensives, and hypoglycemic agents, and changes in lifestyle patterns. However, other mechanisms modify the relationships between biological variability and various health outcomes. In this study, we review recent evidence regarding the role of variability in metabolic parameters and discuss the clinical implications of these findings.

Citations

Citations to this article as recorded by

Capsiate attenuates atherosclerosis by activating Nrf2/GPX4 pathway and reshaping the intestinal microbiota in ApoE −/− mice
Yongbin Shen, Chuanqi Zhang, Xue Jiang, Xianwei Li, Bo Chen, Weiliang Jiang, Yunhe Fu
Microbiology Spectrum.2025;[Epub] CrossRef
Correlation between self-management, psychological cognitive impairment, and quality of life in elderly chronic obstructive pulmonary disease patients
Xiao-Li Zhang, Su-Shu Li, Jian-Qing Qin, Xiao-Yu Han, Xing-Hui Su, Liu-Mei Qin, Chang Pan
World Journal of Psychiatry.2025;[Epub] CrossRef
Investigating the relationship between cardiac autonomic modulation and resting heart rate in youth across physical activity levels
Belkadi Adel, Asli Houcine, Cherara Lalia, Benhammou Saddek, Mokrani Djemal, Sebbane Mohamed
Physical education and sport through the centuries.2025; 12(2): 17. CrossRef
Deep learning for cardiovascular management: optimizing pathways and cost control under diagnosis-related group models
Haohao Chen, Ying Zeng, De Cai
Frontiers in Artificial Intelligence.2025;[Epub] CrossRef
Lipid Variability and the Risk of Incident Peripheral Artery Disease
Ying-Chang Tung, Tsung-Han Tsai, Yu-Jui Hsieh, Tzyy-Jer Hsu, Fu-Chih Hsiao, Chia-Pin Lin, Pao-Hsien Chu
Circulation Journal.2025;[Epub] CrossRef
Sex Differences in Low-Density Lipoprotein Cholesterol Treatment Among Young Israeli Patients Following Premature Acute Coronary Syndrome
Feras Haskiah, Karam Abdelhai, Ranin Hilu, Abid Khaskia
Metabolic Syndrome and Related Disorders.2024; 22(6): 439. CrossRef
Relationship between Alzheimer dementia and QT interval: A meta‐analysis
Simon W. Rabkin
AGING MEDICINE.2024; 7(2): 214. CrossRef
Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE-/- mice
Miaoxin Fu, Qingmei Li, Hang Qian, Xinwen Min, Handong Yang, Zhixin Liu, Wenwen Wu, Jixin Zhong, Hao Xu, Aihua Mei, Jun Chen
International Immunopharmacology.2024; 140: 112844. CrossRef
All-cause and cause-specific mortality risks in individuals with diabetes living alone: A large-scale population-based cohort study
Jae-Seung Yun, Kyungdo Han, Bongseong Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Yu-Bae Ahn, Yong-Moon Mark Park, Seung-Hwan Lee
Diabetes Research and Clinical Practice.2024; 217: 111876. CrossRef
Long-term variability in physiological measures in relation to mortality and epigenetic aging: prospective studies in the USA and China
Hui Chen, Tianjing Zhou, Shaowei Wu, Yaying Cao, Geng Zong, Changzheng Yuan
BMC Medicine.2023;[Epub] CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Relationship between Short- and Mid-Term Glucose Variability and Blood Pressure Profile Parameters: A Scoping Review
Elena Vakali, Dimitrios Rigopoulos, Petros C. Dinas, Ioannis-Alexandros Drosatos, Aikaterini G. Theodosiadi, Andriani Vazeou, George Stergiou, Anastasios Kollias
Journal of Clinical Medicine.2023; 12(6): 2362. CrossRef
Lipid treatment status and goal attainment among patients with premature acute coronary syndrome in Israel
Feras Haskiah, Abid Khaskia
Journal of Clinical Lipidology.2023; 17(3): 367. CrossRef
Research on obesity using the National Health Information Database: recent trends
Eun-Jung Rhee
Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 35. CrossRef
Risk of fracture according to temporal changes of low body weight changes in adults over 40 years: a nationwide population-based cohort study
Jung Guel Kim, Jae-Young Hong, Jiwon Park, Sang-Min Park, Kyungdo Han, Ho-Joong Kim, Jin S. Yeom
BMC Public Health.2023;[Epub] CrossRef
Factors Affecting High Body Weight Variability
Kyungdo Han, Mee Kyoung Kim
Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163. CrossRef
Puerarin Attenuates High-Glucose and High-Lipid-Induced Inflammatory Injury in H9c2 Cardiomyocytes via CAV3 Protein Upregulation
YiFu Tian, CaiXia Zhou, XiaoYang Bu, Qian Lv, Qin Huang
Journal of Inflammation Research.2023; Volume 16: 2707. CrossRef
Visit-to-Visit Glucose Variability, Cognition, and Global Cognitive Decline: The Multi-Ethnic Study of Atherosclerosis
Christopher L Schaich, Michael P Bancks, Kathleen M Hayden, Jingzhong Ding, Stephen R Rapp, Alain G Bertoni, Susan R Heckbert, Timothy M Hughes, Morgana Mongraw-Chaffin
The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e243. CrossRef
Association between lipid variability and the risk of mortality in cancer patients not receiving lipid-lowering agents
Seohyun Kim, Gyuri Kim, So Hyun Cho, Rosa Oh, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
Frontiers in Oncology.2023;[Epub] CrossRef
The Association of Postprandial Triglyceride Variability with Renal Dysfunction and Microalbuminuria in Patients with Type 2 Diabetic Mellitus: A Retrospective and Observational Study
Natsumi Matsuoka-Uchiyama, Haruhito A. Uchida, Shugo Okamoto, Yasuhiro Onishi, Katsuyoshi Katayama, Mariko Tsuchida-Nishiwaki, Hidemi Takeuchi, Rika Takemoto, Yoshiko Hada, Ryoko Umebayashi, Naoko Kurooka, Kenji Tsuji, Jun Eguchi, Hirofumi Nakajima, Kenic
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Associations of variability in body weight and glucose levels with the risk of hip fracture in people with diabetes
Jeongmin Lee, Kyungdo Han, Sang Hyun Park, Mee Kyoung Kim, Dong-Jun Lim, Kun-Ho Yoon, Moo-Il Kang, Seung-Hwan Lee
Metabolism.2022; 129: 155135. CrossRef
The Influence of Obesity and Metabolic Health on Vascular Health
Eun-Jung Rhee
Endocrinology and Metabolism.2022; 37(1): 1. CrossRef
Variability of Metabolic Risk Factors: Causative Factor or Epiphenomenon?
Hye Jin Yoo
Diabetes & Metabolism Journal.2022; 46(2): 257. CrossRef
Changes in Underweight Status and Risk of Hip Fracture: A Korean Nationwide Population-Based Cohort Study
Sangsoo Han, Jiwon Park, Hae-Dong Jang, Kyungdo Han, Choungah Lee, Wonseok Kim, Jae-Young Hong
Journal of Clinical Medicine.2022; 11(7): 1913. CrossRef
Dynamic physical examination indicators of cardiovascular health: A single-center study in Shanghai, China
Rongren Kuang, Yiling Liao, Xinhan Xie, Biao Li, Xiaojuan Lin, Qiang Liu, Xiang Liu, Wenya Yu, Yajing Wang
PLOS ONE.2022; 17(5): e0268358. CrossRef
Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study
Nami Lee, So Jeong Park, Dongwoo Kang, Ja Young Jeon, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Edward J. Boyko, Seung Jin Han
Diabetes Care.2022; 45(5): 1141. CrossRef
Lipid Variability and Risk of Cardiovascular Diseases and All-Cause Mortality: A Systematic Review and Meta-Analysis of Cohort Studies
Shuting Li, Leying Hou, Siyu Zhu, Qian Yi, Wen Liu, Yang Zhao, Feitong Wu, Xue Li, An Pan, Peige Song
Nutrients.2022; 14(12): 2450. CrossRef
Impact of Visit-to-Visit Triglyceride-Glucose Index Variability on the Risk of Cardiovascular Disease in the Elderly
Fei Chen, Ying Pan, Ziqing Liu, Rong Huang, Jing Wang, Jian Shao, Yaqin Gong, Xiyi Sun, Xiaobo Jiang, Weihao Wang, Zhaoqiang Li, Shao Zhong, Qi Pan, Kaixin Zhou, Muhammad Furqan Akhtar
International Journal of Endocrinology.2022; 2022: 1. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Mean versus variability of lipid measurements over 6 years and incident cardiovascular events: More than a decade follow-up
Soroush Masrouri, Leila Cheraghi, Niloofar Deravi, Neda Cheraghloo, Maryam Tohidi, Fereidoun Azizi, Farzad Hadaegh
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Long-Term Variability in Physiological Measures in Relation to Mortality and Epigenetic Aging: Prospective Studies in the US and China
Hui Chen, Tianjing Zhou, Shaowei Wu, Yaying Cao, Geng Zong, Changzheng Yuan
SSRN Electronic Journal .2022;[Epub] CrossRef
Acute Glucose Shift Induces the Activation of the NLRP3 Inflammasome in THP-1 Cells
Ji Yeon Lee, Yup Kang, Hae Jin Kim, Dae Jung Kim, Kwan Woo Lee, Seung Jin Han
International Journal of Molecular Sciences.2021; 22(18): 9952. CrossRef
Body Weight Change and Cardiovascular Disease: Effect of Weight Gain, Weight Loss, and Weight Cycling
Jung-Hwan Cho, Eun-Jung Rhee, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2021; 3(4): 73. CrossRef
Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study
Da Young Lee, Jaeyoung Kim, Sanghyun Park, So Young Park, Ji Hee Yu, Ji A. Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Kyungdo Han, Nan Hee Kim
Journal of Clinical Medicine.2021; 10(24): 5948. CrossRef
Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Studybrief Title: Diabetes of the Exocrine Pancreas
Nami Lee, So Jeong Park, Dongwoo Kang, Ja Young Jeon, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Edward J. Boyko, Seung Jin Han
SSRN Electronic Journal .2021;[Epub] CrossRef
Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis
Minyu Liang, Yichao Pan, Tong Zhong, Yingchun Zeng, Andy S.K. Cheng
Reviews in Cardiovascular Medicine.2021;[Epub] CrossRef
Validation of a wearable cuff-less wristwatch-type blood pressure monitoring device
Joon Ho Moon, Myung-Kyun Kang, Chang-Eun Choi, Jeonghee Min, Hae-Young Lee, Soo Lim
Scientific Reports.2020;[Epub] CrossRef

Original Article

Clinical Study
Vitamin D Deficiency at Mid-Pregnancy Is Associated with a Higher Risk of Postpartum Glucose Intolerance in Women with Gestational Diabetes Mellitus: Kyung-Soo Kim, Seok Won Park, Yong-Wook Cho, Soo-Kyung Kim; Endocrinol Metab. 2020;35(1):97-105. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.97

9,571 View
144 Download
14 Web of Science
13 Crossref

Abstract PDF PubReader ePub

Background

To evaluate the association between serum 25-hydroxyvitamin D (25(OH)D) at mid-pregnancy and postpartum glucose intolerance in women with gestational diabetes mellitus (GDM).

Methods

We enrolled 348 pregnant women diagnosed with GDM from August 2012 to October 2016. We measured serum 25(OH)D levels at mid-pregnancy and carried out a 75-g oral glucose tolerance test at 6 to 12 weeks after delivery. Vitamin D deficiency was defined as serum 25(OH)D <20 ng/mL.

Results

The prevalence of vitamin D deficiency was 76.7% (n=267). Women with vitamin D deficiency had a higher prevalence of postpartum glucose intolerance than did those without vitamin D deficiency (48.7% vs. 32.1%, P=0.011). Serum 25(OH)D level was negatively correlated with hemoglobin A1c at antepartum and postpartum period (antepartum: r=−0.186, P=0.001; postpartum: r=−0.129, P=0.047). Homeostasis model assessment of β-cell function was positively correlated with serum 25(OH)D level only postpartum (r=0.138, P=0.035). The risk of postpartum glucose intolerance was 2.00 times (95% confidence interval, 1.13 to 3.55) higher in women with vitamin D deficiency than in those without vitamin D deficiency (P=0.018).

Conclusion

In women with GDM, vitamin D deficiency at mid-pregnancy is associated with an elevated risk of postpartum glucose intolerance.

Citations

Citations to this article as recorded by

Prevalence of Vitamin D Deficiency in Pregnant Women: Systematic Review and Meta-analysis
Milena Martello Cristófalo, Júlio Oliva de Almeida Garcia, José Fernando Santos Aldrighi, Renan Martello Cristófalo, Maria Laura Marconi França, Liania Alves Luzia, Suleima Pedroza Vasconcelos, José Mendes Aldrighi
Nutrition Reviews.2026; 84(3): 600. CrossRef
Genetic association of vitamin D receptor polymorphisms (ApaI, BsmI, and FokI) with gestational diabetes mellitus in North Indian women: a case–control study
Rakesh Kumar Gupta, Sonal Tiwari, Sakshi Agarwal, Amita Diwakar, Pawan K. Dubey
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Evaluating the effect of vitamin D 3 fortification on physicochemical and sensory properties of yogurt
Saneela Saleem, Zahra Khan, Imtiaz Hussain, Faran Khan, Fahad Al-Asmari, Faima Atta Khan, Alyan Ali Zafar, Muhammad Abdul Rahim, Zongo Eliasse, Mohamed Fawzy Ramadan
Cogent Food & Agriculture.2024;[Epub] CrossRef
Predictive Utility of Biochemical Markers for the Diagnosis and Prognosis of Gestational Diabetes Mellitus
Sathaphone Inthavong, Phudit Jatavan, Theera Tongsong
International Journal of Molecular Sciences.2024; 25(21): 11666. CrossRef
Relationship between vitamin D deficiency and gestational diabetes: a narrative review
Caiqiong Lin, Haiwei Liu
Frontiers in Endocrinology.2024;[Epub] CrossRef
Vitamin D Supplementation for the Outcomes of Patients with Gestational Diabetes Mellitus and Neonates: A Meta-Analysis and Systematic Review
Chunfeng Wu, Yang Song, Xueying Wang, Pier P. Sainaghi
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
Influence of hypovitaminosis D during pregnancy on glycemic and lipid profile, inflammatory indicators and anthropometry of pregnant and newborn
Sara de Figueiredo dos Santos, Paula Normando dos Reis Costa, Thaise Gasser Gouvêa, Nathalia Ferreira Antunes de Almeida, Felipe de Souza Cardoso
Clinical Nutrition ESPEN.2023; 54: 81. CrossRef
Risk factors associated with early postpartum glucose intolerance in women with a history of gestational diabetes mellitus: a systematic review and meta-analysis
Zhe Liu, Qianghuizi Zhang, Leyang Liu, Weiwei Liu
Endocrine.2023; 82(3): 498. CrossRef
Postprandial Free Fatty Acids at Mid-Pregnancy Increase the Risk of Large-for-Gestational-Age Newborns in Women with Gestational Diabetes Mellitus
So-Yeon Kim, Young Shin Song, Soo-Kyung Kim, Yong-Wook Cho, Kyung-Soo Kim
Diabetes & Metabolism Journal.2022; 46(1): 140. CrossRef
Effect of Evidence-Based Diet Nursing on Intestinal Flora and Maternal and Infant Prognosis in Patients with Gestational Diabetes
Ying Jiang, Chunbo Qiu, Yuanping Wang, Bin He, Peng-Yue Zhang
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Vitamin D in gestational diabetes: A broadened frontier
Yu Zhu, Ling Li, Ping Li
Clinica Chimica Acta.2022; 537: 51. CrossRef
The Clinical Characteristics of Gestational Diabetes Mellitus in Korea: A National Health Information Database Study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Endocrinology and Metabolism.2021; 36(3): 628. CrossRef
Fetal Abdominal Obesity Detected At 24 to 28 Weeks of Gestation Persists Until Delivery Despite Management of Gestational Diabetes Mellitus (Diabetes Metab J 2021;45:547-57)
Kyung-Soo Kim
Diabetes & Metabolism Journal.2021; 45(6): 966. CrossRef

Case Report

Evaluation of Glucone Tolerance and Insulin Secretion in Two Patients with Primary Hyperparathyroidism Before and After Surgery.: Sung Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Sang Hyun Chun, Yong Seok Choi, Gun Yong Lee, In Seo Lim, Sung Woo Park; J Korean Endocr Soc. 1994;9(1):54-58. Published online November 6, 2019

1,819 View
22 Download

Abstract PDF: It is reported that patients with primary hyperparathyroidism(PHPT) have disturbances in carbohydrate metabolism: in particular, hyperinsulinemia and insulin resistance are characteristic early metabolic aberrations of this disease. However, it is not clear whether changes of insulin secretion or insulin sensitivity are observed in all patients with PHPT, including those with normal glucose tolerance. Also, it is not clear whether these changes are reversible after surgical correction of PHPT. In the present study, glucose tolerance and insulin secretion were evaluated in 2 symptomatic patients with PHPT during 100g oral glucose tolerance test before and after parathyroid adenoma removal. Comparing these patients before and after surgery, glucose tolerance was not significantly different. However, C-peptide and insulin secretion was low after surgical correction of PHPT compared to the preoperative situation. This observation suggests that insulin hypersecretion in patients with PHPT precedes glucose intolerance and this early disturbance is reversible after surgery.

Review Article

Diabetes
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans: Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies; Endocrinol Metab. 2019;34(3):247-262. Published online September 26, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.3.247

24,244 View
742 Download
150 Web of Science
161 Crossref

Abstract PDF PubReader ePub

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by

Mechanisms of insulin resistance in elderly sarcopenia patients and their bidirectional relationship
Haiyan Du, Yuqing Qu, Zhouyang Huai, Shumin Wang
Geriatric Nursing.2026; 69: 103907. CrossRef
Relevance and Safe Utilization of Amino Acids in Supplements for Human Nutrition: Lessons from Clinical and Preclinical Studies
François Blachier
Nutrients.2026; 18(2): 296. CrossRef
Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial
Mark P.P. Lyngbæk, Grit E. Legaard, Nina S. Nielsen, Cody Durrer, Thomas P. Almdal, Morten Asp Vonsild Lund, Benedikte Liebetrau, Caroline Ewertsen, Carsten Lauridsen, Thomas P.J. Solomon, Kristian Karstoft, Bente K. Pedersen, Mathias Ried-Larsen
Journal of Sport and Health Science.2025; 14: 100999. CrossRef
Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study
Jaehyun Kong, Seoyoung Park, Tae Hyeon Kim, Jae E. Lee, Hanseul Cho, Jiyeon Oh, Sooji Lee, Hyesu Jo, Hayeon Lee, Kyeongmin Lee, Jaeyu Park, Louis Jacob, Damiano Pizzol, Sang Youl Rhee, Sunyoung Kim, Dong Keon Yon
Archives of Gerontology and Geriatrics.2025; 129: 105656. CrossRef
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
Nature Reviews Drug Discovery.2025; 24(3): 171. CrossRef
Medically Tailored Meals in Heart Failure: A Systematic Review of the Literature, 2013-2023
NATHALIE MCINTOSH, HAYLEY BILLINGSLEY, SCOTT L. HUMMEL, WHITNEY L. MILLS
Journal of Cardiac Failure.2025; 31(6): 939. CrossRef
Medical Weight Management Considerations in Plastic Surgery
Alisha B. Paranzino, Brittany Vieira, Caroline M. Apovian, Shailesh Agarwal
Plastic & Reconstructive Surgery.2025; 155(1): 207. CrossRef
GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
Kristen M. Beavers, Tiffany M. Cortes, Colleen M. Foy, Lauren Dinkla, Fernando Reyes San Martin, Jamy D. Ard, Monica C. Serra, Daniel P. Beavers
Obesity.2025; 33(2): 225. CrossRef
Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
Yi-Fei Zhang, Yu-Xiang Liu, Wu-Xiao Yang
World Journal of Cardiology.2025;[Epub] CrossRef
The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, Pratik Choudhary, Emma L. Watson
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
Ashkan Hashemi, Min Ji Kwak, Parag Goyal
Drugs & Aging.2025; 42(2): 95. CrossRef
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
Annals of Internal Medicine.2025; 178(2): 199. CrossRef
Hypoglycemic drugs and sarcopenia
Yu. A. Dolgikh, S. V. Bulgakova, D. P. Kurmaev, E. V. Treneva, O. V. Kosareva, P. Ya. Merzlova, L. A. Sharonova, A. S. Bulgakov
Experimental and Clinical Gastroenterology.2025; (8): 216. CrossRef
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots
Daniel J. McDonough
Physiologia.2025; 5(1): 10. CrossRef
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
Amina A. Al-Awadi, Stuart R. Gray, Ebaa Al-Ozairi
Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 857. CrossRef
Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
Virginia Boccardi, Gülistan Bahat, Cafer Balci, Isabelle Bourdel-Marchasson, Antoine Christiaens, Lorenzo Maria Donini, Sibel Cavdar, Stefania Maggi, Serdar Özkök, Tajana Pavic, Stany Perkisas, Stefano Volpato, Muhammad Shoaib Zaidi, Andrej Zeyfang, Alan
European Geriatric Medicine.2025; 16(4): 1231. CrossRef
Exploring the Potential Effect of GLP1R Agonism on Common Aging-Related Diseases via Glucose Reduction: A Mendelian Randomization Study
Wei Jiang, Kaixi Ding, Maoyi Yang, Zhipeng Hu, Rensong Yue, Lewis A Lipsitz
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
Nature Reviews Disease Primers.2025;[Epub] CrossRef
Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight
Michelle Look, Julia P. Dunn, Robert F. Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin
Diabetes, Obesity and Metabolism.2025; 27(5): 2720. CrossRef
Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes
Yasuhiro Suzuki, Hiroaki Suzuki, Kazushi Maruo, Takaaki Matsuda, Yuki Murayama, Yoko Sugano, Yoshinori Osaki, Hitoshi Iwasaki, Motohiro Sekiya, Yasushi Hada, Hitoshi Shimano
Scientific Reports.2025;[Epub] CrossRef
Non-invasive vestibular nerve stimulation (VeNS) reduces visceral adipose tissue: results of a randomised controlled trial
Erik Viirre, Julie Sittlington, David Wing, Ruth Price, Caomhan Logue, Daniel Moreno, Jeff Ledford-Mills, Cynthia Knott, Carel W. le Roux, David Grieve, Sinead Watson, Jason McKeown, Paul D. McGeoch
Scientific Reports.2025;[Epub] CrossRef
Role of GLP‑1 receptor agonists in sepsis and their therapeutic potential in sepsis‑induced muscle atrophy (Review)
Xuan Zhao, Yukun Liu, Dongfang Wang, Tonghan Li, Zhikai Xu, Zhanfei Li, Xiangjun Bai, Yuchang Wang
International Journal of Molecular Medicine.2025; 55(5): 1. CrossRef
Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial
Sujoy Ghosh, Bipin Sethi, Sanjay Kalra, Manash P. Baruah, Abhishek Mane, Sanjay Choudhari, Anup Petare, Mayur Jadhav, Saiprasad Patil, Hanmant Barkate
Cardiovascular Diabetology – Endocrinology Reports.2025;[Epub] CrossRef
Effectiveness of tele‐guidance for physiotherapy in older patients with type 2 diabetes: A randomized controlled trial
Hiroaki Kataoka, Takuo Nomura, Hiroyuki Oka, Yukio Ikeda
Journal of Diabetes Investigation.2025; 16(7): 1284. CrossRef
How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, Iskandar Idris
Obesity Reviews.2025;[Epub] CrossRef
Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease
Takahiro Yajima, Kaoru Noda, Kumiko Yajima
Clinical Kidney Journal.2025;[Epub] CrossRef
Exercise for Postmenopausal Bone Health – Can We Raise the Bar?
Shejil Kumar, Cassandra Smith, Roderick J. Clifton-Bligh, Belinda R. Beck, Christian M. Girgis
Current Osteoporosis Reports.2025;[Epub] CrossRef
Mechanosensitive Channels Mediate Pancreatic β Cells Reactive Oxygen Species Formation and Downregulation of Essential Genes During Therapeutic Ultrasound Treatment
Mallory Brayer, Vesna Zderic, Aleksandar Jeremic
Journal of Ultrasound in Medicine.2025; 44(9): 1577. CrossRef
Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Winston Wang, Danielle Green, Ramzi Ibrahim, Mahmoud Abdelnabi, Hoang Nhat Pham, Beani Forst, Mohamed Allam, Patrick Sarkis, George Bcharah, Juan Farina, Chadi Ayoub, Dan Sorajja, Reza Arsanjani
Biomedicines.2025; 13(5): 1108. CrossRef
Aerobic, resistance, and specialized exercise training in heart failure with preserved ejection fraction: A state-of-the-art review
Saeid Mirzai, Uttsav Sandesara, Mark J. Haykowsky, Peter H. Brubaker, Dalane W. Kitzman, Anthony E. Peters
Heart Failure Reviews.2025; 30(5): 1015. CrossRef
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
Andrew Gatto, Kevin Liu, Nesa Milan, Stephanie Wong
Current Reviews in Musculoskeletal Medicine.2025; 18(10): 469. CrossRef
GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman
Nature Communications.2025;[Epub] CrossRef
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper
Nature Reviews Endocrinology.2025; 21(8): 482. CrossRef
Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis
Mahdieh Golzarand, Karamollah Toolabi, Parvin Mirmiran
International Journal of Obesity.2025; 49(9): 1676. CrossRef
Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors
Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker
Frontiers in Systems Biology.2025;[Epub] CrossRef
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa San
The American Journal of Clinical Nutrition.2025; 122(1): 344. CrossRef
Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
Obesity.2025; 33(8): 1475. CrossRef
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
American Journal of Lifestyle Medicine.2025;[Epub] CrossRef
Targeting intramyocellular lipids to improve aging muscle function
David W. Russ, Ravikumar Manickam, Srinivas M. Tipparaju
Lipids in Health and Disease.2025;[Epub] CrossRef
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
Obesity Pillars.2025; 15: 100181. CrossRef
Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery
Joshua M. Wiener, Parshva A. Sanghvi, Katelyn Vlastaris, Thomas Mroz, Jonathan Belding, David C. Kaelber, Thomas Olson, Kevin P. Francis, John S. Adams, Nicholas Bernthal, William L. Sheppard
Spine.2025; 50(13): 871. CrossRef
Ultra-processed food consumption is associated with knee osteoarthritis: Data from the Osteoarthritis Initiative
Zehra Akkaya, Wynton M. Sims, John A. Lynch, Maximilian T. Löffler, Felix Gassert, Michael Nevitt, Charles E. McCulloch, Nancy E. Lane, Valentina Pedoia, Katharina Ziegeler, Thomas M. Link, Gabby B. Joseph
Osteoarthritis and Cartilage.2025; 33(9): 1130. CrossRef
Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study
W. Scott Butsch, Suela Sulo, Andrew T. Chang, Jeeyun A. Kim, Kirk W. Kerr, Dominique R. Williams, Refaat Hegazi, Thadchaigeni Panchalingam, Scott Goates, Steven B. Heymsfield
Obesity Pillars.2025; 15: 100186. CrossRef
Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine
Richard M. Rosenfeld, Meagan L. Grega, Micaela C. Karlsen, Abd Moain Abu Dabrh, R. Nisha Aurora, Jonathan P. Bonnet, Lori Donnell, Stephanie L. Fitzpatrick, Beth Frates, Elizabeth A. Joy, Jane F. Kapustin, Dawn R. Noe, Gunadhar Panigrahi, Arun Ram, Lianna
American Journal of Lifestyle Medicine.2025;[Epub] CrossRef
Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis
Shiwen Yang, Qiaozhi Hu, Kexin Liu, Binjie Xiao, Bofei Zhang, Na Su
Frontiers in Pharmacology.2025;[Epub] CrossRef
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies
André J. Scheen
Diabetes & Metabolism.2025; 51(5): 101681. CrossRef
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Zhenqi Liu, Nathan R Weeldreyer, Siddhartha S Angadi
The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2709. CrossRef
Redefining obesity: beyond body mass index
Javed Butler, Francesco Fioretti, Melanie J Davies
European Heart Journal.2025; 46(38): 3758. CrossRef
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, E
The Journal of Clinical Pharmacology.2025; 65(11): 1460. CrossRef
Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition
Dra. M. Isabel T. D. Correia, Nitin Kapoor, Emma Chávez-Manzanera, Luís Henrique Wolff Gowdak, Amira Al Kharusi, Felipe F. Casanueva, Bruno Halpern, Gary Frost, Raed Aldahash
Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 745. CrossRef
Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry
Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W. Holl
Journal of the American Medical Directors Association.2025; 26(8): 105724. CrossRef
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
James W. Connelly, Rajkishen Narayanan, Teeto Ezeonu, Parth Kothari, Nicholas Spina, William Ryan Spiker, Brandon Lawrence, Darrel S. Brodke, Gregory D. Schroeder, Brian A. Karamian
Clinical Spine Surgery.2025;[Epub] CrossRef
GLP-1 Receptor Agonists in Spine Surgery: Current Evidence and Future Directions
Luis M. Salazar, Samuel Alfonsi, Vincent P. Federico, Arash Sayari
Contemporary Spine Surgery.2025; 26(8): 1. CrossRef
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Areesha Moiz, Kristian B. Filion, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
eClinicalMedicine.2025; 86: 103363. CrossRef
The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
Jimmy Wen, Ubaid Ansari, Mouhamad Shehabat, Zaid Ansari, Burhaan Syed, Adam Razick, Daniel Razick, Muzammil Akhtar, Eldo Frezza
Journal of Diabetes.2025;[Epub] CrossRef
Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
Amrutha S Alibilli, Vidur Jain, Heran Mane, Xiaohe Yue, Alexandria Ratzki-Leewing, Junaid S Merchant, Shaniece Criss, Quynh C Nguyen, Rozalina G McCoy, Thu T Nguyen
JMIR Infodemiology.2025; 5: e73619. CrossRef
Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review
Ioana Bujdei-Tebeică, Doina Andrada Mihai, Anca Mihaela Pantea-Stoian, Simona Diana Ștefan, Claudiu Stoicescu, Cristian Serafinceanu
Medicina.2025; 61(8): 1399. CrossRef
Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice
Syed Tareq, Heba A. Ewida, Sumaih Zoubi, Harrison Benson, Dhavalkumar Patel, Hanin Diab, Souvik Patra, Daniela Redrovan, Ehsan Nozohouri, Taysa Berivan Bassani, Alisson Campos Cardoso, Kofi Frimpong-Manson, Lida Khodavirdilou, Md Tareq Aziz, Jenny L. Wilk
Pharmacological Research.2025; 219: 107900. CrossRef
Mortality Risk of Sarcopenia and Malnutrition in Older Patients with Type 2 Diabetes Mellitus
Shinta Yamamoto, Yoshitaka Hashimoto, Fuyuko Takahashi, Ryosuke Sakai, Yuto Saijo, Chihiro Munekawa, Hanako Nakajima, Noriyuki Kitagawa, Rieko Nakatani, Takafumi Osaka, Hiroshi Okada, Naoko Nakanishi, Saori Majima, Emi Ushigome, Masahide Hamaguchi, Michia
Nutrients.2025; 17(16): 2622. CrossRef
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach
Pharmacological Research.2025; 220: 107927. CrossRef
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Yong-ho Lee, Soo Lim, Melanie J. Davies
Nature Reviews Endocrinology.2025; 21(12): 783. CrossRef
The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
Sara Lingow, Nicholas Carris, Jennifer Clements, Lindsay Courtney, Abby Lennon, Christina H. Sherrill, Elizabeth Van Dril
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2025; 8(10): 1078. CrossRef
KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression
Xueqin lu, Shengjun Wang, Yanchun Du, Bixian Xie, Qingyan Chen, Jinzhen Lin, Bailing Chen, Kunyuan Cui, Hanbing Li,
PLOS One.2025; 20(9): e0331768. CrossRef
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Dimitrios Pantazopoulos, Evanthia Gouveri, Dimitrios Papazoglou, Nikolaos Papanas
Diabetes Research and Clinical Practice.2025; 229: 112924. CrossRef
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Ambarish Pandey, Dalane W. Kitzman, Khaja M. Chinnakondepalli, Shachi Patel, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Sanjiv J. Shah, Subodh Verma, Cecilia Rönnbäck, Anne Domdey, Karoline Liisberg, Morten Schou, Eduardo Perna, Fozia Z. Ahmed, Mi
JACC: Heart Failure.2025; 13(10): 102610. CrossRef
Cannabis improves metabolic dysfunction and macrophage signatures in obese mice
Brandon N. VanderVeen, Thomas D. Cardaci, Christian A. Unger, Mitchell M. NeSmith, Jeffrey C. Freeman, Arianna V. Bastian, Kasie Roark, Mansi Upadhyay, Andrew G. Levy, Brooke M. Bullard, Sierra J. McDonald, Kandy T. Velázquez, Reilly T. Enos, Jason L. Kub
American Journal of Physiology-Cell Physiology.2025; 329(4): C1316. CrossRef
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Sahar Soliman, Rebecca Andrews-Dickert, Petra Rocic, Mihail Mitov
Pharmaceuticals.2025; 18(10): 1519. CrossRef
Agonistes du récepteur du GLP-1 et sarcopénie : question émergente ou véritable enjeu clinique ?
Serge Halimi
Médecine des Maladies Métaboliques.2025; 19(8): 593. CrossRef
Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment
Ainhoa González-Luis, Vicente Llinares-Arvelo, Carlos E Martínez-Alberto, Carolina Hernández-Carballo, Carmen Mora-Fernández, Juan F Navarro-González, Javier Donate-Correa
European Journal of Endocrinology.2025; 193(5): R31. CrossRef
Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme
Ambarish Pandey, Michael Moroney, Subodh Verma, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Sanjiv J. Shah, Mark C. Petrie, Cecilia Rönnbäck, Anne Domdey, Søren Rasmussen, Khaja M. Chinnakondepalli, Shachi Patel, Mikhail N. Kosib
European Journal of Heart Failure.2025; 27(11): 2537. CrossRef
Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation
Pamela Kushner, Carlos Campos, Aaron King, Davida F. Kruger, Javier Morales
Clinical Diabetes.2025; 43(5): 681. CrossRef
Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy
Fabian Sanchis-Gomar, Ian J. Neeland, Pilar Ruiz-Lozano, Osama Alnahar, Fatima Rodriguez
Current Cardiology Reports.2025;[Epub] CrossRef
Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
T. Yu. Demidova, K. A. Tolmacheva, S. A. Prilepa
FOCUS. Endocrinology.2025; 6(4): 43. CrossRef
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
Cardiovascular Drugs and Therapy.2024; 38(6): 1289. CrossRef
Drug‐related sarcopenia as a secondary sarcopenia
Masafumi Kuzuya
Geriatrics & Gerontology International.2024; 24(2): 195. CrossRef
Exercise induces tissue-specific adaptations to enhance cardiometabolic health
Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
Cell Metabolism.2024; 36(2): 278. CrossRef
Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
Obesity Pillars.2024; 9: 100098. CrossRef
Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
Diabetes, Obesity and Metabolism.2024; 26(4): 1355. CrossRef
The Current Landscape of Pharmacotherapies for Sarcopenia
Gulistan Bahat, Serdar Ozkok
Drugs & Aging.2024; 41(2): 83. CrossRef
Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
ELISSA DRIGGIN, PARAG GOYAL
Journal of Cardiac Failure.2024; 30(4): 610. CrossRef
Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
Daniel Lee, Jacqueline Capeau
AIDS.2024; 38(4): 603. CrossRef
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
Obesity.2024; 32(5): 840. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
David Ni, Peter Kokkinos, Eric S Nylen
Military Medicine.2024; 189(11-12): 2369. CrossRef
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller
Diabetes Therapy.2024; 15(5): 1069. CrossRef
GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
Michael L. Fragner, Manish A. Parikh, Kaedrea A. Jackson, Michal Laniado Schwartzman, William H. Frishman, Stephen J. Peterson
Cardiology in Review.2024;[Epub] CrossRef
The effects of myosteatosis on skeletal muscle function in older adults
Kathleen Dondero, Ben Friedman, Julie Rekant, Rian Landers‐Ramos, Odessa Addison
Physiological Reports.2024;[Epub] CrossRef
Preservation of healthy lean body mass and function during weight loss
T. J. Wilkinson, D. Papamargaritis, J. A. King, J. A. Sargeant, C. Sutcliffe, L. A. Baker, S. Taheri, T. Yates, M. J. Davies
Clinical Obesity.2024;[Epub] CrossRef
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M.M. van Beek, Nodi Dehvari, Carina Halleskog, Hamza M. Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys, Nicola C. Dijon, Aikaterini Motso, Anna Sandstrom, Evelyn Zacharewicz, I
Molecular Metabolism.2024; 85: 101931. CrossRef
Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
Tom Doyle
Bone & Joint 360.2024; 13(3): 12. CrossRef
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
Guillaume Mahé, Victor Aboyans, Emmanuel Cosson, Kamel Mohammedi, Gabrielle Sarlon-Bartoli, Damien Lanéelle, Tristan Mirault, Patrice Darmon
Cardiovascular Diabetology.2024;[Epub] CrossRef
Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
Diabetes, Obesity and Metabolism.2024; 26(S4): 16. CrossRef
Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, Sandra Di Marco, Grazia Michetti, Gianluca Cerasoli, Marco Di Giacinti, Silvia Coacci, Nadia Francucci, Fabio Petrelli, Giuseppe Ambrosio, Roberto Grinta
Frontiers in Endocrinology.2024;[Epub] CrossRef
Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
Zainab Ridha, Sabrina Guillen Fabi, Raheel Zubair, Steven H Dayan
Aesthetic Surgery Journal.2024; 44(11): NP809. CrossRef
Second Generation Anti-Obesity Medications
Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
Current Pediatrics Reports.2024; 12(4): 138. CrossRef
Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
Oluwaseun Anyiam, Bethan Phillips, Katie Quinn, Daniel Wilkinson, Kenneth Smith, Philip Atherton, Iskandar Idris
Clinical Nutrition.2024; 43(8): 1907. CrossRef
Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams
Obesity Pillars.2024; 11: 100121. CrossRef
Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss
Jordan Wean, Salisha Baranwal, Nicole Miller, Jae Hoon Shin, Robert W. O'Rourke, Charles F. Burant, Randy J. Seeley, Amy E. Rothberg, Nadejda Bozadjieva-Kramer
Diabetes & Metabolism.2024; 50(5): 101570. CrossRef
The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study
Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone
Diabetes Therapy.2024; 15(11): 2323. CrossRef
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis
Expert Opinion on Drug Metabolism & Toxicology.2024; 20(10): 939. CrossRef
Sarcopenia
Avan A. Sayer, Rachel Cooper, Hidenori Arai, Peggy M. Cawthon, Marie-Josiane Ntsama Essomba, Roger A. Fielding, Miranda D. Grounds, Miles D. Witham, Alfonso J. Cruz-Jentoft
Nature Reviews Disease Primers.2024;[Epub] CrossRef
Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
Robert L. Dubin, Steven B. Heymsfield, Eric Ravussin, Frank L. Greenway
Diabetes, Obesity and Metabolism.2024; 26(12): 5503. CrossRef
Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention
Sabrina Warren, Shayla McKee, Erin Yakiwchuk
The Senior Care Pharmacist.2024; 39(10): 350. CrossRef
Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
Louis Talay, Matt Vickers
Obesities.2024; 4(4): 399. CrossRef
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Jennifer Linge, Andreas L. Birkenfeld, Ian J. Neeland
Circulation.2024; 150(16): 1288. CrossRef
Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications
Gregory J Grosicki, Nikhil V Dhurandhar, Jessica L Unick, Shawn M Arent, J Graham Thomas, Holly Lofton, Madelyn C Shepherd, Jessica Kiel, Christopher Coleman, Satya S Jonnalagadda
Current Developments in Nutrition.2024; 8(11): 104486. CrossRef
Malnutrition in patients with obesity: An overview perspective
Cagney Cristancho, Kris M. Mogensen, Malcolm K. Robinson
Nutrition in Clinical Practice.2024; 39(6): 1300. CrossRef
Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies
Karen Feghali, Xilong Li, Naim M. Maalouf
Kidney360.2024; 5(11): 1706. CrossRef
Nutritional Supplementation to Preserve Healthy Lean Mass and Function During Periods of Pharmacological and Nonpharmacological‐Induced Weight Loss: Protocol for a Systematic Review and Meta‐Analysis
Emily James, Ryan J. Kelsey, Jack A. Sargeant, Joe Henson, Tom Yates, Thomas J. Wilkinson
Health Science Reports.2024;[Epub] CrossRef
Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease
Christopher R. Stone, Dwight D. Harris, Mark Broadwin, Meghamsh Kanuparthy, Ju-Woo Nho, Keertana Yalamanchili, Jad Hamze, M. Ruhul Abid, Frank W. Sellke
Arteriosclerosis, Thrombosis, and Vascular Biology.2024;[Epub] CrossRef
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
Current Issues in Molecular Biology.2024; 46(12): 14514. CrossRef
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition and Fluid Status in Cardiovascular Rehabilitation Patients with Coronary Artery Disease and Heart Failure
José C. De La Flor, Blanca Coto Morales, Elena Basabe, María Rey Hernandez, Rocío Zamora González-Mariño, Celia Rodríguez Tudero, Irwing Benites Flores, Carlos Espinoza, Michael Cieza Terrones, Secundino Cigarrán Guldris, Jesús Hernández Vaquero
Medicina.2024; 60(12): 2096. CrossRef
Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
International Journal of Cardiology.2023; 370: 263. CrossRef
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
Obesity.2023; 31(1): 74. CrossRef
Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
Diabetes, Obesity and Metabolism.2023; 25(4): 901. CrossRef
The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
Obesity Reviews.2023;[Epub] CrossRef
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
Cardiovascular Diabetology.2023;[Epub] CrossRef
Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
Diabetic Medicine.2023;[Epub] CrossRef
Cancer cachexia as a blueprint for treating obesity
Nikolai P. Jaschke, Tilman D. Rachner
Trends in Endocrinology & Metabolism.2023; 34(7): 395. CrossRef
The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
Peter N. Benotti, Bruce R. Bistrian
Surgery for Obesity and Related Diseases.2023; 19(9): 1075. CrossRef
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
Frontiers in Endocrinology.2023;[Epub] CrossRef
Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
Diabetes, Obesity and Metabolism.2023; 25(11): 3161. CrossRef
Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
Drugs & Aging.2023; 40(8): 703. CrossRef
Introduction to the dietary management of obesity in adults
Vivian Lee
Clinical Medicine.2023; 23(4): 304. CrossRef
Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
Diabetes, Obesity and Metabolism.2023; 25(12): 3538. CrossRef
Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
Circulation Journal.2023; 88(1): 10. CrossRef
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Baris Afsar, Rengin Elsurer Afsar
Clinical Nutrition.2023; 42(12): 2338. CrossRef
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
Diabetes Therapy.2023; 14(12): 2015. CrossRef
Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
Current Obesity Reports.2023; 12(4): 453. CrossRef
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
Nutrients.2023; 16(1): 63. CrossRef
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Sabine Kahl, Jennifer Pützer, Michael Roden
Seminars in Liver Disease.2022; 42(01): 048. CrossRef
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
Journal of Cardiac Failure.2022; 28(1): 56. CrossRef
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
Molecular and Cellular Endocrinology.2022; 539: 111472. CrossRef
Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
Scientific Reports.2022;[Epub] CrossRef
Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
Obesity Reviews.2022;[Epub] CrossRef
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
Expert Opinion on Drug Safety.2022; 21(10): 1315. CrossRef
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
Expert Opinion on Drug Safety.2022; 21(11): 1411. CrossRef
Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
Lyse Bordier, Jean Doucet, Bernard Bauduceau
Médecine des Maladies Métaboliques.2022; 16(5): 422. CrossRef
Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
Nutrition.2022; 103-104: 111815. CrossRef
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
Medicines.2022; 9(9): 47. CrossRef
Distribution of lean mass and mortality risk in patients with type 2 diabetes
Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
Primary Care Diabetes.2022; 16(6): 824. CrossRef
Cardio-sarcopenia: A syndrome of concern in aging
De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
Frontiers in Medicine.2022;[Epub] CrossRef
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
The Lancet.2022; 400(10365): 1803. CrossRef
Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
Cardiovascular Diabetology.2022;[Epub] CrossRef
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
Expert Opinion on Pharmacotherapy.2021; 22(7): 889. CrossRef
Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
Obesity.2021; 29(3): 529. CrossRef
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
BMJ Open.2021; 11(4): e045844. CrossRef
Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
Cancer Prevention Research.2021; 14(5): 509. CrossRef
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
Journal of Translational Medicine.2021;[Epub] CrossRef
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
Nutrition & Diabetes.2021;[Epub] CrossRef
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
Drugs.2021; 81(11): 1243. CrossRef
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060. CrossRef
Physical activity and exercise in the management of type 2 diabetes: where to start?
Deirdre Harrington, Joe Henson
Practical Diabetes.2021; 38(5): 35. CrossRef
Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

New England Journal of Medicine.2021; 385(22): 2105. CrossRef
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
Current Diabetes Reviews.2021; 17(3): 293. CrossRef
Relationship between serum bilirubin concentration and sarcopenia in patients with type 2 diabetes: a cross-sectional study
Chuan Wang, Chen Jin, Xiaofei Yin, Jidong Liu, Jinbo Liu
Journal of International Medical Research.2021;[Epub] CrossRef
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
Journal of Diabetes Investigation.2020; 11(6): 1542. CrossRef
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
Nutrients.2020; 12(2): 510. CrossRef
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
Cell Reports Medicine.2020; 1(1): 100006. CrossRef
Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
Aging Cell.2020;[Epub] CrossRef

First
Prev
Page of 2
Next
Last

Search